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ABSTRACT 
Polymeric nanoparticles have been demonstrating to be very promising in oral delivery of 
biopharmaceuticals, including for vaccination purposes. In this respect, they should focus 
on optimizing antigen association efficiency, provide stability, tailor the release and elicit 
high levels of long-lasting antibody and cellular immune responses. Nanoparticles may 
benefit oral immunization due to the predominant uptake of particulates by Peyer patches. 
The M cells have been pointed as the primary targets to consider for nanoparticles. After 
nanoparticle uptake, subsequent internalization by professional antigen presentation cells 
is expected to occur, mediating the following immune response. Additionally, nanoparticle 
matrix materials might further help on the potentiation of an immune response, and the 
use of mucoadhesive polymers, the surface chemistry and/or surface ligand conjugation 
play an important role. Locust bean gum (LBG) may contribute in a strong manner for the 
improvement of nanoparticle abilities regarding an application in oral immunization, as the 
chemical composition of this polysaccharide includes mannose residues that may provide 
a preferential targeting of M cells and/or dendritic cells.  
The development of LBG-based nanoparticles for an application in oral immunization was, 
thus, proposed in this thesis. Nanoparticle production occurred by mild polyelectrolyte 
complexation, requiring the chemical modification of LBG. Three LBG derivatives were 
synthesized, namely a positively charged ammonium derivative (LBGA) and negatively 
charged sulfate (LBGS) and carboxylate (LBGC) derivatives. Glycidyltrimethylammonium 
chloride was the alkylating agent allowing to obtain LBGA, a N,N-dimethylformamide 
sulfur trioxide (SO3DMF) complex was the sulfating agent in the synthesis of LBGS, and 
2,2,6,6-tetramethylpiperidine-1-oxyl the oxidizing agent used to produce LBGC. The 
derivatives were characterized by Fourier transform infrared spectroscopy, elemental 
analysis, nuclear magnetic resonance spectroscopy, gel permeation chromatography and 
x-ray diffraction. Since a pharmaceutical application was aimed, a toxicological analysis of 
the derivatives was required. The assessment of the metabolic activity of intestinal Caco-2 
cells following exposure (3 h or 24 h) to LBG and derivatives was performed by the MTT 
test, demonstrating the general safety of LBG derivatives at concentrations up to 1.0 
mg/mL, with the exception of LBGA. Similar observations resulted from a complementary 
cytotoxicity assessment evaluating cell membrane integrity (LDH release assay). 
Several nanoparticle formulations were produced using LBGA or chitosan (either in the 
free amine, CS, or in the hydrochloride salt form, CSup) as positively charged polymers, 
and LBGC or LBGS as negatively charged counterparts. The nanoparticle formulations 
were obtained with production yields up to 58%, while sizes varied between 180 and 830 
 xii 
 
nm and zeta potential between -28 mV and +48 mV, depending on the qualitative and 
quantitative composition. Morphological characterization performed on chosen 
formulations (LBGA/LBGS and CSup/LBGS) by transmission electronic microscopy 
suggested that nanoparticles presented a solid and compact structure with spherical-like 
shape. CSup/LBGS nanoparticles, which were later selected for the subsequent stage of 
antigen association, demonstrated to be stable in suspension for at least 3 months when 
stored at 4 ºC. LBGA/LBGS and CSup/LBGS nanoparticle formulations induced high cell 
viability in Caco-2 cells after 3 h and 24 h of exposure, when tested at concentrations up 
to 1.0 mg/mL (MTT assay), which was a remarkable event particularly considering the 
observation of some toxicity of the bare LBGA derivative. The LDH release assay 
evidenced some cytotoxicity of the CSup/LBGS formulation (24 h; 1.0 mg/mL), not shown 
by the MTT assay.  
Two model antigens (a particulate cellular extract of Salmonella Enteritidis HE, and a 
soluble antigen - ovalbumin, OVA) were associated to CSup/LBGS nanoparticles with 
efficiency around 30%. The process was verified to not induce any deleterious effect on 
antigen structural integrity, while the antigenicity was retained. Nanoparticles exhibited 
adequate physicochemical properties for an application in oral immunization (size of 180 – 
200 nm; positive zeta potential of 10 – 13 mV) and demonstrated to restrain the release of 
the antigens. Regarding the latter, a very limited release of HE in both simulated gastric 
and intestinal fluids was observed, while OVA released a maximum of 40% in the former 
medium. In vivo studies encompassed the administration of either HE-loaded or OVA-
loaded nanoparticles to BALB/c mice. During five (HE) or six (OVA) weeks after oral and 
subcutaneous immunization, the systemic (IgG1 and IgG2a) and mucosal (IgA) 
immunological responses were evaluated. The adjuvant effect of the CSup/LBGS 
nanoparticles in obtaining an immunological response after oral immunization was 
demonstrated, although this was only provided when the soluble antigen OVA was used. 
On the contrary, an absence of effect was observed when the particulate antigen HE was 
tested. Nanoparticles were further found to elicit a balanced Th1/Th2 immune response, 
which is a relevant observation regarding an effective immunological protection. 
Overall, LBGS was the synthesized derivative showing better ability for complexation with 
chitosan regarding the objective of producing nanoparticles with adequate properties for 
oral immunization. Additionally, a preliminary indication on the potential of the system for 
oral immunization is provided, although this is dependent on the antigen type.  
Keywords: Locust bean gum, oral immunization, ovalbumin, polymeric nanoparticles, 
Salmonella Enteritidis antigenic complex   
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RESUMO 
As nanopartículas poliméricas têm demonstrado grande potencial na administração oral 
de biofármacos, incluindo em vacinação. Neste âmbito devem focar a otimização da 
eficiência de encapsulação, proporcionar estabilidade, modular a libertação e induzir 
níveis elevados e duradouros de resposta imunológica humoral e celular. As 
nanopartículas podem beneficiar esta abordagem devido à captura predominante de 
material particulado pelas placas de Peyer. As células M têm sido apontadas como 
principais alvos a considerar e, após internalização, é expectável a captura subsequente 
por células apresentadoras de antigénios profissionais, mediando a resposta imune que 
se segue. Adicionalmente, a matriz das nanopartículas pode potenciar a resposta imune 
e a utilização de polímeros mucoadesivos, com a sua química de superfície 
eventualmente aliada à conjugação superficial de ligandos, têm um papel importante. A 
goma de alfarroba (LBG) pode contribuir fortemente para melhorar a aplicação das 
nanopartículas em imunização oral, porque a sua composição química inclui resíduos de 
manose que podem proporcionar uma vetorização para as células M e/ou dendríticas. 
O desenvolvimento de nanopartículas de LBG para imunização oral é assim proposta 
nesta tese. A produção das nanopartículas ocorreu por complexação polieletrolítica, 
requerendo a modificação química da LBG. Três derivados foram sintetizados, um 
derivado aminado carregado positivamente (LBGA) e os derivados sulfatado (LBGS) e 
carboxilado (LBGC), com carga negativa. O cloreto de glicidiltrimetilamónio foi o agente 
alquilante para obtenção da LBGA, o complexo de trióxido de enxofre e N,N-
dimetilformamida (SO3DMF), o agente sulfatante na síntese da LBGS, e a 2,2,6,6-
tetrametilpiperidina-1-oxil foi o agente oxidante na produção da LBGC. Os derivados 
foram caraterizados por espectroscopia de infravermelho de transformada de Fourier, 
ressonância magnética nuclear, análise elementar, cromatografia de permeação de gel e 
difração de raios-X. A intenção de uma aplicação farmacêutica implicou a análise 
toxicológica dos derivados. A avaliação da atividade metabólica de células Caco-2 após 
exposição (3 h ou 24 h) à LBG ou aos derivados sintetizados foi realizada por MTT, que 
mostrou que, com exceção da LBGA, os materiais induziram viabilidades acima dos 70% 
quando testados em concentrações até 1 mg/mL. Um ensaio complementar que avalia a 
integridade da membrana celular (libertação de LDH) conferiu resultados semelhantes. 
Foram produzidas várias formulações de nanopartículas que utilizaram LBGA ou 
quitosano como polímero carregado positivamente e LBGC ou LBGS como polímero 
negativo. As nanopartículas foram obtidas com rendimento de produção até 58%, 
enquanto os tamanhos variaram entre 180 e 830 nm e o potencial zeta entre -28 mV e 
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+48 mV, dependendo da composição qualitativa e quantitativa. A caraterização 
morfológica realizada em algumas formulações (LBGA/LBGS e CSup/LBGS) por 
microscopia eletrónica de transmissão sugere que as nanopartículas  apresentam uma 
estrutura sólida e compacta e forma aproximadamente esférica. As nanopartículas de 
CSup/LBGS, posteriormente selecionadas para a associação de antigénio, demonstraram 
manter a estabilidade físico-química por pelo menos 3 meses quando armazenadas a 4 
ºC. As nanopartículas de LBGA/LBGS e CSup/LBGS revelaram ausência de 
citotoxicidade em células Caco-2 após 3 h e 24 h de exposição, quando em 
concentrações até 1.0 mg/mL (ensaio MTT), uma observação relevante considerando a 
forte citotoxicidade do derivado LBGA. O ensaio de libertação de LDH revelou maior 
citotoxicidade da formulação CSup/LBGS (24 h; 1.0 mg/mL), não observada no ensaio 
MTT. 
Dois antigénios modelo (um extrato celular particulado de Salmonella Enteritidis – HE, e 
um antigénio solúvel – ovalbumina, OVA) foram associados às nanopartículas 
CSup/LBGS com eficácia aproximada de 30%. Um estudo de estabilidade revelou 
ausência de efeito negativo do processo de associação sobre a integridade estrutural do 
antigénio, mantendo a sua antigenicidade. As nanopartículas exibiram propriedades 
físico-químicas adequadas para uma aplicação em imunização oral (tamanho de 180 – 
200 nm; potencial zeta positivo de 10 – 13 mV) e demonstraram retardar a libertação dos 
antigénios. Neste sentido, observou-se uma libertação muito limitada de HE em meios 
gástrico e intestinal simulados, enquanto a OVA libertou no máximo 40% no primeiro 
meio. Ensaios in vivo incluíram a administração de nanopartículas contendo HE ou OVA 
a ratinhos BALB/c. Durante cinco/seis semanas após imunização oral e subcutânea, a 
resposta imunológica sistémica (IgG1 e IgG2a) e mucosa (IgA) foi avaliada. O efeito 
adjuvante das nanopartículas de CSup/LBGS na resposta imunológica após imunização 
oral foi demonstrado, apesar de se ter verificado apenas para o antigénio solúvel OVA. 
Pelo contrário, verificou-se uma ausência de efeito quando se testou HE, um antigénio 
particulado. As nanopartículas proporcionaram ainda um equilíbrio na resposta Th1/Th2, 
o que é relevante para uma proteção imunológica eficiente. 
De forma geral, o LBGS foi o derivado sintetizado que evidenciou maior capacidade para 
complexação com quitosano com vista à produção de nanopartículas com propriedades 
adequadas para imunização oral. Além disso, há uma indicação preliminar do potencial 
do sistema para imunização oral, apesar de este depender do tipo de antigénio. 
Palavras-chave: complexo antigénico de Salmonella Enteritidis, goma de alfarroba, 
imunização oral, nanopartículas poliméricas, ovalbumina   
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1. General introduction 
1.1. Nanoparticles as carriers in drug delivery 
The recent decades have brought to the market many new biomolecules that have been 
identified as having therapeutic potential. This boom is directly related with advances in 
the biotechnological industry, making available a very considerable number of molecules 
that are protein-based. These molecules are usually called biopharmaceuticals, meaning 
that they are biological in nature and manufactured using biotechnology (1). A 
considerably wide variety of molecules is included in this group, from protein and 
peptides, to antigens and nucleic acids. In many cases their promise is so high that they 
are thought to occupy in the future an undisputed place alongside other established 
therapies. Although therapeutically promising, biopharmaceuticals are very instable 
compounds and their administration is extremely challenging, due to inherent 
physicochemical and biopharmaceutical properties (2, 3). This is the main reason why 
parenteral delivery frequently represents the unique administration possibility, as is often 
verified for vaccines, for example. Nevertheless, the parenteral route involves an invasive 
and painful administration, thus not being easily accepted by the patients and many times 
leading to therapeutic incompliance (3, 4). A gap is, thus, clearly identified which needs to 
be filled, compelling researchers to invest in this area in order to find adequate 
alternatives that permit effective, safe, cheap and comfortable administration of 
biopharmaceutical molecules through other routes. Comparing with the modality of 
parenteral delivery, mucosal administration is advantageous as systemic pathway, mainly 
because it is non-invasive, reducing patient discomfort, but also because it generally does 
not require the involvement of skilled personnel for the administration, thus reducing the 
costs of the process (3, 5). In this manner, the development of non-injectable delivery 
systems for mucosal administration could enhance significantly patient’s compliance, 
thereby leading to increased therapeutic benefits.  
The therapeutic action of proteins and protein-based molecules is not only limited by the 
potential degradation in biological environments, but also compromised by their low ability 
to reach the therapeutic site of action (3, 6, 7). In fact, these limitations are related either 
with the presence of a great number of functional groups susceptible of chemical 
degradation, or with the high hydrophilic character of the proteins, which results in poor 
permeability (8, 9). In addition, drug delivery via mucosal routes faces other major 
restrictions, including specific mechanisms of defense, the possibility to induce immune 
reactions at the delivery site and, generally, limitations in the surface area available for 
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absorption (10). As such, a meaningful challenge for current pharmaceutical scientists has 
been the need to develop suitable vehicles that permit delivering macromolecules through 
alternative routes of administration. These drug delivery carriers should exhibit a sort of 
characteristics, including capacity for high drug association and the ability to enhance 
drug physicochemical stability, providing protection to encapsulated drugs from the 
moment of carrier production until release. Furthermore, in many cases, the carriers are 
expected to regulate the drug release profile, while allowing an intimate contact of 
molecules with mucosal barriers, contributing for their epithelial permeation. In such a 
task, there is a consensus in that the materials and methods used to prepare the referred 
vehicles play relevant roles (11, 12).  
Directing the research efforts towards the development of adequate vehicles for the 
purpose of drug delivery through distinct routes of administration, resulted in the 
appearance of several drug delivery systems like nanoparticles and microspheres. 
Nanoparticulate-based technologies have reached a position of evidence and 
nanoparticles are one of the most approached systems. The International Organization for 
Standardization (ISO) defines nanoparticles as particles with at least one dimension less 
than 100 nm (13). This definition is however not consensual in the field of drug delivery 
and there are many authors considering that nanoparticles are carriers with dimensions 
between 10 and 1000 nm (14-17). The interest in nanosystems (submicron sized 
systems) relies on several differentiating features that include an increased surface-to-
volume ratio, in many cases displaying surface functionality, which offers high potential for 
the association of biopharmaceuticals (15). Biological transport processes have been 
reported to be affected by the physical attributes of nanocarriers, both anatomically and 
down to the cellular ad subcellular levels (18). Actually, nanocarriers have been reported 
to increase drug absorption by reducing the resistance of the epithelium to drug transport 
in a localized area or by carrying the drug across the epithelium (19). In this regard, 
transport has been described as more favorable for nanoparticles than for microparticles 
(2, 20, 21). In addition, colloidal carriers are reported to have improved capacity to interact 
with mucosal epithelial membranes (20), maximum interaction being reported to occur for 
systems within 50 – 500 nm (8). Colloidal carriers have also shown several times the 
ability to control the drug release profile of encapsulated molecules (22-24). Importantly, 
specifically regarding the delivery of biopharmaceuticals, an improvement of molecule 
stability, bioavailability, targeting, uptake and biological activity has been shown (24-26). 
Table 1.1 summarizes the advantages and drawbacks of nanoparticles for drug delivery 
applications. 
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Table 1.1 - Advantages and limitations of nanoparticles for drug delivery applications. 
Advantages Limitations 
High surface/volume ratio Undefined physical shape 
Ease of surface modification Limited capacity to co-associate other 
functional molecules 
Maximised contact with mucosae Unknown toxicity profile 
High drug concentration in desired site Lack of suitable large-scale production 
methods 
Ability to enter cells Low stability in some biological fluids 
Protection of encapsulated molecules Tendency for aggregation 
Possibility to provide controlled release Limited loading capacity (unsuitable for 
less potent drugs) 
Possibility of targeted delivery Small size can provide access to 
unintended environments 
 
 
1.1.1. Methods for nanoparticle production 
Although rather different materials may be used to produce nanoparticles, including 
metals and ceramics, polymers have been one of the most used of the material classes. 
The literature describes many methods to produce polymeric nanoparticles. Naturally, 
each method has its own pros and cons, and the choice of a particular methodology will 
mainly depend on specific characteristics of the drug to be encapsulated and the material 
to be used as matrix (3). The techniques may be categorized into top-down or bottom-up 
approaches. Top-down processes involve the size-reduction of large particles to the 
nanometre range, which can be achieved by milling or high pressure homogenization. 
These processes have much lower application when compared with bottom-up 
techniques, which involve the assembly of molecules in solution to form defined 
nanostructures (27, 28). However, it is important to mention that delivery systems 
resulting from bottom-up technologies usually display size polydispersity (29), which in 
some cases limits nanoparticle usefulness. In fact, it is assumed that in a polydisperse 
system, larger nanoparticles might have higher drug loading capacity, while smaller 
nanoparticles are expected to have higher efficiency at delivering drugs to tissues or cells. 
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In a limit situation, this means that, even if the drug carrier has high association efficiency, 
the efficacy of the delivery may be poor (30). Therefore, fabrication processes should be 
rigorously optimized to provide a compromise between satisfactory association efficiency 
and the most suitable size for the established objective. Interestingly, a recent 
technological development related to a top-down process termed particle replication in 
non-wetting templates, which is a modified soft lithography technique, has demonstrated 
independent control over nanoparticle size, as well as other parameters that include 
shape, modulus (stiffness) and surface chemistry (29, 31).  
Bottom-up techniques might also be classified according to whether the formulation of 
nanoparticles involves a polymerization reaction or is achieved directly from a preformed 
polymer (32). Methods involving polymerization are divided in emulsion polymerization 
and interfacial polymerization (32). When nanoparticles are prepared from preformed 
polymers, which is the most common approach, the diversity of techniques increases, 
involving methods based on emulsification, polymer desolvation, or intermolecular 
electrostatic interactions (11, 32). Contrary to low molecular weight drugs, 
biopharmaceuticals possess organized structures (proteins for example may have 
secondary, tertiary, or even quaternary structure) with labile bonds and side chains of 
chemically reactive groups. This specific structure defines the exact properties and 
activities of the molecules and, therefore, it is crucial to ensure its preservation during the 
association procedures, as its disruption or the modification of side chains can lead to loss 
of activity of the molecule. This fragile nature requires that methods selected for 
association do not damage the molecule structure, reduce their biological activity, or 
render them immunogenic (3).  
Methods based on the establishment of intermolecular electrostatic interactions are one of 
the most reported and are applied when the matrix of nanoparticles is composed by at 
least one polyelectrolyte, that is, a polymer that exhibits charged groups when in solution. 
The principle of this methodology is the ability of polyelectrolytes to establish stable links 
with oppositely charged groups (33). Two different methods are described based on 
electrostatic interaction. Ionic gelation is the used denomination when the polyelectrolyte 
is a polymer with gelling ability (such as chitosan or alginate, for instance) and its gelation 
is induced by small anionic molecules, such as phosphate, citrate and sulfate groups. A 
very typical example is that of chitosan nanoparticles prepared by interaction of chitosan 
amino groups with the phosphate groups of tripolyphosphate (34). In turn, polyelectrolyte 
complexation is the name of the technique when the groups mediating the interaction are 
provided by two oppositely charged polyelectrolytes, instead of involving one small 
molecule (35). The latter approach is often referred to as complex coacervation or 
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interfacial coacervation (36, 37), and includes for example chitosan/alginate (38), 
chitosan/carrageenan (39) or chitosan/dextran sulfate (40) nanoparticles. Figure 1.1 
displays a schematic representation of the method of polyelectrolyte complexation to 
produce nanoparticles. The assembly of nanoparticles is easily and immediately observed 
upon pouring a solution of one polyelectrolyte over a solution of the oppositely charged 
polyelectrolyte, under mild stirring. 
The popularity of the method is mainly due to the fact that it usually involves a complete 
hydrophilic environment and mild preparation conditions (41), avoiding the use of organic 
solvents or high shear forces and making association of labile drugs, such as 
biopharmaceuticals, an easier task (33, 42).  
 
 
Figure 1.1 – Schematic representation of the preparation of nanoparticles by the method 
of polyelectrolyte complexation. 
 
The literature indicates that, in order to obtain nanocarriers with pre-established 
characteristics by this method, an optimization of the process should be performed 
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focusing aspects such as the concentration of polyelectrolytes, the stirring conditions and 
the conditions of centrifugation (43). 
 
1.1.2. Materials for nanoparticle production 
The selection of appropriate materials for drug delivery approaches should be driven by 
several requirements, including biocompatibility, biodegradability, versatility and low 
overall costs of production  (11, 44). As mentioned above, polymeric nanoparticles are 
one of the most representative of nanomedicines, as polymers are among the most 
versatile building units, permitting an easy tailoring of their properties to meet specific 
requirements (44). By definition, polymeric nanoparticles can be produced using either 
synthetic or natural polymers. The former are reported frequently, but in many cases they 
display unsatisfactory biocompatibility, which limits potential clinical applications (45). On 
the contrary, natural polymers comply more easily with the requirements mentioned above 
(46). Actually, it has been claimed that one of the ways of avoiding the potential toxicity of 
nanocarriers, an issue believed to be one of the most relevant in preventing diverse 
clinical applications so far, may be using natural materials (45). Moreover, these have 
some remarkable merits over synthetic ones, namely improved capacity for cell adhesion 
and mechanical properties similar to natural tissues (47).  
The class of natural polymers is divided in proteins and polysaccharides. The latter have 
found a wide range of applications, as there is an extensive variety of materials available 
for exploration, comparing with proteins. Furthermore, many polysaccharides are obtained 
from plants or marine organisms, therefore being less probable to induce adverse 
immunological reactions, as compared with proteins (44). Polysaccharides are complex 
carbohydrates, composed of monosaccharides joined together by glycosidic bonds (44, 
48). The most common basic units composing these carbohydrate polymers include 
several monosaccharides such as D-glucose, D-fructose, D-galactose, L-galactose, D-
mannose, L-arabinose and D-xylose. Some polysaccharides comprise in their structure 
simple sugar acids (glucuronic, mannuronic and iduronic acids) and also monosaccharide 
derivatives, like the amino sugars D-glucosamine and D-galactosamine, as well as their 
derivatives N-acetylneuraminic acid and N-acetylmuramic acid (49). The presence of 
several of these sugar units on the side chain of carbohydrate polymers makes them good 
candidates for targeted delivery by carbohydrate recognizing receptors found on the 
surface of several cells (50, 51). 
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Polysaccharides might have algal, plant, microbial or animal origin, but they all share 
general properties of natural polymers, including the propensity for biocompatibility, low 
cost and hydrophilicity (45, 48, 52). Table 1.2 presents the pros and cons of 
polysaccharides as nanoparticle matrix materials.  
 
Table 1.2 – Pros and cons of polysaccharides as nanoparticle matrix materials (53). 
Advantages Limitations 
Structural flexibility, stability Inter-batch variability 
Low cost Limited availability (if widely used) 
Bioadhesion capacity Complex and varied composition 
Hydrophilicity Difficult to process 
Biocompatibility, biodegradability Immunogenicity 
 
Importantly, polysaccharides are economical, readily available, usually biodegradable and 
with few exceptions, also biocompatible (46, 54). These are the reasons justifying that 
they assume a relevant role as matrix materials for drug delivery systems and, namely, 
nanoparticles. Owing to the potential to exhibit biodegradability, carriers based on 
polysaccharides are expected to be easily eliminated from the organism, as a 
consequence of their metabolization into small sugar units that integrate conventional 
metabolic processes, thereby permitting elimination or re-absorption (45). 
Polysaccharides present diverse physicochemical properties, deriving from multiple 
chemical structures that also translate into different molecular weights (Mw) and intrinsic 
characteristics. Ionic nature, for instance, is one of the greatest items of variation, as 
cationic, anionic and neutral polysaccharides can be found (46, 48). The hydrophilic 
character is particularly important, as it allows the production of nanoparticles by methods 
not involving organic solvents. Additionally, polysaccharides also benefit from a great 
structural flexibility, forming either linear or branched structures and easily permitting 
chemical modifications (44, 55). The more sophisticated applications of these polymers to 
produce nanoparticles, which include controlled or triggered release, or even targeted 
delivery, frequently demand chemical modifications of polysaccharides. These usually 
encompass the introduction of ionic or hydrophobic groups, degradable bonds, spacers or 
targeting moieties (44). The ability to adhere to biological surfaces comprises a relevant 
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advantage in drug delivery applications (48), as these frequently imply an interaction with 
cell surfaces. In this regard, the reactive functional groups of polysaccharides allow the 
formation of non-covalent bonds with cell surfaces, affording enhanced residence time 
and, consequently, increased drug absorption (45, 52). Notwithstanding the relevance of 
the advantages mentioned above, some drawbacks should also be taken into account, 
such as the possibility of generating immunogenic responses and the polymer variability 
related to origin and supplier (47). Regarding the latter, plant-derived polysaccharides 
pose potential challenges, as structural differences might occur according to the location 
and plant collection season (46).  
As understood from what is described above, although polysaccharides have been 
traditionally included in formulations as inert materials, modern pharmaceutical design 
involves these excipients in increasingly relevant roles. In this manner, their application 
usually intends to endow the dosage forms with multi-functional abilities, such as 
controlled release, stabilization, emulsification or bioadhesiveness, among others (46, 48). 
Nevertheless, the set of polysaccharide properties confers a relevant versatility that adds 
to a wide range of biological abilities, thus generally contributing to an increased 
application in drug carrier production.  
The application of polysaccharides in the production of nanoparticles by polyelectrolyte 
complexation or ionic gelation is widely reported (34, 38-40, 56, 57). As these methods 
require hydrophilic materials that exhibit opposite charges, in addition to an absence of 
toxicity, chitosan is the only natural polycationic polysaccharide that satisfies these needs 
(52). On the contrary, there are many negatively charged polysaccharides that can be 
used for this end, including alginate, hyaluronic acid, dextran sulfate, chondroitin sulfate 
and carrageenan, among many others. However, the interest on using other materials that 
do not exhibit charge has also been demonstrated occasionally and, in this regard, the 
synthesis of charged derivatives of these polysaccharides has been reported to serve the 
strategy, as described for pullulan (58, 59). 
Below, the general characteristics of the polysaccharides locust bean gum and chitosan, 
which were used in this work to produce nanoparticles by polyelectrolyte complexation, 
are detailed. 
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1.1.2.1. Locust bean gum 
Locust bean gum (LBG) is a non-starch polysaccharide, mainly comprised of a high 
molecular weight (approximately 50 000 – 3 000 000 Da) neutral galactomannan 
consisting in a linear chain of (1-4)-linked -D-mannopyranosyl units with (1-6)-linked -D-
galactopyranosyl residues as side chains (60), as depicted in Figure 1.2.  
 
 
Figure 1.2 – Chemical structure of locust bean gum. 
 
The polysaccharide is extracted from the seeds of the carob tree (Ceratonia siliqua), 
where it acts as a reserve material utilized during germination. It is also referred in the 
literature by several other synonyms, such as carob bean gum, carob seed gum, carob 
flour or even ceratonia (61) and consists in a white to yellowish white, nearly odorless, 
powder. The carob is a large tree that grows to about 10 m high in 10-15 years, and starts 
to bear good quantities of pods around this age, although it may not be fully grown until it 
is 50 years old. It is very abundant in the Mediterranean region, although its location also 
extends to various regions of North Africa, South America, and Asia. Its fruit is a long 
brown pod containing very hard brown seeds, the kernels, which represent approximately 
10% of the weight of the fruit. In the processing of carob gum, these seeds are first 
dehusked by treating the kernels with dilute sulfuric acid or with a thermal mechanical 
treatment. The seeds are then split lengthwise and the germ portion is separated from the 
endosperm. Following, the isolated endosperm (42-46% of the seed weight) undergoes 
grinding, sifting, grading, and packaging (native LBG). The gum may still be simply 
washed with ethanol or isopropanol to control the biological load (washed LBG) or be 
further clarified by dispersion in hot water, recovery by precipitation with isopropanol or 
ethanol, filtering, drying and milling (clarified LBG). The clarified gum has higher 
galactomannan content, and no longer contains the cell structure. The commercial 
samples of LBG contain approximately 80-85% galactomannan, 5-12% moisture, 1.7-5% 
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acid-soluble matter, 0.4-1% ash, and 3-7% protein; the samples of clarified LBG contain 
approximately 3-10% moisture, 0.1-3% acid-soluble matter, 0.1-1% ash, and 0.1-0.7% 
protein (60, 62-64).  
Galactomannans include several polysaccharides, such as LBG, guar gum and tara gum, 
which mainly differ in the mannose/galactose (M/G) ratio and the substitution pattern of 
side-chain units. The M/G ratio varies depending on the distribution of the galactose units 
over the mannose backbone, being approximately 4:1 for LBG, as results from reported 
mannose and galactose contents varying within 73-86% and 27-14%, respectively (60, 
65). This is an approximate ratio, as it is strongly affected by the varying origins of the 
polymer and plant growth conditions during production (46). This ratio is the main 
characteristic affecting galactomannans solubility, as higher water solubility is afforded by 
higher galactose content (66), because it introduces an entropic and a steric barrier to the 
ordered packing of mannose segments that leads to aggregate formation (67). Galactose 
grafts to the mannose chain are known to not be spaced regularly, instead assuming 
random locations on the linear backbone and leading to low-substituted (“smooth”) and 
densely-substituted (“hairy”) zones (68). These low-substituted blocks of the backbone 
permit, consequently, the formation of strong intramolecular hydrogen bonds that reduce 
the hydration of the gum (69). Displaying an M/G ratio of approximately 4:1, LBG presents 
limited solubility, having propensity to form aggregates in cold water, as the long 
segments of unsubstituted mannose, which can be as large as 50 mannose units, are 
prone to undergo aggregation (47, 67, 69). LBG forms very viscous solutions at relatively 
low concentrations (70). When in solution, galactomannans have an extended rod-like 
conformation and occupy a large volume of gyration. In a process dependent on the 
molecular weight, these gyrating molecules collide with each other and with clusters of 
solvent molecules to produce solutions of high viscosity (69). Being non-ionic in nature, 
LBG viscosity and solubility are little affected by pH changes within the range of 3-11, as 
well as by the addition of salts (62, 63). In this context, chemical modifications of 
galactomannans to perform carboxylation, hydroxylalkylation and phosphorylation have 
been approached to overcome solubility limitations (71, 72).  
Plant resources are renewable and, therefore, one of their important advantages relies on 
the possibility to have constant material supply, which is ensured if the plants are 
cultivated or harvested in a sustainable manner. However, plant-based materials also 
pose potential challenges that include the production of small quantities that may present 
structural differences depending on the location of the plants from which they originate, as 
well as the collecting season. In this context, several studies have evidenced that the 
chemical structure and molecular weight of LBG vary systematically with the type of 
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cultivar and growth conditions (46, 47). Furthermore, dehulling and milling processes, as 
well as dissolution temperature, are reported to influence the chemical (mannose and 
galactose content) and rheological properties of LBG (47, 68, 73, 74). This probably 
justifies, at least in part, why LBG is considered polydisperse from a chemical point of 
view, presenting three types of structural variation: 1) degree of galactose substitution, 2) 
patterning of galactose side groups and 3) chain length; all directly related with 
biosynthesis mechanisms (47). This is possibly one of the major limitations compromising 
a more frequent application of LBG in the pharmaceutical field. LBG is Generally 
Recognized as Safe (GRAS) by the Food and Drug Administration (FDA) and is approved 
in most areas of the world (European Union, United States of America, Japan, Australia, 
etc.), being used as thickening, gelling and stabilizing agent in both food and cosmetic 
industries (75, 76). In food industry it is a food additive, coded as E-410 in the European 
Union (77). Recently it has been indicated as a very useful excipient for pharmaceutical 
applications mainly due to its ability as controlled release excipient in tablets. However, 
other relevant properties and abilities have been demonstrated which contribute for its 
increasing use. The synergistic interaction between xanthan gum and LBG leading to the 
formation of thermally reversible gels is well-known. This effect has been ascribed to a 
denaturant effect of LBG that disturbs the helix-coil equilibrium of xanthan, displacing it 
from an ordered conformation to a more flexible one, facilitating the formation of 
heterotopic junctions between both polymers (78). A mucoadhesive behaviour has been 
indicated for this polysaccharide (79), although of lower potency comparing with others 
like chitosan. Additionally, there are indications on LBG biodegradability (64, 75), 
especially if administered orally, as enzymatic degradation mediated by β-mannanase (80, 
81) or colonic bacteria (82) is expected to occur. Low toxicity and availability at low cost 
(75, 76, 83) have also been referred, contributing for the increased interest on the 
polymer. 
 
1.1.2.1. Chitosan 
Chitosan is a (1–4)-linked 2-amino-2-deoxy-β-D-glucan (Figure 1.3) that is obtained from 
the deacetylation of chitin, the second most abundant natural polymer after cellulose (84). 
The most usual source of chitin is the exoskeleton of crustaceans, but it exists in insects 
and fungi. Despite the widespread occurrence, up to now the main commercial sources of 
chitin have been crab and shrimp shells. Chitosan is the polymer considered to be 
obtained when chitin is deacetylated to such a degree that it becomes completely soluble 
in dilute aqueous acidic systems (85). The partial deacetylation is performed under 
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alkaline conditions (86) and results in the appearance of primary amino groups (87). 
Chitosan has also been reported to be obtained through biotechnological processes (88, 
89). As shown in Figure 3, this polysaccharide is composed of repeating units of N-
acetylglucosamine and D-glucosamine. Contrary to most polysaccharides, such as agar, 
dextran, pectin, cellulose and agarose, which are acidic in nature, chitin and chitosan are 
basic polysaccharides (90).  
 
 
Figure 1.3 – Chemical structure of chitosan. 
 
Chitosan comprises a series of polymers with different molecular weight and degree of 
deacetylation, characteristics which have been proving determinant in its behaviour (84, 
85). Although these features are determined by the conditions selected during 
preparation/extraction of polymers, they can be further modified at a later stage. For 
example, the deacetylation degree can be lowered by reacetylation (91) and the molecular 
weight can be lowered by acidic depolymerization (92).  
In fact, the main difference between chitin and chitosan is the number of acetyl groups. 
Although it is apparently a small difference, it turns to important variances in 
physicochemical properties, including solubility (chitin is insoluble in water and in the most 
common organic solvents and, hence, not useful for pharmaceutical purposes, whereas 
chitosan is soluble in acidic solutions), biodegradability and mucoadhesive capacity (93, 
94). Displaying a pKa of approximately 6.5, chitosan is insoluble in water and solutions of 
alkaline pH, while it becomes soluble in aqueous acidic solutions due to the protonation of 
most amino groups (89). This behaviour has been referred in some occasions to strongly 
affect the biomedical applications of the polymer, because it is insoluble at physiological 
pH (7.4), but it is a fact that it has been often demonstrated that chitosan-based 
formulations improve the therapeutic effect of the associated macromolecules, upon in 
vivo administration through physiological routes (24, 93, 95-99). This demonstrates that 
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the presence of chitosan in the site of action as a dissolved form is not a critical issue 
regarding the therapeutic action of the carried molecules, although it is certainly decisive 
in the preparation of formulations. Directly regarding the influence of deacetylation degree 
on solubility, highly deacetylated chitosans (85% or more) are readily soluble in solutions 
with pH up to 6.5 (94).  
Chitosan is included in marketed dietary supplements, as it attaches to fat and prevents 
its absorption, inducing weight loss (100). It is well known as a non-toxic, biocompatible 
and biodegradable polymer (101, 102), characteristics that render it very attractive for the 
biomedical and pharmaceutical fields. Given the structural similarity to 
glycosaminoglycans, it has been widely proposed for biomedical applications, including 
wound healing and tissue engineering (89). Additionally, it has long been a reference in 
the field of drug delivery, mainly owing to the reported mucoadhesive properties (103) and 
the ability to enhance the permeability of drugs (23, 93, 95, 96, 98, 104-109). The 
electrostatic interactions occurring between cationic amino groups of chitosan and the 
negatively charged mucin have been reported as the main driving force for its strong 
mucoadhesion (110). There is, thus, a direct relation between mucoadhesive capacity and 
the deacetylation degree, because highly deacetylated chitosan has more positively 
charged amino groups available to mediate the interaction with the negatively charged 
mucus components, leading to increased mucoadhesion (107). This explains that most 
scientific research reporting the pharmaceutical application of chitosan is performed with 
highly deacetylated chitosan. The ability to improve the permeability of drug molecules is 
described to be related with both transcellular and paracellular transport. While in 
transcellular pathway the effect is mostly related with the mucoadhesive capacity, in the 
case of the paracellular route it is attributed to a specific interaction with tight junctions, 
leading to their transient opening (111). In the latter case, although it is suggested that the 
temporary disruption of tight junctions is due to multiple mechanisms, it was demonstrated 
that a specific type of transmembrane proteins (claudins) is possibly playing a major role 
(112). 
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1.2. Nanoparticle application in oral immunization 
1.2.1. General concepts in immunization 
The search for successful vaccination has become one of the driving forces of global 
health strategies, because it is an effective approach to overcome diseases, presenting 
low incidence of side effects and great preventive actions (113). Despite this, society, 
cultural and individual beliefs, along with concerns about adverse effects, led to the 
creation of anti-vaccine movements that resulted in disruptions and even cessation of 
vaccine programs. These occurrences have consequently led to increased morbidity and 
mortality (114, 115). 
The history of vaccination is plenty of attempts to treat numerous infectious diseases 
which are responsible for approximately 25% of global mortality, especially in children with 
age below five years (116, 117). The production of a successful vaccine is, however, 
devoid of triviality and requires a strong knowledge anchored on safety, feasibility, cost 
and, above all, demonstration of protective efficacy (Figure 1.4) (118). 
 
 
Figure 1.4 – Contribution of efficacy, safety, feasibility and cost to the development of 
vaccines (118). 
 
Several types of vaccines are available in the market, exhibiting varied degrees of 
immunogenicity, stability and safety (119): live attenuated, killed whole, toxoid, and 
component (subunit) vaccines (120). Live attenuated vaccines are usually created from 
the naturally occurring pathogen itself. These vaccines are prepared from strains that are 
almost or completely devoid of virulence, but are capable of inducing a protective immune 
response (121). This is due to their ability to multiply in the host and provide continuous 
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antigenic stimulation over a period of time, thus often requiring just a single boost (122). 
Nevertheless, the application of these vaccines comprises some limitations, which include 
the possibility to cause severe infections in immunocompromised individuals (120), high 
risk of reverting back to the virulent form (122), and the need for an effective cold chain for 
their distribution. The latter is a clear limitation to their application in developing countries, 
as these might lack the necessary infrastructure (123). Examples of live attenuated 
vaccines are smallpox, polio (Sabin), measles, mumps, rubella, varicella and adenovirus 
(119, 122). Inactivated (killed) vaccines (such as influenza, hepatitis A, polio (Salk)) (119, 
122) contain killed or inactivated microorganisms. These are not able to cause infection, 
but they are still able to stimulate a protective immune response, however usually 
requiring multiple doses to maintain immunity (122, 124). Toxoid vaccines consist in 
inactivated toxins but stimulate the production of neutralizing antibodies (tetanus, 
diphtheria) (122, 125). Subunit vaccines use a defined portion of the pathogen, such as 
proteins, peptides or nucleic acids (120, 122), and their interest mainly relies on the 
provided increased safety, as these cannot revert to a virulent form, as well as on the 
observed lack of contaminants remaining from the original pathogenic organism (122). 
Despite of this, the application of these formulations results in poor immunogenic effect 
when administered alone (120), demanding the use of an adjuvant in order to enhance the 
immunological response (122, 126). 
Adjuvants are a highly heterogeneous group of compounds which share the characteristic 
of providing a modulation or/and enhancement of immune response (127). The 
mechanism mediating the interaction of adjuvants with the immune system is highly 
variable, as is the type of induced immunomodulation process, which consists, in short, in 
Th1, Th2, Th3, Th17 or/and T regulatory mediated response. The Th1 subset is 
characterized by the secretion of cytokines such as interleukin 2 (IL-2) and interferon-γ 
(IFN-γ), to assist in cell-mediated immune response. The Th2 subset assists preferentially 
in antibody immune responses after secreting cytokines like interleukin 4 (IL-4) (120). Th3 
cells secrete interleukin 10 (IL-10) and/or transforming growth factor β (TGF-β), which are 
immunosuppressive cytokines that inhibit the proliferation of and cytokine production by 
effector T cells, including Th1 cells and Th2 cells (128). Th17 cells secrete interleukin 17 
and 22 (IL-17 and IL-22, respectively) and play an important role in host defense against 
bacterial and fungal infection, especially at mucosal surfaces (129). Several functions for 
regulatory T cells include are suggested, which include prevention of autoimmune 
diseases by maintaining self-tolerance; suppression of allergy, asthma and pathogen-
induced immunopathology; feto-maternal tolerance; and oral tolerance (130). Adjuvants 
are described to act through different mechanisms, including the formation of a depot for 
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the antigen, acting as an intermediate to target the antigen to immune cells, a mechanism 
that is assumed to occur when antigen delivery is mediated by particulate delivery 
systems, and even the stimulation of immune cells themselves (120, 131). Many 
compounds and strategies are described as adjuvants (120), but only aluminum-based 
mineral salt (alum), MF59 (an o/w emulsion composed of <250 nm droplets formed when 
squalene (4.3% v/v), polysorbate 80 (0.5% v/v) and sorbitan trioleate (0.5% v/v) are 
emulsified in citrate buffer), Adjuvant System 03 (AS03) (o/w emulsion + α tocopherol) 
and Adjuvant System 04 (AS04) (composed of monophosphoryl lipid A (MPLA) and alum) 
are approved for human usage (120, 122, 131, 132).  
In addition to the urgent need to develop vaccines for emerging diseases, such as Zika or 
Ebola, there are well-known infectious diseases like malaria, tuberculosis and acquired 
immune deficiency syndrome (AIDS), that are still lacking an effective vaccine (133-135). 
The Bacillus Calmette-Guérin (BCG) vaccine has been available for many years against 
tuberculosis and the first vaccine against malaria was approved in 2015, but they are both 
referred as having low-medium efficacy (134, 135). This evidences the need for innovative 
strategies to the development of effective vaccines. 
 
1.2.2. Oral immunization 
The majority of vaccines available nowadays are administered through injection. The need 
for this procedure increases general vaccination costs and requires trained personnel to 
perform the administration, apart from being painful and uncomfortable, which often 
results in diminished patient compliance. In addition, the administration itself presents 
safety risks related to infection, needle reuse and disposal (119, 136), not to mention the 
need for cold-chain distribution (123). Oral vaccination emerges, in this context, as a 
strategy to overcome some of the mentioned drawbacks, benefiting from the general 
advantages of oral administration, but also basing its success on specific immune features 
of the intestine which revealed crucial for immunization. Table 1.3 presents the main 
advantages and disadvantages of oral administration. 
Contrary to parenteral immunization, which is mainly effective at producing systemic 
immune responses, oral vaccines elicit both systemic and mucosal immunity, further 
providing much higher patient’s compliance and being more easily distributed, which is 
relevant for developing countries (119, 137, 138). Additionally, it is estimated that 90% of 
all mammalian infections originate at mucosal surfaces and, thus, mucosal sites are the 
primary access locations for most human pathogens (138). This reinforces the relevance 
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of inducing mucosal immunity towards limiting or preventing pathogen entry, thereby 
avoiding infection (139, 140). 
 
Table 1.3 – Advantages and disadvantages of oral administration (141). 
Advantages Disadvantages 
Large surface area offered for drug 
absorption (200 m2) 
Acidic gastric environment 
Readily accessible and non-invasive High metabolic activity 
Rich blood supply Drug diffusion limited by mucus barrier and 
intestinal motility 
Ease of administration Low permeability of epithelium 
Possibility of prolonged retention Possibility of food interaction 
Patient acceptance and compliance Individual variability 
 Tolerogenicity 
 
Notwithstanding the importance of the above considerations, oral vaccine delivery faces 
the major challenge of antigen uptake, as the intestine is designed to prevent invasion of 
foreign molecules, via epithelial tight junctions and high levels of enzymatic activity (142). 
In addition, many microbial antigens are hydrophilic molecules, thus having low epithelial 
permeability (8). As a result, the fate of many orally administered vaccines is 
gastrointestinal degradation, requiring high antigen doses or several repeated 
administrations to supply sufficient antigen for the induction of immune protection (126). In 
this context, and further considering the poor immunogenic activity of antigens 
administered through the oral route, the association of these macromolecules with 
nanoparticulate carrier systems has been demonstrating to be a promising approach, 
eliciting adequate immune responses (143). 
However, there is still an important barrier to overcome, consisting in the constant 
intestinal fluid secretion, that may cause rapid removal of the applied delivery vehicles. It 
has, therefore, been proposed in several occasions that intestinal immunization could be 
improved by the use of appropriate bioadhesins, such as lectins, that bind specifically to 
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the mucosal surface and increase the carrier/antigen residence time (144). The decoration 
with suitable ligands could, in addition, mediate specific recognition by receptors on 
antigen presenting or sampling cells that direct the type and intensity of the subsequent 
immune response (145). 
The immune response takes place, for example, in the course of an infection. It starts with 
an attraction of leukocytes to the infected region and interaction of the pathogen with the 
immune cells driven by pathogen-associated molecular pattern (PAMP) molecules, which 
have characteristic molecular patterns of infectious agents. These molecules are 
recognized by innate immune receptors called pattern recognition receptors (PRR) 
present on epithelial cells and antigen-presenting cells (APCs) and cause cell activation 
and subsequent migration (146). Toll-like receptors (TLRs) and C-type lectin receptors are 
the PRR families most involved in immune responses (147). While the former are 
expressed either on the cell surface or inside the endosomes (148), the latter are 
expressed on cell surface (149). Table 1.4 presents the different TLRs and their specific 
ligands. 
 
Table 1.4 – Toll-like receptors (TLRs) and their specific ligands (150). 
TLRs Ligands 
TLR-1/ TLR-2 Triacylated lipopeptides 
TLR-2/ TLR-6 Diacylated lipopeptides 
TLR-3 Viral dsRNA 
TLR-4 Lipopolysaccharide 
TLR-5 Flagellin 
TLR-7 Viral ssRNA 
TLR-8 Viral ssRNA 
TLR-9 Bacterial or viral CpG DNA 
TLR-11 Profilin 
TLR-10, 12, 13 Unknown 
CpG DNA: cytosine – phosphate – guanine deoxyribonucleic acid; 
dsRNA: double-stranded ribonucleic acid; ssRNA: single-stranded 
ribonucleic acid  
 
C-type lectin receptors are a set of cell surface receptors that are specialized on the 
recognition of carbohydrate molecules, including mannose, N-acetylglucosamine, L-
fucose, glucose and galactosamine, among others (151), as depicted in Table 1.5. 
General introduction 
 
21 
 
Table 1.5 – Some of the most frequent C-type lectins and their specific ligands (152, 153). 
C-type lectin  Ligands 
Mannose receptor Mannose, fucose, N-acetylglucosamine 
Dectin-1 β-Glucan 
Dectin-2 Mannose 
DC-SIGN Mannose, ICAM-3 
MBL Mannose, glucose, L-fucose, ManNAc, GlcNAc 
SP-A Glucose, mannose, L-fucose, ManNAc 
SP-D Glucose, mannose, maltose, inositol 
DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; 
GlcNAc: N-acetylglucosamine; ICAM-3: Intercellular adhesion molecule 3; ManNAc : N-
acetylmannosamine; MBL: mannose-binding lectin; SP-A: surfactant protein A; SP-D: surfactant 
protein D 
 
 
The professional APCs comprise B lymphocytes, macrophages and dendritic cells (DCs) 
(136, 154), being the latter essential in generating the adaptive response. DCs uptake 
antigens, frequently with mediation of the mannose receptor, also known as CD206, that 
is overexpressed in their surface (155), and initiate a cascade of events that in most cases 
ends up with the elimination of pathogens. The antigens are degraded into peptides and 
these are presented on DCs surface using specific receptors of the major 
histocompatibility complex (MHC) I or II. While processing antigens, DCs initiate their 
maturation process and migrate to the lymph nodes, where they present the antigen 
(known as signal 1) and costimulatory signals (known as signal 2) to T cells (146). The 
antigen is presented together with the MHC of DCs to the T cell receptors (TCRs), while 
the costimulatory signals are the interaction of CD80 and CD86 DCs co-stimulatory 
molecules with CD28 T cell receptor. DCs mostly express CD80 and CD86 co-stimulatory 
molecules when capturing an antigen PAMP-related, which demonstrates the danger 
associated to that antigen. When DCs present the antigen to T cells without these 
costimulatory signals, T cell anergy (tolerance mechanism) to that antigen occurs (150, 
156). The antigens presented by DCs through the MHC-I are recognized by CD8+ T cells 
which are then converted into cytotoxic T cells, giving rise to a cell-cytotoxic immune 
response. Once activated, the cytotoxic T cells are responsible for lysing infected cells, 
thereby avoiding the growth of the microorganism. Furthermore, antigens presented by 
MHC-II are recognized by CD4+ T cells, which differentiate in T helper (Th) cells. These 
cells promote, by releasing specific cytokines, both the cellular immune response and 
antibody response (120, 146). In turn, the B cells recognize extracellular antigens through 
immunoglobulins (Ig) present on their surface, causing their activation. B cells, aided by 
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Th cells, undergo extensive proliferation and generate both high-affinity memory B cells 
and long-lived plasma cells (157), the latter being capable to secrete large amounts of 
specific antibody (158). During this process, memory T and B cells are produced, which 
can quickly proliferate and eliminate the infecting agent (146). 
Immune responses occurring in the intestinal area are mediated by the so called gut-
associated lymphoid tissue (GALT). This comprises diffusely-scattered cells in the lamina 
propria, intra-epithelial lymphocytes, isolated lymphoid follicles present throughout the 
intestine and, most importantly, Peyer's patches (PPs) (141, 159). The latter are the 
structures where immune cells of the intestinal mucosa are mainly located (154), being 
privileged targets for mucosal vaccination due to their crucial role in intestinal mucosal 
immunity (160). The immune cells from the PPs, such as the DCs, are separated from the 
lumen by the Follicle Associated Epithelium (FAE) (159), which is composed of 
enterocytes, goblet cells and microfold cells (M cells) (136, 154). Several works suggest 
that PPs are the predominant site of uptake of nano- and microparticles, a process in 
which the antigen-sampling M cells play an important role (136). The M cells are, 
however, present in a small number in the intestinal tract, representing only 1 out of 10 
million epithelial cells (approximately 5% in humans) (161). In parallel, they constitute 10–
30% of the epithelial cells of the FAE above the PPs (162). These cells are considered the 
main entrance for pathogens invading the organism (163, 164) and are characterized by a 
disorganized brush border and a reduced mucus layer at the apical side, because in FAE 
there are less mucus secreting goblet cells than on the rest of the intestinal epithelium 
(165, 166). Furthermore, M cells contain small cytoplasmatic vesicles, few lysosomes and 
short microvilli (136, 159), and there is evidence that they can transport the antigen 
without any degradation, even in the absence of a protective carrier (167). Importantly, 
although the clear existence of a mannose receptor has not been described yet, M cells 
have been reported to favorably recognize mannose units and mannosylated carriers 
have been described to target M cells (80, 168, 169). The basolateral chamber of M cells 
is deeply invaginated forming a pocket hosting APCs: lymphocytes, macrophages and 
DCs (136, 154). These characteristics of M cells make them particularly suited for the task 
of antigen uptake, because they favor antigen interactions with the apical membrane, 
provide optimized antigen endocytosis, shorten and facilitate antigen access to the 
basolateral compartment, and finally favor rapid and straightforward interactions between 
immune cells and APCs that are present at the basal side (154). Therefore, M cells have 
been signaled as potentials targets to take into account in the design of oral vaccination 
strategies. 
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1.2.3. The role of nanoparticles: Locust bean gum as potential adjuvant 
Polymeric nanoparticles have been demonstrating to be very promising in oral delivery of 
biopharmaceuticals, as many works report their effective role in the enhancement of oral 
drug bioavailability by facilitating cell internalization (19, 170). Their reduced size provides 
an intimate contact with epithelia and, in several occasions, they have shown the capacity 
to carry the encapsulated molecules through the epithelium (8, 19).  
With respect to oral vaccination, the design of suitable antigen delivery systems should 
focus on optimizing antigen association efficiency, ensuring the maintenance of its stability 
during association, tailoring release kinetics and eliciting high levels of long-lasting 
antibody and cellular immune responses. Nanoparticles may provide extra benefits in oral 
immunization strategies, because PPs have shown to be a predominant site for uptake of 
particulates (136). Given their role in intestinal mediated immunization, M cells are the 
primary targets to consider and it has been demonstrated that particle uptake depends on 
various factors, such as particle size, surface charge, concentration, stability and ligand 
conjugation (170). In this context, it is important to highlight that nanoparticles have been 
showing to be better taken up by M cells as compared to microparticles (171-173). Once 
M cell uptake is observed, subsequent uptake by professional APCs, such as 
macrophages and DCs, is expected to occur, mediating the following immune response. 
Importantly, a great advantage of formulating antigens in nanocarriers lies in the 
exploitation of the intrinsic capacity of the referred phagocytic cells (macrophages, DCs, 
etc.), located in the PPs, to internalize foreign particulate materials (174). Another 
remarkable issue comes from studies on mucosal vaccination that have demonstrated 
that particulate antigens are often more immunogenic than antigens in solution, under the 
indication that particulate antigens are more likely to be trafficked across the mucosa and 
taken up by APCs (175).  
A careful selection of nanoparticle matrix materials might further help on the potentiation 
of an immune response. In this context, mucoadhesive polymers may help on the 
prolongation on the intestinal residence time (176), potentiating the uptake by M cells. 
Importantly, the physicochemical characteristics of polymeric nanoparticles can be 
modulated by tuning polymer properties and surface chemistry, while their specificity may 
also be augmented by surface ligand conjugation (15). LBG, one of the polysaccharides 
used in this work for nanoparticle production, may contribute in a strong manner for the 
improvement of nanoparticle abilities regarding an application in oral immunization 
mediated by nanoparticles. The greatest potentiality that is identified comes from the 
proper chemical structure, which is composed of mannose and galactose residues. Given 
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the favorable contact with mannose residues, mentioned above, LBG might act as vector 
with preferential targeting ability towards these cells. Furthermore, it has mucoadhesive 
characteristics (79), although these are not as significant as those described for chitosan, 
which is the other polysaccharide used as matrix material in nanoparticle production. 
Finally, as dendritic cells are described to express mannose receptors (155), LBG 
nanoparticles are also expected to have a privileged contact with these cells, after being 
sampled by M cells. 
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2. Motivations and Objectives 
Successful vaccination approaches are required to face some of the most threatening 
diseases worldwide. Additionally, as many of the most concerning situations occur in 
developing countries, alternatives to the parenteral administration, that has costly 
requirements (cold chain, sterility, skilled personnel, etc.), are demanded (119, 123, 136). 
Oral immunization has thus been reaching a position of evidence in this regard, not only 
because the oral route is the main port of entry of pathogens and permits easy 
administration (138), but also due to specific structural abilities of the intestinal area 
(Peyer’s patches, M cells, antigen presenting cells) regarding immunization approaches 
(136, 154). Some of these structures are known to establish a preferential contact with 
particulates (136). Therefore, the use of nanoparticles as antigen carriers has been 
proposed as a valuable strategy to induce immunological responses. These nanoparticles 
may be further functionalized or display in their structure moieties that provide an extra 
improvement of the targeting ability. In this regard, the use of locust bean gum (LBG) as 
matrix material may contribute for the improvement of nanoparticle abilities regarding oral 
immunization due to the mannose content that mediates a privileged contact with M cells 
and dendritic cells (80, 155, 169). Mucoadhesive materials may also be beneficial, 
providing prolonged intestinal residence time (176), and thus, potentiating the uptake by M 
cells. LBG has been reported to exhibit mucoadhesive characteristics (79), although other 
polysaccharides, like chitosan, are known to display much stronger mucoadhesiveness 
(103).  
Taking into account the motivations referred above, this work is aimed at producing 
nanoparticles based on LBG for an application in oral immunization. To demonstrate the 
feasibility of the approach, Salmonella Enteritidis antigenic complex (HE) and ovalbumin 
(OVA) were used as model antigens.  
To accomplish the referred general objective, several partial objectives were considered, 
which are disclosed below: 
1) To synthesize charged derivatives of LBG (sulfated, carboxylated and ammonium) and 
confirm the effective derivatization using adequate techniques; 
2) To produce LBG-based nanoparticles by polyelectrolyte complexation and select a 
formulation with suitable properties for antigen association and application as carrier in 
oral immunization; 
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3) To associate the model antigens HE and OVA and investigate their release profile in 
media relevant for oral delivery applications; 
4) To evaluate the cytotoxicity of the synthesized LBG derivatives and LBG-based 
nanoparticles in human intestinal epithelial cells (Caco-2); 
5) To evaluate in vivo the immunological response to a selected formulation of LBG-based 
nanoparticles associating the model antigens individually. 
In this manner, it is expected to develop a natural, biocompatible polymeric 
nanoparticulate system which displays ability for the efficient association of antigens and 
suitable physicochemical properties for an application in oral vaccination. 
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LOCUST BEAN GUM DERIVATIVES AND 
PRODUCTION OF NANOPARTICLES 
 
 
 
 
 
 
 
 
 
The information presented in this chapter was submitted for publication in Carbohydrate 
Polymers: 
Braz, L., Grenha, A., Corvo, M., Lourenço, J.P., Ferreira, D., Sarmento, B., Rosa da 
Costa, A.M. Synthesis and characterization of Locust Bean Gum derivatives and their 
application in the production of nanoparticles, submitted for publication 
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3. Synthesis and characterization of Locust Bean Gum derivatives and their 
application in the production of nanoparticles 
3.1. Introduction 
Biopolymers, among them polysaccharides, are an attractive class of polymers, as they 
are derived from natural sources, normally easily available, relatively cheap, many times 
biodegradable, and that can be modified by suitable chemical reagents. The most 
common basic unit of polysaccharides is the monosaccharide D-glucose, although D-
fructose, D-galactose, L-galactose, D-mannose, L-arabinose, D-xylose, and the amino 
sugars D-glucosamine and D-galactosamine, as well as simple sugar acids, like 
glucuronic acid and iduronic acid, and sulfated monosaccharides are also frequently 
present (62).   
Locust bean gum (LBG), also known as carob bean gum, is obtained from the endosperm 
of carob tree (Ceratonia siliqua) seeds, where it is a reserve material. The tree is very 
abundant in the Mediterranean region, including the Algarve. The gum corresponds to a 
galactomannan, and commercial samples of LBG contain approximately 80-85% 
galactomannan, while the remaining content is ascribed to proteins and impurities. LBG is 
reported as biocompatible, biosorbable, biodegradable, non-teratogenic and non-
mutagenic, and its degradation products are excreted readily. Classified by the FDA as 
GRAS material, it is approved in most areas of the world for use in the food industry as 
thickener, stabilizer, emulsifier, and gelling agent (E410), as well as in the pharmaceutical 
industry as excipient in drug formulations, and in biomedical applications (60, 62-64). LBG 
is mainly comprised of a high molecular weight (approximately 50 000 – 3 000 000 Da) 
neutral galactomannan consisting in a linear chain of (1-4)-linked -D-mannopyranosyl 
units with (1-6)-linked -D-galactopyranosyl residues as side chains. The mannose and 
galactose contents have been reported to be 73-86% and 27-14%, respectively, which 
corresponds to a mannose:galactose (M/G) ratio of approximately 4:1 (60). For that 
reason, and in spite of the uneven distribution of galactose units along the mannose 
backbone, leading to low-substituted (“smooth”) and densely-substituted (“hairy”) zones 
(68), LBG is typically represented as shown in Figure 1.2 (chapter 1, general 
introduction). Being non-ionic in nature, its viscosity and solubility are little affected by pH 
changes within the range of 3-11, as well as by the addition of salts (62, 63). 
Recently, there has been a growing interest in the chemical functionalization of 
polysaccharides, particularly those non-animal derived, mainly by making use of the free 
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hydroxyl groups distributed along their backbone, in order to create derivatives with 
tailored properties for desired applications (48). Carboxymethylation of polysaccharides is 
a well-known etherification process achieved by reaction with monochloroacetic acid, and 
leading to products with a variety of promising properties, like increased hydrophilicity, 
water solubility, and solution clarity. Carboxymethyl cellulose, guar gum, LBG, and 
xanthan gum have been successfully used in the production of novel drug delivery 
systems, like beads, microparticles, and nanoparticles (177). The sodium carboxymethyl 
ether of LBG was combined with polyvinyl alcohol (PVA) for the production of 
interpenetrating polymer network (IPN) hydrogel microspheres of buflomedil 
hydrochloride, regarding a controlled drug delivery (178). The introduction of carboxyl 
groups in a galactomannan isolated from the seeds of Leucaema leucocephala, with an 
M/G ratio around 1.3, was successfully performed using 2,2,6,6-tetramethylpiperidine-1-
oxyl (TEMPO) as oxidizing agent. This reagent acts by oxidizing the free C-6 position of 
the monosaccharide units, which, in this case, was demonstrated to be more effective on 
the mannopyranose units than on the galactose ones. As expected, the modified polymer, 
an anionic polyelectrolyte, showed greater water solubility than the original material. The 
fact that in the course of this oxidation reaction aldehyde groups form as intermediate, 
allowed the obtainment of an amphiphilic polymer by reductive amination with an amine 
bearing a long alkyl chain (179). Cellulose (180) and cashew gum (181) were also 
converted in the corresponding polyuronic acids by the above method. Sulfated LBG 
derivatives with various degrees of substitution were obtained by the chlorosulfonic 
acid/pyridine method, which presented significant chain stiffness, due to the electrostatic 
effect (182).  A mixed carboxymethyl sulfate derivative of LBG was prepared by carrying 
out a sulfation reaction with SO3.DMF complex followed by carboxymethylation. Ionotropic 
gelation of this LBG derivative induced by basic aluminum chloride in the presence the 
potent analgesic tramadol hydrochloride, led to the formation of hydrogel beads 
incorporating the drug. These hydrogels disintegrated very quickly in an acidic solution, 
liberating almost all of their content in 15 min, thus constituting a promising system for 
immediate dosage release formulations leading to instant analgesic action (183).  
In this chapter, the chemical modification of LBG, aiming at the obtainment of charged 
derivatives intended for the development of nanoparticulate carriers by polyelectrolyte 
complexation, is described. Two anionic (sulfate and carboxylate) and one cationic 
(trimethylammonium) derivatives were prepared. The former two were obtained by an 
adaptation of a method applied in the sulfation of other polysaccharides, using an 
SO3DMF complex as sulfating agent (184), and using the above described oxidizing 
agent TEMPO (179), respectively. The latter was synthesized by reaction with the 
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alkylating agent glycidyltrimethylammonium chloride (GTMAC), adapting a described 
procedure (185). 
 
3.2. Materials and methods 
3.2.1. Materials 
Locust bean gum (LBG) was a kind gift from Industrial Farense (Faro, Portugal). Chitosan 
(CS, low molecular weight, deacetylation degree = 75 – 85%), glacial acetic acid, 
chlorosulfuric acid (HClSO3), dimethylformamide (DMF), N-glycidyl-N,N,N-
trimethylammonium chloride (GTMAC), sodium hydroxide (NaOH), potassium hydroxide 
(KOH), 2,2,6,6-tetramethypiperidine-1-oxyl (TEMPO), sodium bromide (NaBr), sodium 
hypochlorite solution (NaClO), sodium borohydride (NaBH4), sodium nitrate (NaNO3), 
sodium dihydrogen phosphate (NaH2PO4), sodium azide (NaN3), dialysis tubing (pore size 
2000 Da), phosphotungstate dibasic hydrate, glycerol, phosphate buffered saline (PBS) 
pH 7.4 tablets, Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin 
(10000 units/mL, 10000 µg/mL), non-essential amino acids, L-glutamine 200 mM, trypsin-
EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), trypan blue solution (0.4%), thiazolyl blue 
tetrazolium bromide (MTT), lactate dehydrogenase (LDH) kit, sodium dodecyl sulfate 
(SDS), dimethyl sulfoxide (DMSO), hydrochloric acid (HCl 37%), sodium chloride (NaCl) 
and potassium dihydrogen phosphate (KH2PO4) were purchased from Sigma-Aldrich 
(Germany). Ethanol was supplied by VWR. Potassium bromide (KBr) was obtained from 
Riedel-del-Haën (Germany). Fetal bovine serum (FBS) was obtained from Gibco (USA). 
Ultrapure water (Mili-Q Plus, Milipore Iberica, Madrid, Spain) was used throughout. All 
other chemicals were reagent grade. 
 
3.2.2. Cell line 
The Caco-2 cell line was obtained from the American Type Culture Collection (Rockville, 
USA) and used between passages 77-93. Cell cultures were grown in 75 cm2 flasks in a 
humidified 5% CO2/95% atmospheric air incubator at 37 ºC. Cell culture medium was 
DMEM supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine solution, 1% (v/v) non-
essential amino acids solution and 1% (v/v) penicillin/streptomycin. Medium was changed 
every 2-3 days and cells were subcultured weekly. 
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3.2.3. Synthesis of Locust Bean Gum derivatives 
3.2.3.1. Purification of Locust Bean Gum 
The purification of LBG envisaged the removal of the protein content (3-7%) commonly 
present in commercial samples (60). To do so, a standard procedure was followed (73, 
78), in which LBG (5.0 g) was slowly dispersed in distilled water (1000 mL) previously 
heated to 85 ºC, the dispersion being stirred for 1h. Then, the dispersion was cooled to 
room temperature and, subsequently, centrifuged (22 000 x g, 20 ºC, 1 h). The 
supernatant was collected and added to an equal volume of ethanol. The precipitate was 
collected by vacuum filtration and added again to an equal volume of ethanol. After 
subsequent collection by vacuum filtration, the precipitate was dried in a vacuum oven at 
30 ºC during 72 h affording 3.9 g of white powder. The residue was grinded and stored 
until further use.  
 
3.2.3.2. Sulfation of Locust Bean Gum  
Sulfation of LBG was performed by a method established for the sulfation of other 
polysaccharides (184). 
The sulfation agent, SO3.DMF, was prepared by slowly dropping 5 mL of HClSO3 into 25 
mL of stirred DMF under cooling in an ice water bath,  and continuing the stirring for 1.5 h. 
The obtained solution was stored in the refrigerator until further use. 
 
Method 1 
Purified LBG (500 mg) was dispersed in DMF (35 mL) and stirred at 60 ºC for 30 min, in 
order to provide the dispersion of LBG into the solvent. Then, the SO3.DMF complex was 
added (9.3 mL) and the mixture reacted for 4 h under magnetic stirring. Subsequently, the 
mixture was cooled down to room temperature in an ice bath, neutralized with 30% NaOH 
solution until precipitation, and concentrated under reduced pressure at 60 ºC to 
evaporate the solvent. The residue was dissolved in distilled water (30 mL) and dialyzed 
against distilled water (5 L). The water was changed every 24 h and, after 3 days, the 
solution was concentrated under reduced pressure at 40 ºC. Then, ethanol was added 
into the concentrated solution, in order to precipitate the solute, and the dispersion was 
concentrated under reduced pressure at 40 ºC. The previous step was repeated twice, 
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and the last evaporation was performed until full evaporation of the solvent. The obtained 
powder was dried in a vacuum oven at 40 ºC for 3 days, affording 407 mg of brownish 
powder that was grinded and stored until further use. 
 
Method 2 
Purified LBG (500 mg) was slowly dispersed in distilled water (100 mL) previously heated 
to 85 ºC, and the dispersion was stirred for 1 h. After that time, the dispersion was cooled 
to room temperature and poured into an equal volume of ethanol. The precipitate was 
collected, added to DMF (300 mL) and centrifuged (22 000 x g, 20 ºC, 20 min). The 
precipitate was recovered and added to DMF (100 mL), resting overnight. This dispersion 
was then filtered and the residue was again added to DMF (35 mL), this new mixture 
being stirred at 60 ºC for 30 min, in order to provide the dispersion of LBG into the solvent. 
Then, the SO3.DMF complex was added (9.3 mL) and the mixture reacted for 4 h under 
magnetic stirring. Subsequently, the mixture was cooled down to room temperature in an 
ice bath, neutralized with 30% NaOH solution until precipitation, and concentrated under 
reduced pressure at 60 ºC to evaporate the solvent. The residue was dissolved in distilled 
water (30 mL) and dialyzed against distilled water (5 L). The water was changed every 24 
h and, after 3 days, the solution was concentrated under reduced pressure at 40 ºC. 
Then, ethanol was added into the concentrated solution, in order to precipitate the solute, 
and the dispersion was concentrated under reduced pressure at 40 ºC. The previous step 
was repeated twice, and the last evaporation was performed until full evaporation of the 
solvent. The obtained powder was dried in a vacuum oven at 40 ºC for 3 days, affording 
363 mg of brownish powder that was grinded and stored until further use. 
 
3.2.3.3. Carboxylation of Locust Bean Gum  
The carboxylation of LBG was performed by oxidation with TEMPO (179). Purified LBG 
(500 mg) was dissolved in 200 mL of distilled water under stirring at 80 ºC for 30 min. 
After cooling down, the volume was adjusted to 200 mL and the solution was cooled in an 
ice bath. Then, TEMPO (10 mg) and NaBr (50 mg) were added to the solution under 
stirring. A 15% sodium hypochlorite solution (3.0 mL) with pH adjusted to 9.3 with 2 M HCl 
solution was mixed with the polymer solution. The pH was maintained at 9.3 by addition of 
a 0.05 M aqueous NaOH solution for 4 h. To stop the reaction, sodium borohydride (75 
mg) was added and the solution was stirred for 45 min. Then the pH of the mixture was 
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adjusted to 8 by addition of HCl before precipitation by 2 volumes of ethanol in presence 
of NaCl (up to 10 g/L). The polymer was isolated by filtration under reduced pressure, 
washed several times with ethanol, filtered and dried in a vacuum oven at 30 ºC during 3 
days. A white powder (529 mg) was obtained, grinded and stored until further use. 
 
3.2.3.4. Quaternary ammonium salt of Locust Bean Gum 
The introduction of quaternary ammonium groups in LBG was achieved by alkylation with 
glycidyltrimethylammonium chloride (GTMAC), as follows (185): an aqueous solution (10 
mL) of KOH (0.550 g), was prepared in a round bottom flask, under stirring, at 60 ºC. 
Then, purified LBG (506 mg) and 3.72 mL of GTMAC were added. After 5 h, an equal 
amount of GTMAC was added to the mixture, which was allowed to react until the 
completion of 24 h. It was then diluted with 20 mL of miliQ water, allowed to cool down to 
room temperature, and neutralized with HCl (2M). The resulting solution was dialyzed for 
3 days, the water being replaced every 24 h. Then, the LBGA solution was concentrated 
under reduced pressure at 40 ºC and ethanol was added into the concentrated solution, in 
order to precipitate the solute. The dispersion was concentrated under reduced pressure 
at 40 ºC and ethanol was added again and evaporated under the same conditions until full 
evaporation of the solvent. The obtained powder was dried in a vacuum oven at 40 ºC for 
3 days, affording 423 mg of white powder that was grinded and stored until further use. 
 
3.2.4. Chemical characterization of Locust Bean Gum derivatives 
3.2.4.1. Fourier transform infrared (FTIR) spectroscopy 
For recording FTIR spectra of purified LBG and their derivatives, samples were grounded 
with KBr in a mortar and compressed into discs. For each spectrum, a 32-scan 
interferogram was collected in transmittance mode with a 4 cm-1 resolution in the 4,000-
400 cm-1 region. 
 
3.2.4.2. Elemental analysis 
Elemental analysis data were obtained in a Thermo Finnigan, FLASH EA 1112 Series (C, 
N, S) or in a Fisons Instruments, EA 1108 CHNS-O (O) elemental analyzer. 
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3.2.4.3. Nuclear magnetic resonance (NMR) spectroscopy 
All NMR spectra were acquired in a Bruker Avance III 400 spectrometer equipped with a 
temperature control unit and a pulse gradient unit capable of producing magnetic field 
pulsed gradients in the z-direction of 56.0 G/cm, operating at 400.15 MHz for hydrogen, 
100.61 MHz for carbon, using a multinuclear reverse 5 mm probe (TXI). The samples 
where dissolved in D2O. 1H NMR spectra were recorded with 8.22 KHz spectral window 
digitized with 64 K points. The 13C spectrum was recorded between 0 and 238 ppm using 
24,000 Hz spectral window digitized into 64 K points. 
 
3.2.4.4. GPC/SEC3 analysis 
Triple detection Gel Permeation Chromatography (GPC/SEC3) analysis was performed in 
a modular system constituted by a degasser, HPLC pump (K-1001) and RI detector (K-
2300) from Knauer, and a viscometer and RALLS from Viscotek (Trisec Dual Detector 
Model 270), using two PL aquagel-OH mixed 8 m, 300 x 7.5 mm columns. 
For purified LBG, LBGC and LBGS the eluent was 0.2 M NaNO3, 0.01M NaH2PO4, 0.1% 
w/v NaN3, pH=7, at 1mL/min; the samples were dissolved in the eluent at 1 mg/mL. For 
LBGA the eluent was 0.5 M NaNO3, 0.01M KH2PO4, 0.1% w/v NaN3, pH=2, at the same 
rate; the sample was dissolved at 1mg/mL in 10-2 M HCl. 
 
3.2.4.5. X-ray diffraction (XRD) 
Powder X‐ray diffractograms were recorded on a Panalytical X’Pert Pro diffractometer, 
operating at 45 kV and 35 mA. The patterns of the pristine and modified samples were 
recorded in the range 5‐45 degrees (2) with a step size of 0.0167 and a time per step of 
2 000 seconds, using CuK radiation filtered by Ni and an X’Celerator detector. Prior to 
the analysis, samples were reduced to a fine powder by grinding in a mortar. 
3.2.5. Production of Locust Bean Gum-based nanoparticles 
All nanoparticles were prepared by polyelectrolyte complexation method which consists in 
the electrostatic interaction between the positive and negative charges of the different 
polymers (35), as depicted in Figure 1.1 (chapter 1, general introduction). 
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3.2.5.1. CS/LBGS and CS/LBGC nanoparticles 
Five mass ratios of CS/LBGC (1:0.75; 1:1; 1:1.25; 1:1.5 and 1:2), and CS/LBGS (1:1; 
1:1.25; 1:1.5; 1:2 and 1:2.5) were used to prepare the nanoparticles by polyelectrolyte 
complexation. The stock solution of CS, dissolved in 1% (w/w) acetic acid, was prepared 
to reach a final concentration of 1.0 mg/mL, while those of LBGC and LBGS, dissolved in 
ultrapure water, had a final concentration of 2.0 mg/mL. The solutions were filtered with a 
0.45 µm filter prior to use. The formulations were prepared by slowly adding 1.8 mL of 
LBGC or LBGS to 1.0 mL of CS under gentle magnetic stirring at room temperature, as 
shown in Figure 1.1 (chapter 1, general introduction). The concentration of CS was kept 
constant at 1.0 mg/mL for the preparation of all formulations, while that of LBGC or LBGS 
was modified to obtain the different ratios. 
The suspensions of nanoparticles were mixed by magnetic stirring for 10 min and then 
centrifuged in eppendorfs having a layer of 10 µL of glycerol, in order to facilitate the 
following step of resuspension. The isolation of nanoparticles was performed by 
centrifugation (Thermo Scientific-Heraeus Fresco 17, Germany) at 16 000 x g, for 30 min 
at 15 ºC. After discarding the supernatants, the nanoparticles were resuspended with 200 
µL of ultrapure water. 
 
3.2.5.2. LBGA/LBGS nanoparticles 
Three mass ratios of LBGA/LBGS were used to prepare the nanoparticles by 
polyelectrolyte complexation, in particular 2/1, 1/1 and 1/2. The stock solution of LBGA, 
dissolved in ultrapure water, was prepared to reach a final concentration of 0.5 mg/mL, 
while that of LBGS, dissolved in ultrapure water, had a final concentration of 1.0 mg/mL. 
The solutions were filtered with a 0.45 µm filter prior to use. The formulations 2/1, 1/1 and 
1/2 were prepared by slowly adding 1.8 ml of LBGS to 1.0 ml of LBGA under gentle 
magnetic stirring at room temperature, as shown in Figure 1.1 (chapter 1, general 
introduction). The concentration of LBGA was kept constant at 0.5 mg/mL for the 
preparation of all formulations, while that of LBGS was modified to obtain the different 
ratios. 
As described before, the suspensions of nanoparticles were mixed by magnetic stirring for 
10 min and then centrifuged in eppendorfs with a layer of 10 µL of glycerol, in order to 
facilitate the following step of resuspension. The isolation of nanoparticles was performed 
by centrifugation (Thermo Scientific-Heraeus Fresco 17, Germany) at 16 000 x g, for 30 
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min at 15 ºC. After discarding the supernatants, the nanoparticles were resuspended with 
200 µL of ultrapure water. 
 
3.2.6. Characterization of Locust Bean Gum-based nanoparticles 
3.2.6.1. Size, polydispersion index and ζ potential 
The size, ζ potential and polydispersion index (PdI) determination of the nanoparticles 
were performed on freshly prepared samples. Size and PdI were measured by dynamic 
light scattering and zeta potential was measured by laser Doppler anemometry, using a 
Zetasizer Nano ZS (Malvern instruments, Malvern, UK). To prepare the samples, 20 µL of 
each formulation were diluted in 1 mL of ultrapure water. 
 
3.2.6.2. Production yield 
For determination of nanoparticle production yield, the nanoparticles were prepared as 
described in the previous sections, but without the use of the 10 µL of glycerol. After 
discarding the supernatant of each formulation, the pellets were frozen and then dried on 
a freeze-dryer (Alpha RVC, Christ, Germany). The yield of nanoparticle production (PY) 
was calculated as follows:  
PY = (Nanoparticle sediment weight/Total solids weight) x 100 
where nanoparticle sediment weight is the weight after freeze-drying and total solids 
weight is the total amount of solids added for nanoparticle formation. 
 
3.2.6.3. Morphological analysis 
The morphological examination of LBGA/LBGS nanoparticles was conducted by 
transmission electron microscopy (TEM; JEM-1011, JEOL, Japan). The samples were 
stained with 2% (w/v) phosphotungstic acid and placed on copper grids with carbon films 
(Ted Pella, USA) for TEM observation. 
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3.2.7. Safety evaluation 
The in vitro cell viability and cytotoxicity of bulk LBG, purified LBG and the synthesized 
derivatives was assessed in Caco-2 cells by the MTT assay and the LDH release assay, 
respectively. LBGA/LBGS nanoparticles were evaluated using the MTT assay. 
The cells were seeded at a density of 1×104 cells/well in 96-well plates, in 100 µL of the 
same medium used for culture in cell culture flasks, and were grown at 37 °C in a 5% CO2 
atmosphere for 24 h before use. 
The effect of polymeric solutions and nanoparticle suspensions was evaluated for 3 h and 
24 h at three different concentrations (0.1, 0.5 and 1.0 mg/mL). A SDS solution (2%, w/v) 
was used as a positive control of cell death, while cells incubated with DMEM served as 
negative control. An additional control (DMEM+H2O) consisting in a mixture of DMEM and 
H2O in the same ratio used for the samples was used, in order to evaluate the contribution 
of polymers on cell viability. All formulations and controls were prepared as 
solution/suspensions in pre-warmed cell culture medium without FBS immediately before 
application to the cells. 
To initiate the assay, culture medium of cells at 24 h in culture was replaced by 100 µL of 
fresh medium without FBS containing the test samples or controls. A constant ratio (3:1) 
between the culture medium and the solution/suspension of the materials was used.  After 
3 or 24 h of cell exposure, samples/controls were removed and 30 µL of the MTT solution 
(0.5 mg/mL in PBS, pH 7.4) was added to each well. After 2 h, any generated formazan 
crystals were solubilised with 50 µL of DMSO. Upon complete solubilisation of the 
crystals, the absorbance of each well was measured by spectrophotometry (Infinite M200, 
Tecan, Austria) at 540 nm and corrected for background absorbance using a wavelength 
of 650 nm (186). 
The relative cell viability (%) was calculated as follows: 
Viability (%) = (A – S)/(CM – S)× 100                                                    
where A is the absorbance obtained for each of the concentrations of the test substance, 
S is the absorbance obtained for the 2% SDS and CM is the absorbance obtained for 
untreated cells (incubated with cell culture medium). The latter reading was assumed to 
correspond to 100% cell viability. The assay was performed at least for three occasions 
with six replicates at each concentration of test substance in each instance. 
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Considering the general mild effect observed in the MTT assay, the LDH release assay 
was performed on polymeric solutions and nanoparticle suspensions, after 24 h exposure 
to a concentration of 1.0 mg/mL. This is a colorimetric assay that quantitatively measures 
LDH, a stable cytosolic enzyme that is released upon cell lysis. Released LDH in culture 
supernatants is measured with a 30-min coupled enzymatic assay that results in the 
conversion of a tetrazolium salt into a red formazan product. The amount of color formed 
is proportional to the number of lysed cells (187).  
Samples from the culture medium in the seeding plates were centrifuged (16 000 x g, 5 
min, 15 ºC), and 50 μL were collected and reacted with 100 μL of the LDH reagent at 
room temperature and protected from light. The reaction was stopped after 30 min by 
adding 15 μL HCl 1M. Absorbance was measured by spectrophotometry at a wavelength 
of 490 nm with background correction at 690 nm. The relative LDH release (%) was 
calculated as follows, considering 100% release for samples incubated with the lysis 
solution (positive control of cell death): 
LDH release (%) = Atest/Acontrol × 100 
where Atest is the absorbance of the test sample and Acontrol is the absorbance of positive 
control of cell death. The assay was performed in at least three occasions, with three 
replicates in each instance. 
 
3.2.8. Statistical analyses 
The t-test and the one-way analysis of variance (ANOVA) with the pair wise multiple 
comparison procedures (Holm-Sidak method) were performed to compare two or multiple 
groups, respectively. All analyses were run using the SigmaStat statistical program 
(Version 3.5, SyStat, USA) and differences were considered to be significant at a level of 
P < 0.05. 
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3.3. Results and discussion 
Since commercial LBG contains about 3-7% protein in its constitution (60), it is essential 
to go through a purification step prior to use, in order to avoid interference in the 
modification reactions to be performed. Therefore, it was purified using a method based 
on previously published protocols (73, 78), with a yield of approximately 78%. This purified 
LBG was the material used for subsequent work, unless stated otherwise. 
 
3.3.1. Synthesis and chemical characterization of Locust Bean Gum 
derivatives 
The syntheses of the three charged LBG derivatives were made by adaptation of 
procedures described in the literature for the modification of other polysaccharides (179, 
184, 185). To perform the sulfation reaction, SO3DMF was chosen as sulfating agent 
(184), as it presents advantages over methods involving the manipulation of either 
pyridine or sulfur trioxide (188-190). For the synthesis of the sulfate derivative, two 
approaches were performed as described in the methodology. The difference mainly 
resided in the processing of LBG prior to the addition of SO3DMF. For the introduction of 
trimethylammonium groups in LBG, GTMAC was used as alkylating agent, which proved 
to be efficient in the alkylation of other polysaccharides (58, 185, 191, 192). The reaction 
mechanisms are as follows: 
 
 
 
 
For the transformation of LBG into the corresponding polyuronic acid, TEMPO, a stable 
nitroxyl radical, was chosen as oxidizing agent (179). This has proved to possess a high 
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efficiency in the conversion of high molecular weight polysaccharides. A highly selective 
oxidation of C-6 primary hydroxyl to carboxylic groups can be achieved in an aqueous 
solution of the polysaccharide at pH 9-11 with NaClO and catalytic amounts of TEMPO 
and NaBr (179-181). The mechanism is as follows: 
 
 
The methods described above are summarized in Figure 3.1.  
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Figure 3.1 – Scheme of the chemical modifications introduced in LBG. 
 
As shown in Figure 3.2, LBG sulfate functionalization (LBGS) was confirmed by FTIR, 
through the appearance of a S=O asymmetric stretching band (184) at 1255 cm-1 and that 
of C-O-S symmetric stretching (189) at 817 cm-1. In the carboxylate derivative (LBGC), the 
absorption bands at 1601 cm-1 and 1415 cm-1 are attributed to asymmetric and symmetric 
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stretching vibration of –COO-, respectively (181). Since the quaternary ammonium groups 
do not display characteristic IR absorption bands (193), evidence for formation of the 
amino functionalized derivative (LBGA) comes from the broadening of the band at 1088 
cm-1 (ether C-O symmetric stretching) and the new bands at 1479 and 914 cm-1 (C-H 
scissoring in methyl groups of the ammonium and ether C-O asymmetric stretching, 
respectively) (192). 
 
 
Figure 3.2 – FTIR spectra of purified Locust Bean Gum (LBG) and its ammonium (LBGA), 
carboxylate (LBGC) and sulfate (LBGS) derivatives. 
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In the elemental analysis, the weight percentages found for the analysed elements are 
compiled in Table 3.1. 
 
Table 3.1 – Elemental analysis data from the sulfate (LBGS), carboxylate (LBGC) and 
ammonium (LBGA) derivatives of locust bean gum (LBG). 
Element 
(%) 
Polymer 
LBGS 
(M1)* 
LBGS 
(M2-B1)* 
LBGS 
(M2-B2)* 
LBGS 
(M2-B3)* 
LBGC LBGA 
N --- --- --- --- --- 3.84 
C 25.55 35.06 23.94 28.42 37.39 43.39 
S 7.77 3.50 9.78 7.41 --- --- 
O --- --- --- --- 48.96 --- 
*B1, B2 and B3 refer to LBGS derivatives from batches 1, 2 and 3, respectively; M1 and M2 refer to LBGS 
derivatives synthesized with methods 1 and 2, respectively 
 
For LBGS, different degrees of substitution were obtained, even under the same reaction 
conditions. For the sample of LBGS obtained by the first method (method 1), a C:S molar 
ratio of 8.78 was obtained, which corresponds to a degree of substitution (DS) of 3.5. 
Therefore, if the sulfate groups are assumed to be in the form of sodium salts, a molecular 
formula between C30H47S3O34Na3 and C30H46S4O37Na4, to which corresponds a mean 
molecular weight of 1166 g/mol, is derived. On the other hand, the samples of LBGS 
obtained by the second method (method 2) presented a high variability on C:S molar ratio, 
ranging from 26.76 in batch 1 to 6.55 in batch 2, and batch 3 presenting a value of 10.24. 
These values correspond to values of DS of 1.22, 4.63, and 3, and to the mean molecular 
weights of 932, 1282, and 1111 g/mol, respectively. As indicated in the methods and 
stated above, the difference between the two methods only refers to a preliminary 
treatment of LBG before the sulfation reaction. In the second method, a better dispersion 
of LBG was promoted before the contact with the sulfating agent in an attempt to improve 
the reaction. The need for this pre-treatment was motivated by the poor solubility of LBG 
in DMF. Since in the sulfation reaction the polymer is used as a dispersion in the solvent, 
it would be expected that a more effective dispersion would favour the reaction. 
Notwithstanding and quite surprisingly, it was observed that, although the pre-treatment 
afforded the highest value of DS (4.63), it also gave the lowest substitution (1.22), while in 
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its absence an intermediate value of DS was obtained. This variation in DS translates, in 
the FTIR spectra of the various samples, in different intensities of the band at 1255 cm-1 
relative to other bands in the spectrum, with more substituted samples presenting a more 
intense band (Figure 3.3).  
 
 
Figure 3.3 – FTIR spectra of Locust Bean Gum sulfate derivatives (LBGS) obtained in 
method 1 (M1) and method 2 (M2). B1, B2 and B3 refer to batch 1, 2 and 3, respectively. 
 
Assuming that a better dispersion of LBG leads to a higher reaction efficiency and affords 
higher values of DS, it seems that the dispersibility of LBG in the reaction medium does 
not directly correlate to the method used in its dispersion. One reason for the observed 
variability in DS may be the fact that, contrary to what is observed in the reactions 
described below (oxidation and alkylation), in which LBG progressively dissolves as the 
reactions proceed, in this case a total solubilisation is never reached. This renders the 
outcome of this reaction quite unpredictable and, therefore, this issue will have to be 
tackled in future work. In fact, the reaction of LBG activated by pre-soaking in DMF and 
dispersed in the same solvent, with solid SO3DMF complex, bellow 15 ºC, led to a DS of 
approximately 4 (183). On the other hand, sulfation of LBG dispersed in formamide with 
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SO3pyridine complex, under diverse conditions of reaction time, temperature, and amount 
of sulfating agent, led to DS varying between approximately 2 and nearly 5 (182). Again 
the soaking of LBG with the solvent prior to the reaction led to an intermediate DS relative 
to the range obtained without any pre-treatment, although in the latter case a different 
reagent and solvent were used. Nevertheless, only one batch per reaction conditions 
seems to have been obtained in both these works, and therefore the state of dispersion of 
LBG in each case may very well be the factor governing the substitution obtained, instead 
of the parameters analysed. Moreover, in the latter work, no correlation or trend between 
molecular weights of the obtained derivatives or depolymerisation of the parent 
polysaccharide and degree of substitution is observed. On the contrary, a very erratic 
dispersion of molecular weights with growing DS is obtained, pointing to a random 
behaviour in this reaction. For LBGC, a C:O ratio of 1.02 was found, which corresponds to 
a degree of oxidation (DO) of 4, meaning that all the free C-6 must have been oxidized. 
Assuming all carboxylate groups to be in the sodium salt form, the molecular formula 
would be C30H38O29Na4, and the molecular weight 955 g/mol. This value is not surprising, 
in view of the effectiveness of the oxidizing system, although somewhat higher than DO 
values observed for other galactomannans, which typically lay below 70% of the free units 
(181). In LBGA, the C:N molar ratio was found to be 13.16, corresponding to a DS of 4.24. 
If all the ammonium groups are in the form of chloride salt, this corresponds to a 
molecular formula between C54H106O29N4Cl4 and C60H120O30N5Cl5, and the mean molecular 
weight of 1454 g/mol. This corresponds to a full reaction of the free C-6 hydroxyl groups, 
along with reaction on some secondary hydroxyls, in line with what was observed by us in 
a similar modification performed in pullulan (58). 
Figure 3.4 presents the 1H-NMR spectra of LBG and its three derivatives (LBGA, LBGS, 
and LBGC). In the spectrum of LBG (Figure 3.4 a), there are three signals (5.21, 4.93, 
and 3.74 ppm) resolved from the envelope of peaks between 3.8 and 4.4 ppm. The former 
two are attributed to the anomeric protons H-1 of galactose and mannose units, 
respectively, while the latter is due to the proton in the C-5 of mannose. In the spectrum of 
LBGA (Figure 3.4 b) all the signals shifted upfield as a consequence of the alkylation of 
hydroxyl groups, probably mostly the ones in C-6, as these are the most reactive. Due to 
this shifting, the anomeric protons signals disappeared bellow the strong signal of HOD, 
and the C-5 proton is probably now absorbing at 3.41. Nevertheless, this attribution may 
not be correct, since the sample enormously swelled upon addition of D2O, reaching a 
very dilute state and affording a spectrum with low signal intensities. A noteworthy aspect 
of this spectrum is the intense singlet at 3.15 ppm, which indicates the presence of the 
trimethylammonium methyl groups. The high intensity of this peak is consistent with the 
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obtained DS of over 4. Another change denoting the presence of the N-(2-hydroxypropyl)-
N,N,N-trimethylammonium groups in LBGA is the shoulder in the HOD signal, at nearly 
4.38 ppm, corresponding to the absorbance of the CH(OH) proton. 
 
 
Figure 3.4 – 1H-NMR of (a) LBG, (b) LBGA, (c) LBGS, and (d) LBGC; the big singlet 
centered at 4.7 ppm is due to HOD (identified in grey). 
 
The spectrum of LBGS (Figure 3.4 c) does not differ much from the one of the parent 
polysaccharide, which is not totally unexpected, since this corresponds to a sample with a 
low value of DS (batch 1 in method 2). Still, a new broad signal centred at 4.46 ppm 
appeared, corresponding to the downshift of the H-6 of pyranosyl units with sulfate groups 
attached. The fact that this spectrum was acquired in a more concentrated sample caused 
a reduction of the HOD signal relative to the remaining ones, allowing the integration of 
the two H-1 signals. The area below the signal corresponding to the H-1 of mannose is 
approximately four times higher than that below the peak of the anomeric proton of 
galactose, thus confirming the M:G ratio of 4:1. Superimposed with the former signal is 
that of the downshifted peak of the galactose H-4 from substituted units. However, this is 
a very faint signal, as the DS of this sample is low and substitution occurred mostly in the 
most reactive primary hydroxyl groups of the C-6 carbons, therefore not compromising 
this estimation. The spectrum of LBGC (Figure 3.4 d) is characterized by an upfield shift 
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of most of the signals and therefore not much information may be derived from it. 
However, that is not the case of the 13C-NMR of this derivative (Figure 3.5), in which the 
signals of the C-6 of galactose and unsubstituted mannose units, expected to appear at 
61-62 ppm, are absent, in line with the full oxidation of these carbons estimated from the 
elemental analysis data. Also a relatively broad signal appeared at nearly 176 ppm, due to 
a poor resolution of the signals of the carboxylic acid carbons in galactose and mannose 
units. Moreover, no signals attributable to aldehydic carbons (190-200 ppm) are observed 
in the spectrum, thus confirming the complete oxidation to carboxylic acid. 
 
 
Figure 3.5 – 13C-NMR of LBGC. 
 
Table 3.2 presents the average molecular weights, polydispersity index (PdI), and radius 
of gyration (Rg) of LBG and its derivatives. For the parent polysaccharide (LBG), these 
are in general agreement with the literature (60, 74). Upon chemical modification, an 
increase in both molecular weight and Rg was observed in LBGA, and a big decrease in 
these parameters was patent in LBGC and LBGS. The increase identified in LBGA is 
attributable to the presence of the introduced pendant chains, which lead to an increase in 
the molar mass of the repeating unit and force the polymer, once in solution, and similarly 
to what happens in the crystalline state (XRD results), to adopt a conformation that is 
suitable to accommodate such bulky groups. The results observed in the LBGC and 
LBGS derivatives suggest the occurrence of depolymerization during the chemical 
modification, a common observation when the conditions of either the oxidation (181) or 
the sulfation reaction (189) are applied. The latter was already stated in a similar 
modification performed in pullulan (58). Moreover, no additional dehydration reactions, 
with intra- and/or intermolecular crosslinking leading to a fraction of high molecular weight 
chains, observed in sulfation reactions carried out at higher temperatures (188), occurred 
in this case. The results obtained for LBGS were very similar among the two synthetic 
methods (methods 1 and 2). 
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Table 3.2 – GPC analysis of purified Locust Bean Gum (LBG), and its ammonium 
(LBGA), carboxylate (LBGC) and sulfate (LBGS) derivatives. 
Polymer Mn (Da) Mw (Da) PdI Rg (nm) 
LBG 327 300 589 100 1.80 71.61 
LBGA 500 600 871 000 1.74 86.05 
LBGC 73 790 119 500 1.62 28.19 
LBGS 21 380 26 510 1.24 14.21 
Mn: number average molecular weight; Mw: weight average molecular weight; PdI: 
polydispersity index; Rg: radius of gyration 
 
Figure 3.6 shows the XRD patterns of the pristine and modified LBG samples. The 
pattern of LBG, with a broad peak centered at ca. 20º 2 with shoulders at ca. 7.5 and 15º 
2 reflects the predominantly amorphous nature of the material. These shoulders vanish 
in the pattern of LBG modified with sulfate, probably due to some changes in the 
organization of the polymer chains imposed by the sulfate groups. In what concerns the 
ammonium derivative, the pattern clearly shows an increase of intensity for higher d-
spacings, which is compatible with an increase of the distance between the polymer 
chains, due to the long chain bearing the ammonium group (58). When compared with the 
other modifications, the introduction of carboxylate groups gives rise to the highest degree 
of disruption of the long-range order of the LBG polymer chains. The intensity of the peak 
that appears at 20º 2 in the pattern of the original polymer (LBG) is substantially reduced 
and new broad peaks are now present at ca. 12 and 25º 2This is not surprising, as the 
conversion of galactose and mannose units into the corresponding uronic acids would 
enormously affect the conformation of the polysaccharide chains and, consequently, the 
way they pack in the solid phase. 

Locust bean gum derivatives and production of nanoparticles 
 
52 
 
 
Figure 3.6 – XRD patterns of (a) pristine locust bean gum (LBG), (b) sulfated LBG 
(LBGS), (c) ammonium LBG (LBGA), and (d) carboxylated LBG (LBGC). 
 
3.3.2. Characterization of nanoparticles 
The production of LBG derivatives described above endowed the polymer with charged 
groups, enabling the preparation of nanoparticles by polyelectrolyte complexation. This is 
a mild method occurring in hydrophilic medium, devoid of aggressive conditions such as 
organic solvents or high shear forces, and involving electrostatic interactions between 
oppositely charged polymers (108, 194). Three derivatives were synthesized which were 
used in the production of different formulations of nanoparticles. The negatively charged 
sulfate and carboxylate derivatives were complexed with chitosan to produce CS/LBGS 
and CS/LBGC nanoparticles, respectively. In turn, the ammonium derivative was 
complexed with the sulfate derivative in the innovative approach of producing LBG-only 
nanoparticles (LBGA/LBGS). The results regarding the physicochemical characterization 
of the referred nanoparticle formulations are displayed and discussed below. 
 
 
 
5 15 25 35 452/degrees
a
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3.3.2.1. CS/LBGS and CS/LBGC nanoparticles 
The first approach towards the formulation of CS/LBGS and CS/LBGC nanoparticles 
involved the production of carriers having higher or at least the same amount of LBG 
derivative comparing to chitosan. In this regard, the starting mass ratios selected for the 
production of the referred formulations of nanoparticles were 1:1, 1:1.5 and 1:2. In the 
course of the experiments, the need to test other ratios was identified, not necessarily 
being coincident for each formulation, thus justifying the slight differences observed 
between the two formulations. 
Table 3.3 displays the physicochemical characteristics of CS/LBGS nanoparticles. For the 
production of these nanoparticles, LBGS corresponding to method 1 was used. With 
CS/LBGS mass ratios varying between 1:1 and 1:2.5, and recalling that CS amount 
remains constant in all formulations, it was verified that nanoparticle size generally 
increased with increasing amounts of LBGS. The minimum size was 364 nm (CS/LBGS = 
1:1, w/w) and the highest size was 589 nm (CS/LBGS = 1:2.5, w/w) (P < 0.05). 
 
Table 3.3 - Physicochemical characteristics and production yield of CS/LBGS unloaded 
nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant differences in each 
parameter (P < 0.05). 
CS/LBGS 
(w/w) 
Size 
(nm) 
PdI Zeta potential 
(mV) 
Production 
yield (%) 
1:1 364.1 ± 30.0 a 0.34 ± 0.09 +45.6 ± 1.2 d 37.3 ± 5.6 h 
1:1.25 403.7 ± 37.7 ab 0.40 ± 0.06 +40.0 ± 0.8 e 58.1 ± 2.7 i 
1:1.5 pp* 1.0 ± 0.0 -5.9 ± 4.4 f n.d. 
1:2 500.3 ± 59.6 bc 0.47 ± 0.08 -23.9 ± 2.7 g 56.6 ± 7.2 i 
1:2.5 589.0 ± 69.5 c 0.54 ± 0.03 -28.5 ± 5.0 g n.d. 
n.d.: not determined; pp: precipitate; *slight precipitation compromised the measurement of this parameter 
 
The registered increase in size as higher amount of LBGS is included in the formulations 
as compared with CS, might be explained by the increase of total mass of polymers that is 
present. This effect was also reported in other works using the same nanoparticle 
production method (39, 195). Precipitation was found to occur for an intermediate 
formulation (CS/LBGS = 1:1.5, w/w), being coincident with a zeta potential close to zero (-
5.9 mV) that possibly is not sufficient to provide particle repulsion, thus leading to 
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aggregation. A clear Tyndall effect was observed in all the other nanoparticle formulations. 
The formulations 1:1 and 1:1.25 (w/w) exhibited a strong positive zeta potential of more 
than 40 mV. The incorporation of a higher amount of LBGS, from formulation 1:1 to 1:1.25 
(w/w) resulted in a corresponding decrease in the zeta potential from +46 mV to +40 mV 
(P < 0.05). The formulations 1:2 and 1:2.5 (w/w) presented a complete shift in the zeta 
potential as the nanoparticles became negatively charged with zeta potential reaching -29 
mV. Again, the incorporation of a higher amount of LBGS led to a nominal decrease in the 
zeta potential, although this is not statistically significant. This absolute shift of 
nanoparticle charge occurring between the formulations 1:1.25 and 1:2 (w/w) reflects the 
higher amount of LBGS that is present in the nanoparticles but also demonstrates that 
both polymers have different charge density. Zeta potential results are perfectly in line 
with the charge ratios that were calculated for each formulation of nanoparticles, as is 
depicted in Figure 3.7. This figure shows the effect of charge ratios on the zeta potential 
of CS/LBGS nanoparticles prepared with varying polymeric ratios. 
 
 
Figure 3.7 – Effect of charge ratio (-/+) on the zeta potential of CS/LBGS nanoparticles. 
 
For each polymer, by dividing the charge of the repeating unit by its molar mass, a charge 
per mass ratio may be obtained. CS has a higher charge per mass ratio than LBGS (4.72 
x 10-3 vs 3.00 x 10-3 charges/g, respectively), which justifies why formulations CS/LBGS = 
1:1 and 1:1.25 (w/w) have a -/+ charge ratio below 1. The strong positive zeta potential (> 
40 mV) of these nanoparticles is due to the predominance of positive charges. In turn, the 
occurrence of precipitation in the formulation 1:1.5 (w/w) was coincident with a charge 
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ratio around 1, justifying that the determined zeta potential was close to neutrality. In fact, 
although a 1:1 -/+ charge stoichiometry might not imply the occurrence of complete 
charge neutralization, due to different charge spacing in the intervenient species and to 
steric limitations (195), one may assume a preferential interaction between the sulfate and 
the ammonium groups, both weakly hydrated, instead of with the strongly hydrated 
counterions (196). This leads to mainly an intrinsic charge matching in detriment of an 
extrinsic charge compensation and, thus, to a small deviation from neutrality. Finally, the 
continued addition of the negative polymer (formulations CS/LBGS = 1:2 and 1:2.5, w/w) 
produced an excess of negative charges, resulting in -/+ charge ratio above 1 and, 
consequently, negatively charged nanoparticles. A similar behavior concerning the charge 
ratios leading to either the precipitation or the formation of nanoparticles, was previously 
described (195). 
The polydispersity index varied between 0.3 and 0.5, which is considered high. Regarding 
the production yield, very reasonable values for this nanoparticle production methodology, 
were obtained. A yield of 37% was registered for formulation 1:1 (w/w) which increased to 
58% (P < 0.05) for formulation 1:1.25 (w/w). This is a result of the proper mechanism of 
nanoparticle formation, based on the neutralization of chitosan amino groups by the 
sulfate groups of LBGS. The incorporation of a higher amount of LBGS provides an 
additional amount of sulfate groups that interacted with chitosan, thus forming a higher 
amount of nanoparticles (106). However, this effect occurs up to a certain limit. As 
observed, further increasing the amount of LBGS led to precipitation, certainly because of 
the demonstrated neutralization of charges, as referred above. On keeping increasing 
LBGS mass, nanoparticles are again formed (CS/LBGS 1:2 and 1:2.5, w/w), this time with 
an opposite charge and a high yield (57% for formulation 1:2, w/w). 
The results obtained for CS/LBGC nanoparticles were rather different comparing to those 
described above regarding CS/LBGS formulations. In this case, as shown in Table 3.4, 
the initially approached formulation of CS/LBGC 1:1 (w/w) resulted in a size of 479 nm, 
which is more than 30% higher than the corresponding CS/LBGS formulation (P < 0.05). 
The formulation 1:1.5 (w/w) already presented precipitation, similarly to 1:2 (w/w) and 
therefore the intermediate formulation 1:1.25 (w/w) was produced. 
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Table 3.4 - Physicochemical characteristics and production yield of CS/LBGC unloaded 
nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant differences in each 
parameter (P < 0.05). 
CS/LBGC 
(w/w) Size (nm) PdI 
Zeta potential 
(mV) 
Production 
yield (%) 
1:0.75 489.9 ± 63.6 a 0.45 ± 0.04 +45.5 ± 13.0 b 49.0 ± 5.0 d 
1:1 479.1 ± 30.8 a 0.51 ± 0.07 +42.2 ± 7.4 b 54.3 ± 7.0 d 
1:1.25 828.8 ± 299.8 a 0.64 ± 0.15 +28.8 ± 7.3 b n.d. 
1:1.5 pp* 1.0 ± 0.0 -2.5 ± 8.3 c n.d. 
1:2 pp* 1.0 ± 0.0 -15.2 ± 7.4 c n.d. 
n.d.: not determined; pp: precipitate; *slight precipitation compromised the measurement of this parameter 
 
The registered size revealed a strong increase to 829 nm, although this is not statistically 
significant as is accompanied by an extremely high standard deviation, which indicates 
reproducibility issues. This formulation also presented a high polydispersity index and thus 
was not characterized for production yield. An attempt was also performed to produce 
nanoparticles at a CS/LBGC ratio of 1:0.75 (w/w), but the characteristics were very 
similar, under all aspects, to those of ratio 1:1 (w/w). The polydispersity index was around 
0.5 – 0.6, which is even higher than those registered for CS/LBGS nanoparticles, 
reinforcing the difficulty in producing suitable nanoparticles with the LBGC derivative. The 
zeta potentials are highly positive (around +45 mV), which probably contributes to the 
system stability. The determination of the charge ratios involved in each formulation of 
nanoparticles is depicted in Figure 3.8. 
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Figure 3.8 – Effect of charge ratio (-/+) on the zeta potential of CS/LBGC nanoparticles. 
 
As observed, formulations 1:0.75 and 1:1 (w/w) have a -/+ charge ratio between 0.5 and 
0.7 which does not translate into significant differences in the zeta potential. Nanoparticles 
1:1.25 (w/w) displayed a -/+ charge ratio of 0.85 which induced a nominal decrease of the 
zeta potential to +29 mV, although not to a statistically significant level. As observed 
above for CS/LBGS nanoparticles, reaching a -/+ charge ratio around 1 (formulation 1:1.5, 
w/w) resulted in precipitation. However, in this case the continued addition of the negative 
polymer to formulate CS/LBGC = 1:2 (w/w) nanoparticles still resulted in precipitation, 
despite the -/+ charge ratio of 1.4. It is important to highlight that, while the resulting zeta 
potential for this formulation was of -15 mV, in the CS/LBGS corresponding formulation 
was -24 mV, which possibly permitted enough repulsion to stabilize the formed 
nanoparticles.  
The determined production yields are satisfactory for this methodology, as referred above, 
being around 50%. When comparing the zeta potentials of these nanoparticles with those 
obtained for CS/LBGS nanoparticles (Table 3.3), a similar trend is observed. In this 
regard, increasing the amount of LBGC present in the formulation reflects in a decrease of 
the surface charge, owing to the higher amount of negative groups being incorporated. 
Similarly to CS/LBGS nanoparticles, the formulation 1:1.5 is the one showing neutrality 
(zeta potential of -2.5 mV) and the further incorporation of LBGC led to a decrease in the 
surface charge. The precipitation verified for the latter was possibly due to the fact that the 
existing surface charges were not sufficient to ensure particle repulsion. The resemblance 
of the trend, particularly regarding the shift of the zeta potential (occurring for mass ratio of 
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1:1.5), suggests the similarity of charge density in both derivatives. In fact, LBGS has a 
charge per mass ratio of 3.00 x 10-3 charges/g, as stated before, and LBGC has 3.14 x 10-
3 charges/g. 
 
3.3.2.2. LBGA/LBGS nanoparticles 
One of the great novelties of producing LBG charged derivatives is the possibility of using 
these to produce, for the first time, LBG-only nanoparticles. Given the difficulties in 
producing nanoparticles with the LBGC derivative, as stated above, it was decided to 
produce the LBG-only nanoparticles using just LBGS as negative counterpart. The 
nanoparticles were produced by complexation of this derivative (method 2 – 50/50 
mixtures of batches 2 and 3) with the ammonium derivative (LBGA) by the same 
methodology reported in the other cases (polyelectrolyte complexation). 
After observing the precipitation of the formulation LBGA/LBGS 1:1 (w/w), possibly 
resulting from a (-/+) charge ratio of 1.09, formulations 1:2 (w/w) and 2:1 (w/w) were 
approached, which results are depicted in Table 3.5. 
 
Table 3.5 - Physicochemical characteristics and production yield of LBGA/LBGS unloaded 
nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant differences in each 
parameter (P < 0.05). 
LBGA/LBGS 
(w/w) 
Size (nm) PdI Zeta potential 
(mV) 
Production 
yield (%) 
1:2 206.6 ± 5.0 a 0.13 ± 0.03 -27.8 ± 1.4 c 30.0 ± 8.6 e 
1:1 pp - - - 
2:1 368.3 ± 19.3 b 0.38 ± 0.05 +48.1 ± 1.5 d 16.7 ± 3.8 f 
pp: precipitate 
 
The formulation containing the highest amount of LBGS registered a size of 207 nm and a 
low polydispersity index of 0.13. Naturally, the zeta potential was negative (-28 mV), 
reflecting the higher content of negatively charged derivative, which translated into a (-/+) 
charge ratio of 2.17. As expected, the formulation having more LBGA exhibited a strongly 
positive zeta potential (+48 mV; P < 0.05), as a result of the (-/+) charge ratio of 0.54. 
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However, this particular formulation presented higher size (368 nm) along with higher 
polydispersity index (P < 0.05). At a first evaluation, the size differences could be 
considered unexpected. In fact, for the preparation of these nanoparticles, LBGA is kept 
constant at 0.5 mg/mL and LBGS concentration is adapted to meet the desired ratio. 
Therefore, formulation 1:2 (w/w) accounts with a total polymeric mass of 1.5 mg while 
formulation 2:1 (w/w) accounts with 0.75 mg. In line with this, formulation 1:2 (w/w) was 
perhaps expected to have a higher size. However, if one considers the molecular weight 
of the derivatives, reported in section 3.3.1, LBGA has a much higher Mn than LBGS (500 
600 vs 21 380). In this regard, it becomes justifiable that nanoparticles having double 
amount of LBGA comparing with LBGS are those displaying the higher size. 
Regarding the production yield, this was very different between the two formulations. 
While formulation 1:2 (w/w) resulted in 30%, formulation 2:1 (w/w) presented 17% (P < 
0.05). This difference is probably due to variances in the molecular weight of the two 
derivatives. In formulation 1:2 (w/w), there is a determined amount of a high molecular 
weight polymeric chain and a double amount of a shorter macromolecule that possibly 
presents higher diffusion. On the contrary, in formulation 2:1 (w/w) the amount of the 
polymer with higher molecular weight is double comparing with that of the smaller 
polymer, thus resulting in a lower number of interactions and limiting the amount of 
nanoparticles formed. 
LBG-only nanoparticles were morphologically characterized by TEM and the specific 
formulation LBGA/LBGS 1:2 (w/w) was considered representative for this end. As shown 
in Figure 3.9 the nanoparticles present a spherical shape and have a compact structure. 
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Figure 3.9 – TEM microphotograph of LBGA/LBGS = 1:2 (w/w) nanoparticles. 
 
3.3.3. Safety evaluation 
Addressing the biocompatibility of materials to be used in drug delivery is a major issue in 
formulation development (52, 197, 198). Additionally, current international guidelines 
indicate the need to contextualize biocompatibility with a specific route of administration 
and dose of the material (198). According to the guidelines issued by the International 
Organization for Standardization (ISO), testing biocompatibility implies the performance of 
a complete set of assays, addressing at first cellular morphology, membrane integrity and 
metabolic efficiency, among other tests (197, 199-201). In this work we performed two of 
the most used assays to test the toxicological effect of materials, which are the metabolic 
assay MTT and the membrane integrity assay based on LDH release. The MTT assay 
assesses cell metabolic efficiency, relying on the evaluation of enzymatic function. To do 
so, after the exposure to the test materials, cells are incubated with yellow tetrazolium 
(MTT) salts which are reduced to purple-blue formazan crystals by active mitochondrial 
dehydrogenases (197). In this manner, a higher concentration of the formazan dye 
corresponds to a higher amount of metabolically active cells, which is usually interpreted 
as higher cell viability. The LDH release assay provides a mean to determine the amount 
of LDH in cell culture medium upon exposure to potential toxicants. As LDH is a 
cytoplasmic enzyme, its presence in the cell culture medium is an indicator of irreversible 
cell death due to cell membrane damage (202, 203). The assay thus evaluates cell 
membrane integrity and complements the results obtained by the MTT assay. 
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Caco-2 cells are derived from a human colorectal carcinoma and are the most frequently 
used as in vitro intestinal cell culture model. The epithelial cells in the intestinal region are 
a heterogeneous population of cells that include enterocytes or absorptive cells, goblet 
cells that secrete mucin, endocrine cells and M cells, among others. The most common 
epithelial cells are the enterocytes that are responsible for the majority of the absorption of 
both nutrients and drugs in the small intestine (204, 205). Despite their colonic origin, 
Caco-2 cells undergo spontaneous differentiation in culture conditions to assume the 
characteristics of small intestinal cells. These include morphological and functional 
attributes, rendering the cell line a model of mature enterocytes (206). Owing to these 
features, Caco-2 cells are the most reported in the studies of drug absorption and toxicity 
(207, 208). 
In this work, Caco-2 cells were used to evaluate the toxicological profile of LBG and the 
synthesized derivatives. Figure 3.10 and Figure 3.11 represent the Caco-2 cell viability 
obtained after exposure to the mentioned materials at different concentrations, for a 
period of 3 h and 24 h. Cell viability values were calculated in relation to the 100% cell 
viability considered for the incubation with DMEM (negative control of cell death). The 
evaluation of LBG-based samples generally evidenced a mild effect on cell viability, 
considered to be devoid of biological relevance. In fact, with the exception of LBGA, all the 
other samples resulted in viabilities above 70% after 3 h or 24 h of exposure, when tested 
at concentrations varying within 0.1 and 1.0 mg/mL. While at 3 h values remained above 
88% in all conditions, the prolonged exposure until 24 h induced slight alterations. 
However, these were in most cases devoid of physiological relevance and the only 
remarkable effect resides in the decrease of the viability induced by the contact with 
LBGC at the highest concentration tested (1.0 mg/mL) (P < 0.05) to a value around 70%. 
Importantly, this is the value considered by ISO 10993-5 (201) as the level below which a 
toxic effect is assumed to occur. 
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Figure 3.10 - Caco-2 cell viability measured by the MTT assay after 3 h exposure to 
increasing concentrations of bulk Locust Bean Gum, purified Locust Bean Gum (LBG) and 
its ammonium (LBGA), carboxylate (LBGC) and sulfate (LBGS) derivatives. Data 
represent mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). 
Dashed line indicates 70%. * P < 0.05 compared with DMEM. 
 
 
Figure 3.11 - Caco-2 cell viability measured by the MTT assay after 24 h exposure to 
increasing concentrations of bulk Locust Bean Gum, purified Locust Bean Gum (LBG) and 
its ammonium (LBGA), carboxylate (LBGC) and sulfate (LBGS) derivatives. Data 
represent mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). 
Dashed line indicates 70%. * P < 0.05 compared with DMEM. 
 
Although not directly proposed herein as matrix material per se, unmodified LBG was also 
tested, because its application in drug delivery has been reported, in many occasions 
addressing oral delivery strategies (83, 209-219), but data on its effect on epithelial cells 
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are not available on the literature. Moreover, a comparison between bulk LBG and LBG 
was performed, revealing no significant differences, which indicates an absence of effect 
of the purification process in the cytotoxic profile of the material. It is important to mention 
that the results shown for LBGS sample correspond to the derivative obtained by the 
second method of synthesis (method 2 – batch 1), which were similar to those registered 
for the derivative obtained in the first method (method 1; data not shown). 
As mentioned before, LBGA is the material that presents the most distinct behavior, 
appearing as the exception to the mild effect observed for the tested materials. In fact, as 
shown in Figure 3.10, a strong decrease of cell viability to approximately 30% is obtained 
for any of the tested concentrations already upon a 3 h exposure. The effect is even more 
drastic after 24 h, when a very low level of cell survival was registered (P < 0.05; Figure 
3.11). Regarding concentration, there are no evidences of a statistically significant 
concentration-dependent effect. The influence of surface charges on cytotoxicity remains 
largely unresolved and sometimes the literature reports contradictory results. This is 
possibly due to different characteristics of basic materials being used and also to 
dissimilar assay conditions, which are frequently not described in sufficient detail. 
Nevertheless, there are many indications suggesting that surface charge has a role on 
cellular uptake (220, 221) and on the toxicological effect of substances. In this context, 
positively charged materials have been frequently found to be more cytotoxic than neutral 
or negatively charged counterparts, because positive charges provide a means for 
stronger interaction with cell surfaces, in many cases associated with internalization of the 
material (221-225). These statements are coincident with the results of our work, since the 
neutral (bulk LBG and LBG) and negatively charged materials (LBGC and LBGS) are 
devoid of a toxic effect. Another parameter that could be indicated as playing a significant 
role on toxicity consists on the molecular weight of the polymers. In this regard, although it 
could be suggested that smaller sizes have higher probability to be internalized by the 
cells, the literature has been reporting no correlation (226). In this work, the molecular 
weight of the polymers also seems to not be driving the cytotoxic behavior, as LBGS is the 
smallest molecule and shows no toxic effect. 
Comparing to LBGA, a very similar toxicological profile was observed for an ammonium 
derivative of another polysaccharide, pullulan, which was synthesized using the same 
methodology (58, 59). In that case, the assessment was performed in Calu-3 cells 
(bronchial cell line) and cell viabilities around 50-60% were observed after 3 h, decreasing 
to 40% at 24 h. Although a time-dependent effect is also clearly observed, the effect on 
cell viability is not as strong as for LBGA. The first consideration to take into account is the 
fact that the assessment was performed in different cell lines, which might translate into 
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different sensitivity. Additionally, different charge density of the polymers might be 
indicated as possible justification. In this regard, LBGA has a DS of 4.24, while the 
corresponding pullulan derivative (ammonium pullulan) has a DS of 2 (58). A higher 
number of positive charges results in stronger interactions and, thus, in lower cell viability. 
Complementing this idea, a work reporting the cytotoxic effect of cationic pullulan 
microparticles on human leukemic K562(S) cells, has established that toxicity increased 
with the increase molar concentration of amino groups (227). In the work reporting the 
cytotoxic evaluation of pullulan derivatives, a sulfate derivative of that polysaccharide was 
also assessed. Similarly to what was observed for LBGS, the registered cell viability was 
well above 80% (59). 
Considering that polymer samples were solubilized in water and diluted with cell culture 
medium prior to incubation with the cells, an additional control was performed consisting 
in a mixture of DMEM and H2O in the same ratio used for the samples. This enables a real 
evaluation of the contribution of the polymers on the final cell viability. As observed in 
Figure 3.10 and Figure 3.11, the cell viability induced by this control varied between 72% 
and 80%. Upon 3 h of contact there is a statistically significant difference between the 
control (DMEM + H2O) and all samples but with LBGS (Figure 3.10). In fact, higher cell 
viability is observed upon exposure to bulk LBG, LBG and LBGC, suggesting a positive 
effect of the presence of the polymers. Interestingly, after 24 h exposure (Figure 3.11), a 
shift is observed in the effect induced by LBGC and LBGS. In the former, the prolonged 
contact with the cells at the two highest concentrations reverts the positive effect on cell 
viability observed at 3 h. For LBGS, the results demonstrate that at the two lowest 
concentrations, the more prolonged contact improves cell viability, which was not 
registered at 3 h. 
One of the most important information provided by the evaluation performed with the MTT 
assay, is that only the more prolonged exposure to the highest concentration tested (1.0 
mg/mL; 24 h) induced a relevant decrease of Caco-2 cell viability (exception for LBGA). 
Therefore, it was deemed important to complement the results at these conditions by 
means of the quantification of the amount of LDH released by Caco-2 cells. To perform 
this assay, DMEM was used as negative control of LDH release and a lysis buffer was 
used as positive control. Thus, the negative control (DMEM) corresponds to a normal cell 
death, while the positive control (lysis buffer) represents 100% cell death. 
Figure 3.12 shows the results of LDH release after 24 h exposure to the materials at the 
concentration of 1.0 mg/mL. No statistically significant differences were observed between 
the negative control (DMEM), bulk LBG, LBG, LBGC and LBGS, which means that these 
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materials do not compromise Caco-2 cell membrane integrity, as no increased LDH 
release was induced as compared with that observed upon incubation with cell culture 
medium (DMEM). On the contrary, the contact with LBGA resulted in 90% LDH release, 
which is considered comparable to that induced by the lysis buffer, thus indicating a high 
cytotoxic effect that results in cell membrane disruption. The results obtained in this assay 
reinforce those found in the MTT tests, confirming the high cytotoxicity of LBGA. 
 
 
Figure 3.12 – Caco-2 cell viability measured by the LDH release assay after 24 h 
exposure to 1 mg/mL solutions of bulk Locust Bean Gum, purified Locust Bean Gum 
(LBG) and its ammonium (LBGA), carboxylate (LBGC) and sulfate (LBGS) derivatives. 
Data represent mean ± SEM (n ≥ 3, three replicates per experiment). * P < 0.05 compared 
with DMEM. 
 
The overall results obtained with these complementary cytotoxicity assays indicate that, 
with the exception of LBGA, LBG and negatively charged derivatives, present no 
cytotoxicity towards this in vitro intestinal model. This was observed even for the highest 
concentration tested (1.0 mg/mL) and for prolonged contact (24 h), suggesting their 
relative safety for an application as matrix materials of oral drug delivery systems.  
Complementarily, the effect on cell viability provided by LBGS (method 2 – batch 1) was 
assessed in Calu-3 and A549 cells (respiratory epithelial cells) and the results, displayed 
in Figure 3.13 and Figure 3.14, are in line with those observed for Caco-2 cells. 
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Figure 3.13 – A549 cell viability measured by the MTT assay after 3 h and 24 h exposure 
to increasing concentrations of sulfate locust bean gum (LBGS) derivative. Data represent 
mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). Dashed line 
indicates 70%. * P < 0.05 compared with respective control (DMEM). 
 
 
Figure 3.14 – Calu-3 cell viability measured by the MTT assay after 3 h and 24 h 
exposure to increasing concentrations of sulfate locust bean gum (LBGS) derivative. Data 
represent mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). 
Dashed line indicates 70%. * P < 0.05 compared with respective control (DMEM). 
 
Proposing materials for drug delivery applications requires testing the developed carriers 
and not only assume the apparent absence of cytotoxicity of the polymers. In this regard, 
it is consensual that carriers exhibit new and unique properties, thus generating potential 
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different risks as compared to the raw materials of the same chemistry (228), as observed 
in other works (58, 59). In this regard, in addition to the evaluation of the polymer and the 
synthesized derivatives, a preliminary evaluation of LBG-based nanoparticles was further 
performed using the MTT assay. Although several formulations were proposed and 
developed herein, that corresponding to LBG-only nanoparticles was selected for this step 
due to the novelty of the polymer in nanoparticle production. 
The viability of Caco-2 cells upon exposure to LBGA/LBGS nanoparticles is shown in 
Figure 3.15 (3 h) and Figure 3.16 (24 h). The two developed formulations (LBGA/LBGS 
2:1 and 1:2, w/w) were assessed. For formulation 2:1 (w/w) the comparison of results 
obtained for each tested time revealed a statistically significant difference between 
concentrations 0.1 and 1.0 mg/mL (P < 0.05). Formulation 1:2 (w/w) did not evidence 
significant differences between all concentrations at the two tested times. A similar 
observation was made after comparing the same concentrations for different times (3 h 
and 24 h). The most remarkable result is that no significant effect on cell viability is 
observed for both formulations at all concentrations, up to 24 h. Actually, the registered 
viability was over 80% in all cases, which, as said before, is considered very acceptable 
according to the ISO10993-5 (201). 
  
 
Figure 3.15 – Caco-2 cell viability measured by the MTT assay after 3 h exposure to 
increasing concentrations of ammonium Locust Bean Gum (LBGA) derivative, sulfate 
Locust Bean Gum (LBGS) derivative and LBGA/LBGS nanoparticles (NP). Data represent 
mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). Dashed line 
indicates 70%. * P < 0.05 compared with DMEM. 
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Figure 3.16 – Caco-2 cell viability measured by the MTT assay after 24 h exposure to 
increasing concentrations of ammonium Locust Bean Gum (LBGA) derivative, sulfate 
Locust Bean Gum (LBGS) derivative and LBGA/LBGS nanoparticles (NP). Data represent 
mean ± SEM (n ≥ 3, six replicates per experiment at each concentration). Dashed line 
indicates 70%. * P < 0.05 compared with DMEM. 
 
Curiously, the same figures also demonstrate that the exposure of the cells to the 
formulation LBGA/LBGS 2:1 (w/w) resulted in an increase of cell viability with the increase 
of nanoparticle concentration at 3 h and at 24 h (P < 0.05). This was unexpected and may 
be due to the fact that LBG is a polysaccharide with capacity to promote cell proliferation 
in some cell lines, as reported in the literature (229). Despite the formulation LBGA/LBGS 
2:1 (w/w) could improve cell proliferation with increasing concentrations, formulation 
LBGA/LBGS 1:2 (w/w), generally induced constant cell viability near 100%, irrespective of 
the concentration. 
Comparing with the control (DMEM + H2O) it is observed that the nanoparticles generally 
elicit higher cell viability, varying between 82% and 100% (P < 0.05). The most 
remarkable observation in the whole set of cell viability assessment is that, in spite of the 
strong decrease in cell viability induced by the contact with LBGA, this effect was 
completely reverted when the cells are exposed to a nanoparticulate form of the 
derivative. This was also observed in works using an ammonium derivative of pullulan, in 
which the derivative elicited around 40% cell viability upon 24 h of exposure, while 
nanoparticles produced with the polymer registered increased cell viabilities to values of 
70% - 80% (58, 59). The different impact on cell viability generated by LBGA in form of 
polymer and of nanoparticles is possibly explained by a differential contact of each of the 
materials with the cells. While the polymer in form of a solute is presented as an extended 
chain and, thus, has a higher surface of contact with the cells, nanoparticles have 
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comparatively a lower contact. Additionally, the number of positive charges available for 
interaction with the negatively charged cells upon complexation with LBGS is significantly 
decreased, thus decreasing the potential toxicity (226). This reinforces the need to 
evaluate separately the carriers and the raw materials, as the former may exhibit different 
properties, that may encompass different risks (228). 
These preliminary results suggest an absence of overt toxicity of LBG-only nanoparticles, 
thus potentiating possible applications, although it is recognized that further studies need 
to be performed to reach a more accurate conclusion in this regard. 
 
3.4. Conclusions 
LBG demonstrated to be a good substrate for the production of charged derivatives, 
permitting the synthesis of ammonium, sulfated and carboxylated LBG. Several 
characterization techniques were used to confirm the presence of the new chemical 
groups introduced in each new derivative. 
Using a method of polyelectrolyte complexation, the produced derivatives were applied in 
the preparation of different formulations of LBG-based nanoparticles, reported herein for 
the first time. When the negatively charged derivatives (sulfated and carboxylated LBG) 
were used, chitosan was the applied positively charged polyelectrolite. In turn, ammonium 
LBG was complexed with sulfated LBG to obtain LBG-only nanoparticles. The 
physicochemical characteristics of nanoparticles were highly dependent on their 
composition and on the charge ratios applied in each complexation being performed. 
Generally, the observed characteristics, with sizes around 200-400 nm in certain cases, 
and tailorable zeta potential according to setup conditions, are suggested as adequate for 
drug delivery applications.  
A preliminary toxicological evaluation of LBG derivatives and the produced nanoparticles 
was performed, assessing both the metabolic activity and the cell membrane integrity of 
representative intestinal cells (Caco-2 cells) after an exposure of up to 24 h to 
concentrations as higher as 1 mg/mL. Severe cytotoxicity was found for the ammonium 
derivative of LBG, but this was clearly reverted after the assembly of nanoparticles, which 
evidenced a very mild effect on Caco-2 cell viability. The results as a whole indicate the 
possibility to use the synthesized LBG derivatives to produce nanoparticles for drug 
delivery applications. 
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                                             CHAPTER 4 
 
LOCUST BEAN GUM NANOPARTICLES: 
APPLICATION IN ORAL IMMUNIZATION 
 
 
 
 
 
 
 
 
 
The information presented in this chapter was submitted for publication in International 
Journal of Pharmaceutics: 
Braz, L., Camacho, A., Grenha, A., Ferreira, D., Rosa da Costa, A.M., Gamazo, C., 
Sarmento, B., Chitosan/Sulfated Locust Bean Gum nanoparticles: in vitro and in vivo 
evaluation towards an application in oral immunization, submitted for publication 
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4. Chitosan/Sulfated Locust Bean Gum nanoparticles: in vitro and in vivo 
evaluation towards an application in oral immunization 
4.1. Introduction 
The search for alternative vaccination approaches that may circumvent the limitations of 
parenteral delivery is not new. Mucosal vaccination has thus been gaining popularity in 
the recent decades and some mucosal vaccines are currently available in the market 
(175, 230). Apart from leading to higher patient’s compliance, as the discomfort 
associated with parenteral administration is avoided, mucosal vaccines permit an easier 
chain of distribution, mainly because a cold-chain is not necessary, which is relevant for 
developing countries (119, 137). The oral route is the one gathering higher interest 
concerning this alternative vaccination concept, not only because of the general 
advantages associated with oral administration, but also due to relevant features of the 
intestine for immunization. In this regard, a special mention is due to the gut associated 
mucosal tissue (GALT), which has sites where immune responses are initiated and 
effector sites where adaptive immune responses are executed (175). The Peyer’s patches 
existing in the GALT comprise the main location of immune cells associated to the 
intestinal mucosa (154) and are separated from the intestinal lumen by the follicle 
associated epithelium (FAE) (159). FAE is composed of enterocytes, goblet cells and 
microfold cells (M cells) (136, 154), the latter being reported to have a thinner mucus 
layer, and good ability for antigen uptake and transport to antigen presenting cells (APCs) 
(231). Apart from these anatomical specificities, mucosal sites are considered locations of 
primary access for most human pathogens (138), many accessing the organism through 
the mouth. As mucosal immunization is expected to elicit both systemic and mucosal 
immunity, the development of the latter at the intestinal level becomes a relevant tool 
towards limiting or preventing pathogen entry, thus inhibiting the consequent infection 
(139, 140).  
Notwithstanding the evident ability of the intestinal area for antigen recognition, antigens 
are biopharmaceuticals, thus being highly sensitive molecules that require specific 
precautions regarding their formulation and delivery. Indeed, the protein-based structure 
hinders the possibility of a direct oral administration, mainly because of the low gastric pH 
and the high content of proteases (232, 233). Suitable particles are therefore demanded 
for a successful oral immunization approach and nanoparticles have been indicated many 
times as very useful in mediating this process. Apart from providing the associated 
antigens with protection from the harsh gastrointestinal conditions referred above, their 
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small size is expected to permit an intimate contact with the epithelial surface, where cells 
with relevant roles in the generation of an immune response are located (234). In addition, 
nanoparticles may also act as immunomodulator adjuvants, meaning that the particles 
further mediate the development of the immune response. The particles may facilitate 
both the antigen uptake and internalization by GALT and, also, the antigenic cross-
presentation by APCs (235). The use of The use of particle vehicles exhibiting targeting 
moieties that have a favoured interaction with epithelial glycoconjugates that are 
specifically activated by pathogens, such as the TLR family or the mannose receptor, has 
been proposed as a strategy that mimics microbial behaviour in the development of 
immune responses (235).  
The uptake of particles is reported to primarily occur via the M cells (175), which have 
been referred to provide a privileged contact with mannose residues (80, 169) and, 
therefore, might be used as privileged target for mannose-containing particles. Locust 
bean gum (LBG) is a polysaccharide of the class of galactomannans, thus having a 
chemical structure composed of both galactose and mannose units (64), as depicted in 
Figure 1.2, from chapter 1 (general introduction). Therefore, it potentially has the ability to 
provide the said privileged contact between the particle and the M cells. 
This paper proposes the design of nanoparticles based on LBG and chitosan, another 
polysaccharide, to be used as antigen particles for oral immunization purposes. A 
negatively charged derivative of LBG was produced (sulfated LBG) to enable the 
production of nanoparticles by polyelectrolyte complexation. Two model antigens were 
associated to the nanoparticles, an antigenic complex of Salmonella enterica serovar 
Enteritidis and ovalbumin; and in vivo studies were performed. 
 
4.2. Materials and methods 
4.2.1. Materials 
Chitosan (CSup) in the form of hydrochloride salt (Protasan® UP Cl 113, deacetylation 
degree = 75% – 90%, molecular weight < 200 kDa), was purchased from Pronova 
Biopolymer (Sandvika, Norway). Locust bean gum (LBG) was a kind gift from Industrial 
Farense (Faro, Portugal). Immunogenic subcellular extract obtained from 
whole Salmonella Enteritidis cells (HE) was kindly provided by Professor Carlos Gamazo 
(University of Navarra, Spain). Ovalbumin (OVA), bovine serum albumin (BSA), 
phosphotungstate dibasic hydrate, glycerol, phosphate buffered saline (PBS) pH 7.4 
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tablets, Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin (10000 
units/mL, 10000 µg/mL), non-essential amino acids, L-glutamine 200 mM, trypsin-EDTA 
solution (2.5 g/L trypsin, 0.5 g/L EDTA), trypan blue solution (0.4%), thiazolyl blue 
tetrazolium bromide (MTT), lactate dehydrogenase (LDH) kit, sodium dodecyl sulfate 
(SDS), Ponceau S red staining solution, protease inhibitor cocktail, dimethyl sulfoxide 
(DMSO), HCl 37%, H2O2, 4-chloro-1-naphtol, NaCl, KH2PO4 and NaOH were purchased 
from Sigma-Aldrich (Germany). XT sample buffer, Criterion XT bis-tris gel, XT MOPS 
running buffer, Coomassie blue and Tris-glycine buffer were provided by Bio-Rad (USA) 
and PBS-tween (PBS-T) and 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) by VWR 
(Portugal). Fetal bovine serum (FBS) was obtained from Gibco (USA), molecular mass 
markers (Novex Sharp Pre-stained Protein Standard) from Invitrogen (Germany). 
Peroxidase-conjugated goat anti-mouse IgG1, IgG2a and IgA antibodies were purchased 
from Nordic Immunology (Netherlands) and skimmed milk from Continente (Portugal). 
Ultrapure water (Mili-Q Plus, Milipore Iberica, Madrid, Spain) was used throughout. All 
other chemicals were reagent grade. 
 
4.2.2. Cell line 
The Caco-2 cell line was obtained from the American Type Culture Collection (Rockville, 
USA) and used between passages 77-93. Cell cultures were grown in 75 cm2 flasks in a 
humidified 5% CO2/95% atmospheric air incubator at 37 ºC. Cell culture medium was 
DMEM supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine solution, 1% (v/v) non-
essential amino acids solution and 1% (v/v) penicillin/streptomycin. Medium was changed 
every 2-3 days and cells were subcultured weekly. 
 
4.2.3. Production of Locust Bean Gum-based nanoparticles 
All nanoparticles (NP) were prepared by polyelectrolyte complexation method which 
consists in the electrostatic interaction between the positive and negative charges of the 
different polymers (35). 
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4.2.3.1. CSup/LBGS nanoparticles 
Nine mass ratios of CSup/LBGS (1:1; 1:1.25; 1:1.5; 1:1.75; 1:2; 1:3; 1:3.25; 1:3.5 and 1:4) 
were used to prepare the nanoparticles by polyelectrolyte complexation. The stock 
solution of CSup, dissolved in ultrapure water, was prepared to reach a final concentration 
of 1.0 mg/mL, while LBGS was dissolved in ultrapure water, at final concentration of 4.0 
mg/mL. The solutions were filtered with a 0.45 µm filter prior to use. The formulations 
were prepared by slowly adding 1.8 ml of LBGS to 1.0 ml of CSup under gentle magnetic 
stirring at room temperature, as shown in Figure 1.1 (chapter 1, general introduction). The 
concentration of CSup was kept constant at 1.0 mg/mL for the preparation of all 
formulations, but that of LBGS was modified to obtain the different ratios. 
After the addition of the LBGS solutions to the CSup solution was possible to see, almost 
immediately, the Tyndall effect evidencing the formation of nanoparticles. The 
suspensions of nanoparticles were mixed by magnetic stirring for 10 min and then 
centrifuged in eppendorfs with a layer of 10 µL of glycerol, in order to facilitate the 
following step of ressuspension. The isolation of nanoparticles was performed by 
centrifugation (Thermo Scientific-Heraeus Fresco 17, Germany) at 16 000 x g, for 30 min 
at 15 ºC. After discarding the supernatants, the nanoparticles were ressuspended with 
200 µL of ultrapure water. 
 
4.2.3.2. Association of a bacterial antigenic complex to CSup/LBGS 
nanoparticles 
An antigenic complex, HE, consisting of vesicles of outer membrane, was obtained from 
Salmonella Enteritidis. Its association was performed to the CSup/LBGS 1:1.5 and 1:2 
(w/w) nanoparticle formulations, which selection was mainly driven by the production 
yield. The stock solution of the HE antigenic complex was prepared by dissolving it in 
ultrapure water (0.4 mg/mL) using the ultra-sound bath during 15 min at room 
temperature. The solution was filtered with a 0.22 µm low protein binding filter (Millex® - 
GV, Millipore, Spain) prior to use. The NP-HE were prepared using the same methodology 
used for the unloaded nanoparticles, but the concentration of LBGS solutions were 
adjusted using different concentrations of HE solutions, in order to obtain a theoretical 
content of 2%, 4% or 8% (w/w) of the total amount of polymers. 
 
Locust bean gum nanoparticles: Application in oral immunization 
 
77 
 
4.2.3.3. Association of OVA to CSup/LBGS nanoparticles 
The association of OVA was performed to the CSup/LBGS 1:2 (w/w) nanoparticle 
formulation. The stock solution of OVA was prepared by dissolving it in ultrapure water 
(0.3 mg/mL) under magnetic stirring during 15 min at room temperature. The solution was 
filtered with a 0.22 µm low protein binding filter (Millex® - GV, Millipore, Spain) prior to use. 
The NP-OVA was prepared using the same methodology used for the unloaded 
nanoparticles, but the concentration of LBGS solution was adjusted using the stock OVA 
solution, in order to obtain a theoretical content of 8% (w/w) of the total amount of 
polymers. 
 
4.2.4. Characterization of CSup/LBGS nanoparticles 
4.2.4.1. Size, zeta potential and polidispersion index 
The size, zeta potential and polidispersion index (PdI) determination of the nanoparticles 
was performed on freshly prepared samples. Size and PdI were measured by dynamic 
light scattering and zeta potential was measured by laser Doppler anemometry, using a 
Zetasizer Nano ZS (Malvern instruments, UK). To prepare the samples, 20 µL of each 
formulation were diluted in 1 mL of ultrapure water. 
 
4.2.4.2. Production yield 
For determination of nanoparticle production yield, the nanoparticles were prepared as 
described in the previous sections but without the use of the 10 µL of glycerol. After 
discarding the supernatant of each formulation, the pellets were frozen and then dried on 
a freeze-dryer (Alpha RVC, Germany). The yield of nanoparticle production (PY) was 
calculated as follows:  
PY = (Nanoparticle sediment weight/Total solids weight) x 100 
where nanoparticle sediment weight is the weight after freeze-drying and total solids 
weight is the total amount of solids added for nanoparticle formation. 
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4.2.4.3. Association efficiency 
HE and OVA encapsulated in nanoparticles were quantified in each sample using the 
Micro BCA Protein Assay Kit (Pierce, USA), which provides a colorimetric method 
optimized to quantify reduced amounts of protein (0.5-20 μg/mL). A purple-coloured 
water-soluble reaction product is formed by the chelation of two molecules of BCA with 
one cuprous ion (Cu+1), which exhibits a strong absorbance at 562 nm that is linear with 
increasing protein concentrations. High absorbance is therefore interpreted as high 
protein concentration.  
Different calibration curves were performed for each formulation (NP-HE or NP-OVA) 
using ultrapure water as solvent. Supernatants obtained upon centrifugation of the 
nanoparticle production media were incubated with the MicroBCA reagent (2 h, 37 ºC) in a 
96-well plate. After that time, samples were analysed by spectrophotometry (Infinite M200 
Tecan, Austria) at 562 nm. The supernatants of unloaded nanoparticles were used for 
blank correction. 
The protein association efficiency (AE) and loading capacity (LC) were calculated as 
follows:   
AE (%) = [(Total antigen amount – Free antigen amount)/Total antigen amount] x 100 
LC (%) = [Total antigen amount – Free antigen amount)/Nanoparticle weight] x 100 
 
4.2.4.4. Morphological analysis 
The morphological examination of CSup/LBGS nanoparticles was conducted by 
transmission electron microscopy (TEM; JEM-1011, JEOL, Japan). The samples were 
stained with 2% (w/v) phosphotungstic acid and placed on copper grids with carbon films 
(Ted Pella, USA) for TEM observation. 
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4.2.5. In vitro evaluation of CSup/LBGS nanoparticles 
4.2.5.1. Evaluation of the structural integrity and antigenicity of the 
loaded antigens 
4.2.5.1.1. HE-loaded CSup/LBGS nanoparticles 
The integrity of HE antigens upon association was confirmed using SDS polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis. Pellets of fresh NP-HE and free HE were 
dispersed in electrophoresis sample buffer (XT sample buffer) at a concentration of 1 mg 
of HE/mL. The mixtures were left in ultrasound bath for 15 min and then heated at 100 ºC 
for 10 min. After centrifugation (16 000 x g, 30 min, 15 ºC) the supernatants were 
collected and heated at 100 ºC for 10 min. SDS-PAGE was performed with Criterion XT 
bis-tris gel, run with XT MOPS running buffer at 200 mA for 1 h and finally stained with 
Coomassie blue. 
The antigenicity study was performed by immunoblotting using sera from a pool of mice 
experimentally immunized with HE (40 µg, subcutaneously). After SDS-PAGE, the gel 
was transferred to a nitrocellulose membrane (pore size of 0.45 mm; Whatman, UK) by 
using a semidry electroblotter (Bio-Rad, USA) at 200 mA for 30 min, in a transfer buffer 
(0.2 M glycine; 24 mM Tris; 20% methanol, pH 8.3). The blot was placed in blocking buffer 
(3% skimmed milk PBS) overnight at 4 ºC. After washing with PBS-Tween (PBS-T) the 
blot was incubated with serum diluted 1:100 in PBS-T with 1% (w/v) skimmed milk for 3 h. 
After washing with PBS-T, the blot was incubated for 1 h at room temperature with the 
peroxidase-conjugated goat anti-mouse IgG1 (Nordic Immunology) diluted 1:100 in PBS-T 
with 1% (w/v) BSA. The blot was washed with PBS-T and developed by incubation in a 
solution containing H2O2 and 4-chloro-1-naphtol for 3 min in the dark. 
The apparent molecular masses of the proteins present in the antigenic extract were 
determined by comparing their electrophoretic mobility with that of molecular mass 
markers. 
 
4.2.5.1.2. OVA-loaded CSup/LBGS nanoparticles 
The integrity of OVA antigen upon association was confirmed by an SDS-PAGE analysis. 
Pellets of fresh NP-OVA and OVA were dispersed in electrophoresis sample buffer (XT 
sample buffer) at a concentration of 1 mg of OVA/mL. The mixtures were left in ultrasound 
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bath for 15 min and then heated at 100 ºC for 10 min. After centrifugation (16 000 x g, 30 
min, 15 ºC) the supernatants were collected and heated at 100 ºC for 10 min. SDS-PAGE 
was performed in 10% polyacrylamide gel, run with tris-glycine buffer at 200 mA for 1 h 
and transferred to a nitrocellulose membrane, as indicated below. Finally, the membrane 
was stained with Ponceau S red staining solution and images were taken using the 
ChemiDoc XRS+ imaging system (Bio-Rad, USA) after several washes with ultrapure 
water. 
The antigenicity study was performed by immunoblotting using sera from a pool of mice 
experimentally immunized with OVA (20 µg, subcutaneously). After SDS-PAGE, the gel 
was transferred to a nitrocellulose membrane (pore size of 0.45 mm; Whatman, UK) at 
200 mA for 1 h, in a transfer buffer (0.2 M glycine; 24 mM Tris; 20% methanol, pH 8.3) 
(wet transfer). The blot was placed in blocking buffer (5% skimmed milk PBS) during 3 h. 
After washing with PBS-T, the blot was incubated with serum diluted 1:100 in PBS-T with 
1% (w/v) skimmed milk for 2 h at room temperature and then overnight at 4 ºC. After 
another washing step with PBS-T, the blot was incubated for 1 h at room temperature with 
the peroxidase-conjugated goat anti-mouse IgG1 diluted 1:100 in PBS-T with 1% (w/v) 
BSA. The blot was again washed with PBS-T and developed by incubation in a solution 
containing H2O2 and 4-chloro-1-naphtol for 15 min in the dark. 
The apparent molecular masses of the proteins present in the antigen were determined by 
comparing their electrophoretic mobility with that of molecular mass markers. 
 
4.2.5.2. Stability evaluation on storage 
Aliquots of unloaded nanoparticle formulations (1:1; 1:1.5 and 1:2) and HE-loaded 
formulations (1:1.5 and 1:2) were stored at 4 ºC. Nanoparticle size and zeta potential were 
monitored as a function of time for 6 months, using the methodology described above (n ≥ 
3). 
 
4.2.5.3. In vitro release in SGF and SIF 
HE and OVA release profiles were determined in simulated gastric fluid (SGF) and 
simulated intestinal fluid (SIF) (236). In these studies, 2.5 mg of NP-HE and 7.02 mg of 
NP-OVA were incubated in SGF or SIF (37 ºC, 100 rpm), and at appropriate time intervals 
samples were collected, centrifuged (16 000 x g, 10 min, 15 ºC) and the released HE or 
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OVA determined by the microBCA (Pierce, USA) assay. Unloaded nanoparticles were 
submitted to the same conditions and used as blank. All experiments were performed at 
least in triplicate (n ≥ 3). 
 
4.2.5.4. Safety evaluation of unloaded nanoparticles 
The in vitro cell viability and cytotoxicity of CSup/LBGS nanoparticles, as well as that of 
the raw materials involved in nanoparticle production, was assessed by the metabolic 
assay MTT and the LDH release assay, respectively. 
The cells were seeded at a density of 1×104 cells/well in 96-well plates, in 100 µL of the 
same medium used for culture in cell culture flasks, and were grown at 37 °C in a 5% CO2 
atmosphere for 24 h before use. The effect on cell viability induced by three different 
concentrations (0.1, 0.5 and 1.0 mg/mL) of unloaded nanoparticles, as well as that of raw 
materials involved in nanoparticle production, was evaluated over 3 h and 24 h. A SDS 
solution (2%, w/v) was used as a positive control of cell death, while cells incubated with 
DMEM served as negative control. An additional control (DMEM+H2O) consisting in a 
mixture of DMEM and H2O in the same ratio used for the samples was used, in order to 
evaluate the contribution of materials on cell viability. All formulations and controls were 
prepared as solution/suspensions in pre-warmed cell culture medium without FBS 
immediately before application to the cells. 
To initiate the assay, culture medium of cells at 24 h in culture was replaced by 100 µL of 
fresh medium without FBS containing the test samples or controls. A constant ratio (3:1) 
between the culture medium and the solution/suspension of the materials was used.  After 
3 or 24 h of cell exposure, samples/controls were removed and 30 µL of the MTT solution 
(0.5 mg/mL in PBS, pH 7.4) was added to each well. After 2 h, any generated formazan 
crystals were solubilised with 50 µL of DMSO. Upon complete solubilisation of the 
crystals, the absorbance of each well was measured by spectrophotometry (Infinite M200, 
Tecan, Austria) at 540 nm and corrected for background absorbance using a wavelength 
of 650 nm (186). 
The relative cell viability (%) was calculated as follows: 
Viability (%) = (A – S)/(CM – S)× 100                                                     
where A is the absorbance obtained for each of the concentrations of the test substance, 
S is the absorbance obtained for the 2% SDS and CM is the absorbance obtained for 
Locust bean gum nanoparticles: Application in oral immunization 
 
82 
 
untreated cells (incubated with cell culture medium). The latter reading was assumed to 
correspond to 100% cell viability. The assay was performed at least for three occasions 
with six replicates at each concentration of test substance in each instance. 
Considering the mild effect observed in the MTT assay, the LDH release assay was 
performed on polymeric solutions and nanoparticle suspensions, after 24 h exposure to a 
concentration of 1.0 mg/mL. This is a colorimetric assay that quantitatively measures 
LDH, a stable cytosolic enzyme that is released upon cell lysis. Released LDH in culture 
supernatants was measured with a 30-min coupled enzymatic assay that results in the 
conversion of a tetrazolium salt into a red formazan product. The amount of color formed 
is proportional to the number of lysed cells (187).  
Samples from the culture medium in the seeding plates were centrifuged (16 000 x g, 5 
min, 15 ºC), and 50 μL was collected and reacted with 100 μL of the LDH release reagent 
at room temperature and protected from light. The reaction was stopped after 30 min by 
adding 15 μL HCl 1N. Absorbance was measured by spectrophotometry at a wavelength 
of 490 nm with background correction at 690 nm. The relative LDH release (%) was 
calculated as follows, considering 100% release for samples incubated with the lysis 
solution (positive control of cell death): 
LDH release (%) = Atest/Acontrol × 100 
where Atest is the absorbance of the test sample and Acontrol is the absorbance of positive 
control of cell death. The assay was performed in at least three occasions, with three 
replicates in each instance. 
 
4.2.6. In vivo evaluation of the immune response in BALB/c mice 
4.2.6.1. HE-loaded CSup/LBGS nanoparticles 
The experiments were performed in compliance with the regulations of the responsible 
committee of the University of Navarra (Pamplona, Spain) and in strict accordance with 
good animal practice under the Declaration of Helsinki and the Directive 2010/63/EU. Six 
groups of five female BALB/c mice (20 ± 1 g), 6 weeks old (Harlan Iterfauna Ibérica, 
Spain), were starved 7 h before immunization and only allowed free access to water. The 
groups were immunized orally with 200 µL of: 200 µg of HE in PBS, 200 µg of HE 
encapsulated in NP (NP-HE in PBS), 2.33 mg of unloaded nanoparticles (NP in PBS); and 
Locust bean gum nanoparticles: Application in oral immunization 
 
83 
 
subcutaneously with 50 µL of: 40 µg of HE in PBS, 40 µg of HE encapsulated in NP (NP-
HE in PBS), 466.25 µg of unloaded nanoparticles (NP in PBS). Blood samples and faeces 
were collected weekly from week 0 to 5 post immunization, centrifuged (10 000 x g, 10 
min, room temperature) and stored at -20 ºC until being analyzed. The faeces, before 
centrifugation, were vortexed in PBS with 3% (w/v) of skimmed milk (100 mg/mL), and 
stored, after centrifugation, with addition of a protease inhibitor cocktail (10 µL/mL). 
Specific antibodies (IgG1 and IgG2a from sera; IgA from feaces) against HE were 
determined by ELISA using 96 microtiter plates (Nunc MaxiSorp, Thermo Scientific). For 
that purpose, wells were coated overnight with 1 µg of HE in PBS at 4 ºC and then 
blocked with 1% (w/v) BSA (sera samples) or 3% (w/v) skimmed milk in PBS–T for 1 h at 
room temperature (faeces samples). After washing with PBS-T, samples were added 
diluted 1:40 (oral immunization) or 1:100 (S.C. immunization) in PBS-T and incubated at 
37 ºC, for 4 h (serum); or diluted 1:2 in PBS-T and incubated overnight at 4 ºC (faeces). 
Then, washed wells were incubated for 1 h at room temperature with antibodies 
peroxidase-conjugated goat anti-mouse IgG1, IgG2a or IgA. For the color development, 
the substrate-chromogen used was H2O2-ABTS and after 15 min (serum) or 30 min 
(faeces) the absorbance was determined at λmax 405 nm. 
 
4.2.6.2. OVA-loaded CSup/LBGS nanoparticles 
The experiments were performed in strict accordance with good animal practice under the 
Declaration of Helsinki, the Directive 2010/63/EU and the Portuguese law DL 113/2013. 
Four groups of six female BALB/c mice (20 ± 1 g), 6 weeks old (Instituto Gulbenkian de 
Ciência, Portugal), were starved 7 h before immunization and only allowed free access to 
water. The groups were immunized orally with 200 µL of: 100 µg of OVA, 100 µg of OVA 
encapsulated in NP (NP-OVA); and subcutaneously with 50 µL of: 20 µg of OVA, 20 µg of 
OVA encapsulated in NP (NP-OVA). Blood samples and faeces were collected at weeks 
0, 1, 2, 4 and 6 post immunization, centrifuged (10 000 x g, 10 min, room temperature) 
and stored at -20 ºC until being analyzed. The faeces, before centrifugation, were 
vortexed in PBS with 3% (w/v) of skimmed milk (100 mg/mL), and stored, after 
centrifugation, with addition of a protease inhibitor cocktail (10 µL/mL). 
Specific antibodies (IgG1 and IgG2a from sera; IgA from feaces) against OVA were 
determined by ELISA using 96 microtiter plates (Nunc MaxiSorp, Thermo Scientific). For 
that purpose, wells were coated overnight with 1 µg of OVA in PBS at 4 ºC and then 
blocked with 1% (w/v) BSA (sera samples) or 3% (w/v) skimmed milk in PBS–T for 1 h at 
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room temperature (faeces samples). After washing with PBS-T, a pool of samples were 
added in twofold serial dilutions in PBS-T starting with 1:40, and incubated at 37 ºC, for 4 
h (serum); or starting with 1:1 and incubated overnight at 4 ºC (faeces). Then, washed 
wells were incubated for 1 h at room temperature with antibodies peroxidase-conjugated 
goat anti-mouse IgG1, IgG2a or IgA. For the color development, the substrate-chromogen 
used was H2O2-ABTS and after 15 min (serum) or 30 min (faeces) the absorbance was 
determined at λmax 405 nm. The end titers were determined as the dilution of sample 
giving the mean O.D. ≥ 0.2 the obtained from untreated mice sera. 
 
4.2.7. Statistical analyses 
The t-test and the one-way analysis of variance (ANOVA) with the pair wise multiple 
comparison procedures (Holm-Sidak method) were performed to compare two or multiple 
groups, respectively. All analyses were run using the SigmaStat statistical program 
(Version 3.5, SyStat, USA) and differences were considered to be significant at a level of 
P < 0.05. 
 
4.3. Results and discussion 
4.3.1. Characterization of unloaded CSup/LBGS nanoparticles 
Several formulations of LBG-based nanoparticles were produced by a very mild 
polyelectrolyte complexation, according to a procedure detailed in the experimental 
section. Polyelectrolyte complexation is a process that involves electrostatic interaction 
between oppositely charged groups. This procedure takes the advantage of occurring in a 
hydrophilic environment with mild preparation conditions, avoiding the use of organic 
solvents or high shear forces that might compromise the stability of encapsulated 
materials (108, 194). LBG is a natural polymer with neutral charge, which hinders the 
application of the mentioned methodology to directly obtain nanoparticles. In order to 
overcome that relevant limitation, a sulfate derivative of LBG was produced, exhibiting a 
negative charge. When CSup and LBGS solutions are mixed, an electrostatic interaction 
is established between the negatively charged sulfate groups of LBGS and the positively 
charged amino groups of CSup, leading to nanoparticle formation (Figure 1.1). 
Considering the pH of the involved solutions (4.3 for CSup and 5.6 for LBGS), the 
polymers display positive and negative charges, respectively. In the case of CSup, a 
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degree of deacetylation of 86%, to which corresponds 0.86 positive charges per 
monomer, and a Mw of 113 kDa, have been reported (237). The mean molar mass for the 
monomer (198 g/mol) may be obtained by ponderation of the molar masses of the 
acetylated and deacetylated units. In turn, for LBGS a C:S molar ratio of 26.76 was 
determined, to which corresponds a DS of 1.22 and a mean molar mass of 932 g/mol for 
the monomer. An Mw of 27 kDa was determined by GPC analysis. 
As the aim of this work was to disclose the effect of LBGS in the production of 
nanoparticles, the produced formulations accounted with a similar or higher amount of this 
polymer comparing with CSup. Nine formulations of CSup/LBGS nanoparticles were 
produced with polymeric mass ratios varying within 1:1 and 1:4. After the preparation 
procedures, nanoparticles were characterized in terms of size, polydispersion index (PdI), 
zeta potential and production yield. The detailed results are shown in Table 4.1. 
 
Table 4.1 - Physicochemical characteristics and production yield of CSup/LBGS unloaded 
nanoparticles (mean ± SD; n ≥ 3). Different letters represent significant differences in each 
parameter (P < 0.05). 
CSup/LBGS 
(w/w) Size (nm) PdI 
Zeta potential 
(mV) 
Production 
yield (%) 
1:1 174.8 ± 13.1 a 0.10 ± 0.005 +13.0 ± 2.7 b 9.1 ± 5.0 c 
1:1.25 183.0 ± 4.7 a 0.10 ± 0.03 +14.5 ± 1.3 b n.d. 
1:1.5 184.0 ± 4.1 a 0.09 ± 0.01 +13.0 ± 0.8 b 12.5 ± 3.9 c 
1:1.75 182.5 ± 5.0 a 0.09 ± 0.01 +13.3 ± 1.0 b n.d. 
1:2 183.0 ± 6.1 a 0.13 ± 0.02 +13.5 ± 0.6 b 30.2 ± 2.8 d 
1:3 198.0 ± 26.0 a 0.12 ± 0.01 +13.0 ± 1.0 b n.d. 
1:3.25 pp - - - 
1:3.5 pp - - - 
1:4 pp - - - 
CSup: ultrapure chitosan; LBGS: sulfated locust bean gum; n.d.: not determined; PdI: polydispersity index; pp: 
precipitate 
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Formulations with a higher amount of LBGS (ratios ≥ 1:3.25, w/w) resulted in precipitation. 
Considering that a constant amount of CSup is used to produce all the formulations, the 
observed precipitation is possibly due to the presence of an excess of anionic charges, 
which neutralize CSup positive charges and, thus, reduce or eliminate electrostatic 
repulsion, leading to precipitation. For all the other tested mass ratios, a clear Tyndall 
effect was observed upon mixing the two polysaccharides, indicating the presence of 
colloidal particles. Nanoparticles were thus successfully obtained for mass ratios varying 
between 1:1 and 1:3. Surprisingly, the size of the particles did not present significant 
variations among the tested ratios, being in all cases of approximately 180 nm. The ratio 
1:3 resulted in nanoparticles with an average size of 198 nm but the standard deviation 
increased  4-5 times (26 nm), which suggests the beginning of the destabilization of the 
process of nanoparticle formation, which is reinforced by the precipitation occurred in the 
following ratio (1:3.25, w/w). The absence of variations was not expected, as varying the 
amount of one of the polymers, and therefore the amount of charges, should result in 
different nanoparticle characteristics. The nanoparticles evidenced a very narrow PdI 
(around 0.1) and a positive zeta potential around +13 mV. As observed for the size, it was 
also unexpected that the zeta potential did not vary with the alteration of the mass ratios. 
This effect is better analyzed considering the charge ratios involved in each formulation. 
By dividing the charge of each repeating unit by its molar mass, a charge per mass ratio is 
obtained for each polymer. In a 1/n formulation of CSup/LBGS, the -/+ charge ratio is 
calculated by: 
-/+ charge ratio = n . charge per mass (LBGS) / charge per mass (CSup) 
Figure 4.1 demonstrates the influence of -/+ charge ratio on the zeta potential. As 
observed, the charge ratio varies between 0.30 and 0.91 without significant effect on the 
resulting zeta potential. This pattern is relatively similar to that observed in the 
nanoparticles presented in the previous chapter, when charge ratios vary without reaching 
a value around 1. In these CSup/LBGS nanoparticles, on reaching -/+ charge ratios of 
0.98, 1.06 and 1.21 precipitation occurred. Although this behavior was unexpected, it has 
been reported in other works regarding polysaccharide nanoparticles produced by the 
same methodology (58, 59, 195, 238, 239). 
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Figure 4.1 – Effect of charge ratio (-/+) on the zeta potential of CSup/LBGS nanoparticles. 
 
It was previously demonstrated that the process leading to the assembly of polyelectrolyte 
complexes has two major steps: the rapid formation of molecular or primary complex 
particles, and a subsequent phase corresponding to the aggregation of primary particles 
to secondary particles. While the primary particles are held together by long-range 
electrostatic interactions, the formation of secondary particles involves short-range 
dispersive interactions (240, 241). In this case, considering the differences between the 
charge densities of the two polysaccharides (0.86 charges/monomer in CSup and 0.24 
charges/monomer in LBGS), a very inefficient charge pairing should be expected. 
Therefore, and also regarding the differences in the molecular weights of the 
polysaccharides, in formulations 1:1 to 1:1.5, a reduced number of primary complexes 
should form. The poor charge neutralization should result in enhanced electrostatic 
repulsion between primary particles, leading to low dispersive attraction and smaller 
particle sizes, as well as to low yields. By increasing the amount of LBGS, towards the 1:2 
formulation, a larger number of primary particles form, which should tend to aggregate in 
larger particles as the (-/+) charge ratio increases to 0.60. However, that was not the case, 
with all formulations presenting almost invariant particle sizes, which should mean that 
more particles formed; thus, the slight increase in yield observed in the latter formulation 
(241). The fact that all formulations present similar surface potentials of ~13 mV, seems to 
corroborate this hypothesis, as this potential should correspond to a repulsive electrostatic 
force overcoming the dispersive interactions and therefore preventing the particles from 
growing further. This behavior was observed in other works (238), normally associated to 
the use of CSup. Therefore, another possible explanation may reside in conformational 
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features of CS when the free base form is dissolved in acetic acid or when the 
hydrochloride salt is dissolved in water. 
Taking into account the previous observations regarding the similarity of physicochemical 
characteristics and the suggested destabilization starting in formulation CSup/LBGS 1:3 
(w/w), it was decided to determine the production yield of nanoparticles 1:1, 1:1.5 and 1:2 
(w/w). While no significant differences were observed between the first two, with yields of 
9-13%, the latter registered a much higher yield around 30% (P < 0.05). This is the trend 
that is usually observed (39, 195, 242, 243) and reflects the fact that, up to a certain limit, 
when increased amounts of LBGS are incorporated, the occurrence of electrostatic 
interactions is also increased, resulting in the formation of a higher number of 
nanoparticles (106). 
In order to restrict the number of formulations for the subsequent tasks, and considering 
that the production yield was the most differentiating characteristic of the nanoparticles, it 
was decided to select the formulations CSup/LBGS 1:1.5 and 1:2 (w/w) for the rest of the 
studies. Figure 4.2 displays the morphological characterization of representative 
nanoparticles (CSup/LBGS 1:2, w/w). This was performed by TEM and revealed a solid 
and compact structure, showing a tendency to exhibit a spherical-like shape. 
 
 
Figure 4.2 - TEM microphotograph of CSup/LBGS 1:2 (w/w) nanoparticles. 
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4.3.2. Characterization of loaded nanoparticles 
Bearing in mind the main objective of proposing CSup/LBGS nanoparticles for oral 
vaccination, the first approach regarding the association of an antigen relied on using an 
immunogenic subcellular extract obtained from whole Salmonella Enteritidis cells (HE) 
(244, 245). After performing the in vivo studies, which results are reported in a subsequent 
section (section 4.3.4), the need to test soluble antigens was identified, in order to permit 
a more clear evaluation of the real adjuvant properties of the formulated nanoparticles. 
Therefore, in a second stage of the work the protein ovalbumin (OVA) was associated as 
model antigen. Additionally, as being one of the mostly used molecules for the antigen 
effect, it enables further comparisons with the literature. As pertinent information, the HE 
extracts are mainly composed of proteins (29%) and lipopolysaccharides (59%) (246). It is 
well reported in the literature that lipopolysaccharide fractions have great ability to 
generate immunological responses, since they are prototypical PAMP’s (247). Therefore, 
taking into account that OVA is a protein, devoid of PAMP components, it is assumed as 
less immunogenic than HE. 
 
4.3.2.1. HE-loaded CSup/LBGS 
As said above, the first demonstration of the usefulness of the developed nanoparticles to 
act as adjuvants in a vaccination strategy relies on the determination of their ability to 
associate antigens. In order to verify this, different amounts of the bacterial HE antigens 
were tested and the resulting nanoparticles characterized. Departing from initial 
concentrations of 2%, 4% and 8% (w/w) of the total amount of the polymers, an effective 
and similar association was observed in all cases. In fact, the association efficiency varied 
within 29-36% (Table 4.2), independently of both the initial concentration of antigen and 
the formulation. These resulted in loading capacities up to 12%. Taking into account that 
HE is negatively charged when in the LBGS-HE solution, and also considering the high 
density of free amino groups present in the chitosan solution, it could be assumed that the 
main factor affecting HE association to the nanoparticles was an electrostatic interaction. 
This is in agreement with many other works reporting the association of protein-based 
macromolecules to nanoparticles produced by polyelectrolyte complexation (40, 106, 248, 
249). In turn, although it could be expected that HE and LBGS might compete in their 
interaction with chitosan, the obtained results do not show an influence of LBGS content 
on HE association. This may be due to the fact that LBGS could also interact with HE by 
means of hydrophobic interactions, hydrogen bonding and other intermolecular forces 
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(242). The absence of a concentration-dependent effect regarding HE was also 
unexpected, although it has been observed in other works (39, 106). 
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Table 4.2 further displays the physicochemical characteristics of HE-loaded CSup/LBGS 
nanoparticles. The size of the particles was around 190-200 nm independently of the 
specific formulation and the amount of HE associated. When comparing with the 
corresponding unloaded nanoparticles, which had a size of 183-184 nm, no significant 
differences were generally observed. An exception was only observed when 8% HE was 
associated, for both formulations, with sizes reaching approximately 200 nm (P < 0.05), 
but this observation is considered to be devoid of physiological relevance. The PdI of the 
nanoparticles remained remarkably low after association of HE (around 0.1) and a very 
slight decrease of 2-3 mV in zeta potential was generally observed (P < 0.05). Regarding 
the latter, the only exception was for the formulation 1:2, again when 8% HE was 
associated (zeta potential of +12.5 mV), in which no significant variation was observed 
comparing with the equivalent unloaded nanoparticles. Regarding the yield of the process 
of nanoparticle production, it was also observed an absence of effect upon association of 
HE antigens, independently of the used concentration. Considering that size and zeta 
potential values remained approximately similar after the association of the antigen, the 
maintenance of the production yield is indicative of displacement of the polymers to permit 
the incorporation of the active molecule. 
Taking into account the properties exhibited by HE-loaded nanoparticles, it was decided to 
select the formulation CSup/LBGS 1:2 with 8% of HE associated, to perform subsequent 
studies. This selection was driven by the presence of a higher theoretical amount of LBG 
and HE antigens. The morphological examination of this specific formulation was 
performed by TEM (Figure 4.3) and revealed the maintenance of the solid and compact 
structure of the unloaded nanoparticles, also showing a tendency to exhibit a spherical-
like shape. 
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Figure 4.3 – TEM microphotograph of HE-loaded CSup/LBGS (1:2, w/w; 8% HE) 
nanoparticles. 
 
As shown in Table 4.2, the developed HE-loaded CSup/LBGS nanoparticles evidence 
adequate physicochemical properties for the objective of oral delivery aimed at mucosal 
vaccination, with a size around 200 nm and a positive zeta potential. In fact, the size is 
small enough to permit an intimate contact with epithelial surfaces, which is maximal at 
50–500 nm (20, 21). In turn, the positive zeta potential further potentiates the interaction 
with epithelia, as this is negatively charged and, thus, an electrostatic interaction is 
enabled. In summary, these characteristics are expected to provide a prolonged retention 
of nanoparticles close to epithelial surfaces, potentiating the uptake by M cells and/or 
antigen release. 
 
4.3.2.2. OVA-loaded CSup/LBGS 
As mentioned above, the need to associate a second antigen was identified and OVA was 
selected for this end. Considering that CSup/LBGS nanoparticles 1:2 (w/w) containing 8% 
HE had been previously selected for further studies, the production of OVA-loaded 
nanoparticles respected the same composition, in order to effectively evaluate the particle 
contribution as vaccination adjuvant. As stated in Table 4.3, OVA was successfully 
encapsulated with a similar efficiency as that for HE (26.4%), which resulted in a loading 
of 5.2%. Regarding the physicochemical characteristics of OVA-loaded nanoparticles, 
there are no statistically significant differences in size when comparing with unloaded 
particles, while a slight decrease of zeta potential around 4 mV was observed (P < 0.05). 
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The production yield registered a significant increase from 30% to 38% (P < 0.05). When 
a comparison with HE-loaded nanoparticles is performed, considering the corresponding 
formulation, it should be highlighted that OVA-loaded nanoparticles have a significantly 
lower size (179 nm vs 203 nm) and higher production yield (38% vs 30%) (P < 0.05). A 
significant difference was also found for zeta potential, but only decreasing around 3 mV 
(P < 0.05). 
Naturally, the literature does not report similar nanoparticles, as LBG is being proposed 
for the first time herein, but chitosan-based nanoparticles have been suggested many 
times regarding oral vaccination (250-257). Occasionally, ovalbumin was the tested 
antigen (252), resulting in nanoparticle size around 300 nm and a strong positive zeta 
potential (+43 mV). As said above, the positive zeta potential is a desirable characteristic 
to mediate and favor the interaction with the epithelium. In our work, the proposed 
nanoparticles present a lower zeta potential, but also a lower size, which further benefits 
this interaction, due to an increased surface area.  
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4.3.3. In vitro evaluation of Locust Bean Gum-based nanoparticles 
4.3.3.1. Evaluation of the structural integrity and antigenicity of the 
loaded antigens 
As detailed above, the association of either HE or OVA into nanoparticles was performed 
by means of a mild ionic interaction. Along with the determination of the ability of the 
developed nanoparticles to associate the selected antigens, it is also of utmost 
importance to ensure that the particles and the procedure used for their production enable 
the preservation of the structural integrity and antigenicity of the encapsulated molecules. 
SDS-PAGE analysis followed by immunoblotting was the method used to perform this 
evaluation.  
The results of this evaluation are depicted in Figure 4.4 and Figure 4.5, for HE and OVA, 
respectively. Regarding HE, SDS-PAGE results shown in Figure 4.4-b demonstrate that 
the procedure used for HE entrapment did not affect the structural integrity of the 
molecules, as no additional fragments are observed in the HE released from nanoparticles 
(lane 2) when compared with the control HE solution (lane 1). 
 
 
Figure 4.4 – Immunoblot (a) and SDS-PAGE (b) analyses of free HE (1) and HE released 
from HE-loaded CSup/LBGS nanoparticles (2) (PS: standard proteins). 
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Moreover, the immunoblot membrane shown in Figure 4.4-a demonstrated that the HE-
specific antibodies from sera of a pool of mice experimentally immunized with HE, 
recognized the antigen epitopes in a similar way as for the control HE solution. This 
confirms that the antigenicity of the HE antigenic complex was not altered after the 
entrapment into the nanoparticles. 
Concerning the association of OVA, similar results were observed. As demonstrated in 
Figure 4.5, the SDS-PAGE of OVA released from nanoparticles (Figure 4.5-a) showed 
identical bands for the entrapped (lane 2) and native OVA (lane 1) and there were no 
additional bands indicating the presence of aggregates or fragments greater or less than 
45K (molecular weight of OVA). Hence, the data suggest that the structural integrity of 
ovalbumin was not significantly affected by the entrapment procedure. The antigenicity of 
OVA was also not modified after association, as the immunoblot bands from OVA solution 
(Figure 4.5-b, lane 1) and OVA released from nanoparticles (Figure 4.5-b, lane 2) were 
identical. 
 
 
Figure 4.5 – SDS-PAGE (a) and immunoblot (b) analyses of free OVA (1) and OVA 
released from OVA-loaded CSup/LBGS nanoparticles (2) (PS: standard proteins). 
 
Altogether, these results indicate the adequacy of polyelectrolyte complexation as a 
method to provide the association of antigens in polymeric nanoparticles, reinforcing 
results already available in the literature. In fact, several works reporting the preparation of 
Locust bean gum nanoparticles: Application in oral immunization
 
98 
 
nanoparticles using methodologies involving electrostatic interaction and using materials 
such as chitosan, its derivatives and alginate, have demonstrated to provide protection to 
various model antigens including inactivated influenza virus (258), bovine serum albumin 
(259), tetanus toxoid (260) and diphtheria toxoid (261). 
 
4.3.3.2. Stability evaluation on storage 
Nanoparticles are usually formulated as aqueous suspensions, as in this work, and one of 
the most reported limitations of these systems relies on their tendency for aggregation. 
Both physical (aggregation/particle fusion) and chemical issues (hydrolysis of polymer and 
chemical reactivity) are known to play significant roles in this context, thus contributing for 
the low stability that is frequently reported for colloidal drug carriers (262-264). The main 
reason for this phenomenon is the higher attractive potential existing between two 
particles coming into contact, when comparing with the kinetic energy that could induce 
their separation (265). The natural tendency for aggregation during the storage period is, 
therefore, one of the most important limitations preventing nanoparticle applications (266, 
267). In this regard, the use of charged nanoparticles might prevent aggregation and has 
been proposed as strategy to increase nanoparticle stability. Although in this work 
nanoparticles do not exhibit a strong surface charge as compared with other chitosan-
based nanoparticle formulations (56, 57, 59, 195, 268), there is still a positive surface 
charge that might help on this effect. 
In order to study the nanoparticle behavior on storage, the size and zeta potential of HE-
loaded and unloaded CSup/LBGS nanoparticles in the aqueous suspension were 
monitored along time. The rationale of conducting this assay in water was the interest in 
obtaining information on nanoparticle stability in the resuspension medium. Several 
formulations were evaluated for both HE-loaded and unloaded nanoparticles and similar 
behaviors were observed. Figure 4.6 represent the results obtained for the formulation 
1:2 (w/w) but are representative of the observations performed for the other formulations 
(1:1 and 1:1.5). It was observed that, both formulations perfectly maintain the initial 
physicochemical characteristics when stored at 4 ºC, no alterations being observed either 
on size or zeta potential for up to 6 months. These results demonstrate the physical 
stability of the developed nanoparticles, suggesting that the zeta potential is sufficiently 
high to induce repulsion on nanoparticles. Chitosan-based nanoparticles have been 
reported to exhibit physicochemical stability in similar time intervals (59, 195, 269, 270). 
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However, a direct comparison with locust bean gum based nanoparticles is not possible -
as no such system was reported before. 
 
 
Figure 4.6 – Size (square marks) and zeta potential (triangular marks) evolution as 
function of time upon storage at 4 ºC of CSup/LBGS 1:2 (w/w) unloaded nanoparticles 
(empty marks) and HE-loaded nanoparticles (8% w/w; filled marks); (mean ± SD, n ≥ 3). 
 
4.3.3.3. In vitro release in SGF and SIF 
Considering the design of these nanoparticles for an oral vaccination approach, it is 
adequate to determine the release of the encapsulated antigens in media simulating both 
the gastric (SGF) and intestinal (SIF) environments. In this association approach it is 
important that the nanoparticles not only provide protection to the antigens regarding the 
harsh conditions of the gastric medium, but also prevent the release of the antigens, in 
order to maximize the antigen internalization by the M cells mediated by the particle. 
Figure 4.7 shows the release profile of HE and OVA in SGF and SIF. As can be 
observed, HE is considered to not present significant release in any of the tested media. 
In fact, in SGF it releases a maximum amount of 7.5% in 2 h, while releasing 4.3% in SIF 
after 4 h. Moreover, although it might not be relevant from a physiological point of view, 
HE release at the end of 24 h was 21.6% ± 2.0 and 13.2% ± 4.8 in SGF and SIF, 
respectively. In turn, OVA presented a rather different behavior. In this case, the release 
in the SGF was of 45.0% at the end of 2 h, and 3.0% in SIF at the end of 4 h.  
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Figure 4.7 – Antigen released overtime from CSup/LBGS nanoparticles in simulated 
gastric fluid (SGF) and simulated intestinal fluid (SIF), at 37 ºC (mean ± SD; n ≥ 3). 
 
Considering what was stated above, in the case of OVA-loaded nanoparticles, it could be 
assumed that a high amount of encapsulated OVA releases in the harsh conditions of 
gastric environment, affecting the biological activity of the molecule. This difference 
observed for HE-loaded and OVA-loaded nanoparticles could be hypothetically explained 
by a greater association of HE into the particle, contrasting with a substantial adsorption of 
OVA onto its surface. Although the determined physicochemical properties do not confirm 
these effects, it should be reminded that a very small amount of protein is being 
associated (theoretical load of 8% (w/w)). OVA release at the end of 24 h was 75.5% ± 
13.1 and 9.8% ± 1.5 in SGF and SIF, respectively. It is remarkable that an insignificant 
amount of antigen was observed to release in SIF in both cases. This means that a great 
amount of antigen remains associated to the nanoparticles until they reach the contact 
with the Peyer patches, where the nanoparticles are expected to have a favored contact 
with the M cells, which will potentiate the immunological response. 
Despite the existence of many works proposing the application of nanoparticles in oral 
immunization, a limited number of works reports the use of either HE or OVA as model 
antigens. Works reporting release studies are even narrower and, from those, none 
involves polyelectrolyte complexation or ionic gelation. One sole work studied HE release, 
registering 10% release in SGF (after 30 min) and 12% in SIF (after 3 h) from Gantrez® 
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AN nanoparticles (271), values slightly higher than those obtained in our study. The 
release of OVA was studied from poly(d,l-lactide-co-glycolide) (PLGA)-based 
nanoparticles. Pegylated PLGA-based nanoparticles which were surface decorated with 
RGD molecules to target M cells (OVA association efficiency of 30 – 50%) registered 5% 
release after 2 h of incubation in gastric medium (HCl 0.1 M) and 10 – 20% in intestinal 
medium (154). In turn, PLGA-lipid nanoparticles conjugated with ulex europaeus 
agglutinin-1 and containing the Toll-like receptor agonist monophosphoryl lipid A (95% 
OVA association efficiency), released 17% of the protein after 2 h incubation in gastric 
acid medium (0.1 M HCl) and 3 h in intestinal medium (PBS pH 6.8) (272). Comparatively, 
our work registered higher release of this protein after cumulative contact with the two 
media, but we expect that the remaining amount suffices for an adequate immunization 
effect.  
While no studies report the release of OVA as model antigen from chitosan nanoparticles 
proposed for oral immunization, there are some works on chitosan-based microparticles. 
The results are however uneven, certainly as a result of different methods of preparation 
of microparticles and the use of diverse chitosan molecules. In fact, different works 
reported either immediate release of OVA in SGF (273), or only 50% in 2 h (274). The 
latter behavior is similar to that registered in our work, where 45% released in 2 h. The 
results regarding the release in SIF or PBS pH 7.3 were more coincident, where a 
maximum release of 10% - 20% was determined after 1 h (273) (159, 274). This is not far 
from the 3% registered in our work at the end of 4 h. 
 
4.3.3.4. Safety evaluation of unloaded nanoparticles 
Assessing the biocompatibility of drug delivery systems is a major issue in designing drug 
carriers (52, 197, 198). Although the toxic effects of formulations can only be accurately 
determined by in vivo assays, several in vitro tests can be performed in adequate cell 
lines to give the first indications on the systems cytotoxicity (197, 201). Additionally, 
current international guidelines indicate the need to contextualize biocompatibility with a 
specific route of administration and dose of the material (198). Moreover, the materials 
composing the matrix of the particles and the particle itself should be regarded as different 
entities. In line with this assumption, these should be evaluated separately, since the 
particle structure, among others, might affect the final toxicological behavior (198, 228). 
According to the guidelines issued by the International Organization for Standardization 
(ISO), testing biocompatibility implies the performance of a complete set of assays, 
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addressing at first cellular morphology, membrane integrity and metabolic efficiency, 
among other tests (197, 199-201). In this work we performed two of the most used assays 
to test the cytotoxicity of materials, namely the metabolic assay MTT and the membrane 
integrity assay based on LDH release. The MTT assay assesses cell metabolic efficiency, 
relying on the evaluation of enzymatic function. To do so, after the exposure to the matrix 
materials used for the nanoparticles production or the nanoparticles themselves, cells are 
incubated with yellow tetrazolium (MTT) salts which are reduced to purple-blue formazan 
crystals by active mitochondrial dehydrogenases (197). In this manner, a higher 
concentration of the formazan dye corresponds to a higher amount of metabolically active 
cells, which is usually interpreted as higher cell viability. The LDH release assay provides 
a mean to determine the amount of LDH in cell culture medium upon exposure to 
potentially toxic substances. As LDH is a cytoplasmic enzyme, its presence in the cell 
culture medium is an indicator of irreversible cell death due to cell membrane damage 
(202, 203). The assay thus evaluates cell membrane integrity and complements the 
results obtained by the MTT assay. 
In this work, Caco-2 cells were used to evaluate the toxicological profile of CSup, LBGS 
and the nanoparticles resulting from the combination of these polymers. Figure 4.8 and 
Figure 4.9 represent the Caco-2 cell viability obtained after exposure to the mentioned 
materials at different concentrations, for a period of 3 h and 24 h. The overall observation 
of the results reveals a mild effect on cell viability from both the polymers and 
nanoparticles, considered to be devoid of biological relevance. In fact, all samples 
resulted in viabilities above 70% after 3 h or 24 h of exposure, when tested at 
concentrations varying within 0.1 and 1.0 mg/mL. At 3 h cell viability remained above 88% 
in all cases (Figure 4.8), the lower values being observed for the raw material LBGS, 
although not to a statistically significant level. As observed in the previous chapter for LBG 
and LBG derivatives, prolonging the exposure until 24 h resulted in slight alterations 
(Figure 4.9). These were actually considered very mild, as cell viability did not decrease 
below 70% in any case. This value is that considered by ISO 10993-5 (201) as the level 
below which a toxic effect occurs. The only observation deserving a mention is that the 
exposure to the highest concentration tested (1.0 mg/mL) of CSup and the nanoparticle 
formulation, decreased cell viability to around 70% and 90%, respectively (P < 0.05).  
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Figure 4.8 – Caco-2 cell viability measured by the MTT assay after 3 h exposure to 
increasing concentrations of Chitosan (CSup), sulfate Locust Bean Gum (LBGS) 
derivative and CSup/LBGS nanoparticles (NP). Data represent mean ± SEM (n ≥ 3, six 
replicates per experiment at each concentration). Dashed line indicates 70%. * P < 0.05 
compared with DMEM. 
 
A control was used that consists in a mixture of DMEM and H2O in the same ratio used for 
the samples, taking into account that both the raw materials and the nanoparticles were 
solubilized/suspended in water and diluted with cell culture medium prior to incubation 
with the cells. This enables a real evaluation on the contribution of these materials on the 
final cell viability. As observed in Figure 4.8 and Figure 4.9, the cell viability induced by 
this control varied between 80 and 72% when tested at 3 h and 24 h. While at 3 h CSup 
and nanoparticles comparatively induced higher cell viability (100% or more), after 24 h 
the incubation with 1.0 mg/mL of CSup was found to decrease cell viability (71%) to a 
level comparable to that of this control (DMEM + H2O). Remarkably, focusing on the 
concentration of 1.0 mg/mL, the cell viability obtained by exposure to the nanoparticles 
was higher than that registered for CSup assessed individually and the control of DMEM + 
H2O (P < 0.05). 
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Figure 4.9 – Caco-2 cell viability measured by the MTT assay after 24 h exposure to 
increasing concentrations of Chitosan (CSup), sulfate Locust Bean Gum (LBGS) 
derivative and CSup/LBGS nanoparticles (NP). Data represent mean ± SEM (n ≥ 3, six 
replicates per experiment at each concentration). Dashed line indicates 70%. * P < 0.05 
compared with DMEM. 
 
LBG-based nanoparticles are now being reported for the first time. Therefore, the 
literature does not report any information regarding the cytotoxic effect of the particles, 
hindering the establishment of any comparison. In contrast, chitosan-based nanoparticles 
have been reported for a long time. As chitosan is one of the most used polymers in drug 
delivery, nanocarriers other than nanoparticles have been proposed, such as 
nanocapsules and nanoemulsions, for instance. This diversity affects viability results 
(108), but even when similar carriers are at play, it is frequently difficult to establish valid 
comparisons taking into account the large variety of chitosan molecules (chitosan 
base/salt(s), molecular weight, deacetylation degree, etc.) which is also known to have a 
role on cell viability (275). Notwithstanding these limitations, the general outcome 
regarding chitosan-based nanoparticles is a very mild effect on Caco-2 cells viability. 
Attempting to perform a direct and accurate comparison, other works assessing a 
nanoparticle concentration of 1.0 mg/mL reported similar results to those found in this 
work, both at 3 h (276) and 24 h (277, 278). 
As mentioned above, the quantification of LDH released by the cells provides a 
complementary indication on the cytotoxicity of materials to which the cells were exposed 
to. If the materials affect the integrity of cell membrane, the leaking of this cytoplasmic 
enzyme occurs and its quantification is enabled. The loss of intracellular LDH and its 
release to the culture medium is therefore an indicator of irreversible cell death due to cell 
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membrane damage (202, 203). In this study, the amount of LDH released by Caco-2 cells 
exposed to CSup/LBGS nanoparticles was determined, using as control both the 
incubation with cell culture medium (negative control of cell death) and the exposure to a 
lysis buffer (positive control of cell death, assumed as 100%). The latter corresponds to 
the maximum amount of cytoplasmic enzyme that can be released, while the former is the 
minimum. As observed in Figure 4.10, the exposure to the raw materials CSup and LBGS 
induced the release of an amount of LDH (around 25%) that is comparable to that of the 
negative control, as no statistically significant differences were detected. On the contrary, 
the contact with CSup/LBGS nanoparticles resulted in an unexpected increased level of 
LDH release (43%; P < 0.05), which is indicative of cytotoxicity.  
 
 
Figure 4.10 – Caco-2 cell viability measured by the LDH release assay after 24 h 
exposure to 1 mg/mL solutions of Chitosan (CSup), sulfate Locust Bean Gum (LBGS) 
derivative and CSup/LBGS nanoparticles (NP). Data represent mean ± SEM (n ≥ 3, three 
replicates per experiment). * P < 0.05 compared with DMEM. 
 
If a direct correlation between LDH release and cell death is assumed, the contact with 
the nanoparticles results in approximately 60% cell viability, comparing with the 80% 
elicited by DMEM. Surprisingly, this does not correspond with the observations resulting 
from the MTT assay, in which a cell viability of 90% was observed for this condition. One 
possible explanation is that these nanoparticles act as metabolic enhancers, thus 
although with a lower number of available cells (as indicated by the LDH assay), MTT 
conversion into formazan is accelerated, resulting in the overestimation of the cell viability. 
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This difference in the results of the two assays reinforces the need to perform various and 
different tests to conclude on the cytotoxic profile of nanoparticles. 
 
4.3.4. In vivo evaluation of the immune response in BALB/c mice 
After verifying the ability of LBG derivatives to produce nanoparticles with capacity to 
associate antigens of interest and evaluating the cytotoxicity of the nanoparticles in an 
intestinal model, an in vivo assay was designed and setup to evaluate the adjuvant effect 
of the particles towards an immunization strategy. Two different model antigens were 
used, HE and OVA, and the immunization experiments performed with each antigen were 
conducted in different laboratories, applying different methodologies for the analysis of 
results. In the former (HE) a serum dilution was selected and the O.D. for each animal 
was determined, the data being presented as mean ± SEM. In the latter (OVA), a pool 
with the samples of different animals was used and data presented as log2 titers. 
 
4.3.4.1. HE-loaded CSup/LBGS nanoparticles 
The immunization of mice was performed by either oral or subcutaneous route, in order to 
permit a comparison of effects. Serum and faeces from the mice were collected before the 
immunization and at weeks 1-5 post immunization. The collection of both types of 
samples enables the determination of immune responses at both the systemic (IgG1 and 
IgG2a) and mucosal (IgA) levels. The results obtained upon oral immunization are shown 
in Figure 4.11. The transversal observation is that, as expected, unloaded particles did 
not induce any type of immune response. Concerning the systemic antibody response 
(Figure 4.11 – A and B) no statistical differences were observed between the groups 
corresponding to free HE (which is the control) and the NP-HE groups. Moreover, the 
results also show that, five weeks after immunization, a similar Th1/Th2-mediated 
antibody response for both formulations was elicited. Regarding this, it is important to 
refer that the literature reports that to achieve a protective response against Salmonella 
Enteritidis infection, a balance between antibody response and cellular mediated immune 
response is demanded (279, 280). In this way, a balance between Th1 and Th2 type 
responses is required, and Salmonella attenuated vaccines are reported to normally 
induce Th1 type responses, being less effective at inducing Th2 type responses (281-
283). In this study, the nanoparticle formulation of HE (NP-HE) induced the required 
balanced Th1/Th2 response since the beginning of the study, which can be explained by 
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the presence of mannose groups, as was suggested in a study performed with 
mannosylated nanoparticles (120, 284). In that work it was verified that mannosylated 
nanoparticles induced a more balanced Th1/Th2 response comparing with non-
mannosylated nanoparticles, an effect justified by the authors to be due to the high 
tropism of mannosylated particles for uptake by PPs rich in APCs (271). In our work, the 
presence of mannose groups in LBG may possibly mediate a stronger interaction of LBG 
nanoparticles with the M cells of PPs, contributing to the observed balance in the Th1/Th2 
response. 
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Figure 4.11 – Immunogenicity of HE after oral administration in mice. Serum A) IgG1 and 
B) IgG2a systemic response, and C) IgA mucosal response after oral immunization of 5 
female BALB/c mice with 200 µg of HE solution (HE), 200 µg of encapsulated HE (NP-
HE) and the corresponding mass of blank nanoparticles (NP). In the HE group the results 
of one mouse were rejected due to the high initial absorbance (week 0) (mean ± SEM; n ≥ 
4). 
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The mucosal antibody response (Figure 4.11 – C) was also determined and, between 
weeks 2 and 4, it is observed a higher response from the group immunized with free HE 
compared with the NP-HE group (P < 0.05). Five weeks after immunization a shift is 
observed, with the NP-HE group presenting a higher response than the HE group (P < 
0.05). 
When the formulations were administered via the subcutaneous route an antibody 
response profile was elicited for HE and NP-HE groups (Figure 4.12). It was also 
observed that both groups elicited identical Th1/Th2 antibody immune responses from the 
first week on (Figure 4.12 – A and B). 
 
Locust bean gum nanoparticles: Application in oral immunization
 
110 
 
 
Figure 4.12 – Immunogenicity of HE after S.C. administration in mice. Serum A) IgG1 and 
B) IgG2a systemic response, and C) IgA mucosal response after S.C. immunization of 5 
female BALB/c mice with 40 µg of HE solution (HE), 40 µg of encapsulated HE (NP-HE) 
and the corresponding mass of blank nanoparticles (NP) (mean ± SEM; n = 5). 
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However, free HE induced a much higher IgA response than NP-HE (P < 0.05), 
particularly until week 3 (Figure 4.12 – C). It could be argued that free HE is immediately 
available to induce a mucosal response, comparing with HE encapsulated into 
nanoparticles. Similarly to what was observed for the oral route, unloaded nanoparticles 
did not produce an immune response. 
A relevant observation regarding the obtained results relies on the confirmation of the 
mildness of the nanoparticle production method, as the results indicate that the 
association process did not alter the immunogenicity of HE antigens. Nevertheless, 
although in fact no differences were generally observed to a statistically significant level, 
the trend indicates that free HE has a more favorable performance, when comparing with 
encapsulated antigens. Overall, the results suggest that HE antigens are possibly too 
robust and capable of inducing a strong immune response when administered in free 
form, thus not potentiating the observation of an adjuvant effect by the nanoparticles. This 
fact may be explained by the particulate nature of HE (liposome-like), and the high content 
of LPS in the HE extract. It is known that LPS is recognized by TLR-4 (150). Considering 
the hypothesis that the majority of the HE antigens in the nanoparticle formulation is 
entrapped into the matrix, the recognition by DCs will be preferably made by the mannose 
receptor, which is a C-type lectin receptor (152). It is reported that the uptake of antigens 
by C-type lectin receptors does not necessarily result in the induction of potent effector T-
cells, although it facilitates the antigen-presentation capacity of DCs. Moreover, uptake of 
antigen by C-type lectin receptors without any TLR binding may induce antigen-specific 
tolerance. In contrast, TLR binding usually leads to DCs maturation and activation 
resulting in a robust activation of immune responses and the induction of effector T-cells 
(285). 
It seems, thus, that the presence of mannose units in LBG nanoparticles, potentially 
recognized by the M cells and expected to improve the immune response, was not as 
good as the effect of the particulate antigen itself. Therefore, a need was identified to 
select and test a second antigen. For this effect, the same formulation of nanoparticles 
was associated with OVA and administered under the same protocol.  
 
4.3.4.2. OVA-loaded CSup/LBGS nanoparticles 
In order to evaluate the effect of OVA-loaded nanoparticles, these were administered by 
oral or subcutaneous routes, as was performed for HE-loaded nanoparticles. Taking into 
account the results described above for the unloaded particles, it was considered 
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unnecessary to include a group of animals immunized with unloaded particles. Therefore, 
only two groups were established, corresponding to OVA-loaded nanoparticles and free 
OVA, as a control. Similarly to the previous assay, serum and faeces from the mice were 
collected before the immunization and at weeks 1-6 post immunization. 
Figure 4.13 and Figure 4.14 show the serum titers of IgG1 and IgG2a (systemic 
response), and IgA (mucosal response) after an oral or subcutaneous immunization of 
mice by a single dose of OVA-loaded nanoparticles or free OVA. Overall, it is observed 
the adjuvant effect of nanoparticle formulations compared to free OVA in both routes. 
Focusing on the oral immunization (Figure 4.13), the elicited IgG1 specific response (Th2) 
was significant after OVA immunization, either free or encapsulated. Nanoparticles did not 
improve the effect of OVA regarding Th2 activation (IgG1, Figure 4.13 – A), but, however, 
a strong improvement was observed regarding Th1 activation (IgG2a, Figure 4.13 – B), 
as the respective area under the curve (AUC) was five times higher than that determined 
for free OVA. Intestinal immune system has a predisposition towards Th2 cell responses 
since antigen presentation by DCs from PPs are characterized by the production of IL-4, 
IL-6, and IL-10, which inhibit a Th1 response (286). It is also important to refer that soluble 
antigens usually elicit high levels of IgG1 antibodies (Th2 response), but very low levels of 
IgG2a (Th1 response) (287). Therefore, under these circumstances, the role of the 
adjuvant becomes critical in order to achieve a more balanced Th1/Th2 response. A 
similar positive effect of association was apparent regarding the mucosal response (IgA), 
as shown in Figure 4.13 – C. In this respect, OVA-loaded nanoparticles registered a 3-
fold higher AUC when comparing with free OVA.  
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Figure 4.13 – Immunogenicity of OVA after oral administration in mice. Serum anti-OVA 
A) IgG1; B) IgG2a and C) faecal anti-OVA IgA response in BALB/c mice (n = 6) after oral 
immunization with 100 µg of OVA solution (OVA) or 100 µg of encapsulated OVA (NP-
OVA). Antibody titers were determined in pooled serum samples at days 0, 7, 14, 21 and 
28 post-administration. 
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When considering the determined AUC, a comparable mucosal response was elicited 
when the formulation was administered by subcutaneous route (Figure 4.14 – C). 
However, the pattern registered for the responses was markedly different. In fact, while 
the oral immunization induced a response that was detected from week one, the response 
obtained upon subcutaneous immunization was only observed starting from week two to 
four. In turn, the subcutaneous administration of nanoencapsulated OVA showed a similar 
activation of Th2 (IgG1, Figure 4.14 – A) and Th1 (IgG2a, Figure 4.14 – B) to that 
described for free OVA. 
After oral immunization, OVA-loaded nanoparticles showed a predominant Th2 response 
compared to the slightly elicited Th1 one (AUCTh2 was seven times higher than AUCTh1), 
consistent with results obtained by others (252, 284, 288-290). On the contrary, 
subcutaneous immunization with OVA-loaded nanoparticles elicited a more balanced Th1 
and Th2 response. In order to perform a semi-quantitative comparison between the 
nanoparticle formulation and the free OVA, the AUC of the titers representing the systemic 
immune response (AUCTh1, AUCTh2) were measured and summed. Regarding the oral 
immunization, an increase of 34% in the total AUC was accounted for the encapsulated 
OVA. In turn, this association only induced a 13% increase in the response after 
subcutaneous immunization. This is possibly justified by the presence of mannose units in 
LBG nanoparticles, potentiating a stronger interaction with M cells and the mediation of a 
stronger immune response when the nanoparticles are administered by the oral route.   
The mucosal IgA antibodies obtained after oral immunization with OVA-loaded 
nanoparticles were higher than after subcutaneous administration. This phenomenon may 
be related to the effective uptake of nanoparticles by gut Peyer’s patches, obviously only 
possible after oral delivery, and the passage of the particulate system to lymphocytes 
causing an effective generation of mucosal IgA. However, it should be taken into account 
that a 5-fold higher dose of antigen was administered by oral route. 
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Figure 4.14 – Immunogenicity of OVA after S.C. administration in mice. Serum anti-OVA 
A) IgG1; B) IgG2a and C) faecal anti-OVA IgA response in BALB/c mice (n = 6) after S.C. 
immunization with 20 µg of OVA solution (OVA) or 20 µg of encapsulated OVA (NP-OVA). 
Antibody titers were determined in pooled faecal samples at days 0, 7, 14, 21 and 28 
post-administration. 
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Considering the in vivo results as a whole, CSup/LBGS nanoparticles did not demonstrate 
an extra-adjuvant effect when the self-adjuvant multicomponent HE was used to 
immunize; in contrast, a significant adjuvant effect was demonstrated when using OVA as 
a model antigen. This is certainly a consequence of the fact that HE is a particulate 
antigen and stronger immunological responses are known to be generated to this type of 
antigens in comparison with soluble ones, like OVA. Therefore, the suitability of 
CSup/LBGS nanoparticles to provide an adjuvant effect in oral immunization is suggested, 
although it is strongly dependent on the used antigen. Both the presence of mannose 
units in LBG, which target M cells and DC’s, and the mucoadhesive characteristics of 
CSup, are thought to have played a role in the improved response mediated by 
nanoparticles. Additionally, results obtained by others suggest that targeting to M cells 
and/or mucosal DCs should be the way to achieve a better and/or more balanced immune 
response (252, 284, 288-290). It is worth to mention that the oral immunization performed 
in these in vivo assays, truly evaluates the system capability, since it was made by oral 
gavage (not intraduodenally) and no prior administration of sodium bicarbonate solution, 
in order to neutralize the acid environment of the stomach, was made. The role of M cells 
and mucosal DCs to achieve the adjuvant properties suggested herein should be 
demonstrated. 
 
4.4. Conclusions 
This work reports for the first time the production of nanoparticles based on locust bean 
gum, demonstrating the ability of the produced sulfate derivative of locust bean gum to 
form nanoparticulate complexes with chitosan by means of an electrostatic interaction. 
The produced nanoparticles were proposed as adjuvants in oral immunization, efficiently 
associating two model antigens (HE antigenic complex and OVA) without compromising 
their structural integrity. Displaying a size around 180 - 200 nm and a positive zeta 
potential, the antigen-loaded nanoparticles were deemed adequate for the proposed 
application in oral immunization. These characteristics, along with the mannose content of 
LBG and the bioadhesive properties of chitosan, are expected to mediate both a 
prolonged contact with the intestinal mucosa and a favored interaction with intestinal M 
cells and mucosal DC’s. Nanoparticles were also demonstrated to be stable in suspension 
for at least 3 months when stored at 4 ºC. The cytotoxic assessment performed in Caco-2 
cells revealed no alterations at the level of cell metabolic activity upon exposure to the 
nanoparticles, but a mild negative effect on cell membrane integrity was observed. The in 
vivo proof of concept demonstrated the adjuvant effect of the proposed system when OVA 
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was used as soluble antigen model, although this effect was not observed when a 
particulate antigen like HE was tested. Nanoparticles were found to elicit a balanced 
Th1/Th2 immune response, which is a relevant effect towards an effective immunological 
protection. Additionally and as expected, nanoparticles were capable of inducing not only 
a systemic response, but also a response at the mucosal level. 
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5. General conclusions  
The results of the work presented in this thesis indicate the potential of the polymeric 
nanoparticulate system based on polysaccharides for an application in oral immunization, 
especially for soluble antigens. 
In a more detailed manner, the described results permitted the following conclusions: 
- Locust bean gum (LBG) is a neutral polysaccharide with a chemical composition 
corresponding to a galactomannan. Its high content in OH groups enabled the 
performance of chemical modifications to attribute charged functions to the molecule, 
resulting in the synthesis of charged derivatives of LBG. Sulfated (LBGS), carboxylated 
(LBGC) and ammonium LBG (LBGA) derivatives were synthesized; 
- Varied methods were applied for the characterization of LBG and its derivatives, which 
demonstrated the effective functionalization of the original polysaccharide. The charged 
LBG derivatives permitted the production of LBG-based nanoparticles by a mild method of 
polyelectrolyte complexation. Chitosan (CS or CSup)/LBGS, CS/LBGC and LBGA/LBGS 
nanoparticles were developed; 
- CSup/LBGS nanoparticles were selected to deepen the studies, demonstrating to be 
stable up to 180 days when stored at 4 ºC; 
- Two model antigens (a particulate cellular extract of Salmonella Enteritidis, HE, and a 
soluble antigen, ovalbumin) were effectively associated to CSup/LBGS nanoparticles 
without any deleterious effect on their structural integrity, while their antigenicity was 
retained. The nanoparticles exhibited adequate physicochemical properties for an 
application in oral immunization and demonstrated to restrain the release of the antigens. 
In this regard, HE had very limited release in either simulated gastric or intestinal fluids 
and ovalbumin released a maximum of 40% in simulated gastric medium; 
- The determination of the cytotoxic profile of LBG derivatives revealed severe cytotoxicity 
of the ammonium derivative towards a model of the intestinal epithelium (Caco-2 cells), 
contrasting to a very mild effect of either original LBG or the negatively charged 
derivatives (LBGS and LBGC). This toxicological effect was reverted when LBGA was 
converted to nanoparticulate form (LBGA/LBGS nanoparticles). CSup/LBGS nanoparticles 
induced cell viabilities around 100% in a test of metabolic activity, although an 
assessment of membrane integrity evidenced higher cytotoxicity, thus reinforcing the need 
to widen the set of assays used to determine the toxicological profile of the formulations; 
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-  In vivo studies demonstrated the adjuvant effect of the CSup/LBGS nanoparticles in 
obtaining an immunological response (systemic and mucosal) after oral immunization. 
This effect was only provided when the soluble antigen ovalbumin was used, contrasting 
with an absence of effect when the particulate antigen HE was tested. Nanoparticles were 
further found to elicit a balanced Th1/Th2 immune response, which is a relevant 
observation regarding an effective immunological protection. 
 
Future perspectives 
In the sequence of the studies described in this thesis and the drawn conclusions, there is 
great room for further testing and improving. One of the greatest challenges of 
nanoparticle design concerns the scaling up of their production. As seen in the description 
of results, the final properties of nanoparticles produced by polyelectrolyte complexation 
are sensitive to small alterations, such as a slight variation in concentration. The use of a 
larger scale does not permit such a good control, comparing with the lab scale, over all 
the parameters (stirring speed, addition of one solution over other, etc.) and some of the 
desired features of nanoparticles can be lost (291). Interestingly, the controlled scaled up 
production of chitosan nanoparticles by ionic gelation with tripolyphosphate was reported 
by using a static mixer, indicating the value of the device in this regard (292). It would be 
interesting to test and optimize conditions for scaling of the nanoparticle production. 
Another important challenge regarding nanoparticle production relies on their stabilization. 
In most cases nanoparticles are produced in aqueous medium, as is the case of 
CSup/LBGS nanoparticles. Although we have demonstrated that their physicochemical 
properties remain unaltered up to 180 days when stored at 4 ºC, longer shelf-life is 
needed. Additionally, storage and transport costs need to be reduced as possible, 
requiring the preparation of solid forms of nanoparticles. This may be done by freeze-
drying and our group has endeavored several strategies that improve the stability of 
protein-loaded nanoparticles, which could be applied in this case. These include not only 
freeze-drying in presence of different cryo- and lyoprotectants like sugars (sucrose, 
glucose, trehalose, mannitol), cyclodextrins, surfactants (polyvinylalcohol, Pluronic) (26), 
but also using annealing as a strategy to optimize lyophilization (293). 
One of the limitations identified in the work is the relatively low association efficiency. 
Therefore, establishing strategies that could improve that parameter would also be an 
important advancement. As the method of nanoparticle production and antigen 
association involves electrostatic interactions, an adequate approach would consist in 
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testing varied pH values, playing with the exhibited charges and establishing the 
conditions of maximized association. Additionally, it would be important to test other 
soluble antigens of interest for oral delivery, such as toxins, to demonstrate the adjuvant 
effect of the nanoparticles. Distribution in gastrointestinal tract and uptake by Peyer’s 
patches using fluorescently labelled antigen/nanoparticle can be studied to unveil the 
establishment of a real interaction with the M cells. Moreover, it would be beneficial to 
perform in vivo tests in other animals, such as dogs or pigs, which have organic functions 
closer to those of humans and permit a more realistic approach of the real effect of 
nanoparticles (294). 
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